Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
1 Abbreviated Title:  Anti-SLAMF7 CAR T cells for  MM 
CC Protocol #:  19-C-0102 C 
IBC# : RD-19-III-02  
NCT# : [STUDY_ID_REMOVED]  
Version Date:  April 1 4, 2020 
Title:  A Phase I Clinical Trial of T -cells Expressing  an anti -SLAMF7  CAR for Treating 
Multiple Myeloma 
Principal Investigator:                      James N Kochenderfer, M.D.  
                                                                                            Surgery Branch 
                                                             Center for Cancer Research,  
                                                             National Cancer Institute, National Institutes of Health  
                                                             10 Center Drive, Rm. 6B17, MSC 1203 
                                                             Telephone:  240-760-6062  
      Email:  kochendj@mail.nih.gov  
 
 
  
Agent Name:  Anti-SLAMF7 CAR - transduced 
autologous T cells  Rimiducid  
IND 
Number:  18793 18793 
Sponsor:  Center for Cancer Research  Center for Cancer Research  
Manufacturer  NIH DTM  Bellicum Inc.  
 
Commercial Agents : Cyclophosphamide, fludarabine  
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
2 PRÉCIS  
Background:  
• Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells.  
• T cells can be genetically modified to express chimeric antigen receptors (CARs) that target 
malignancy -associated antigens.  
• SLAMF7 is highly and uniformly expressed on MM cells but is absent on normal tissues except for some  leukocytes, including a subset of C D8
+ T cells, natural killer (NK) cells, B cells, plasma 
cells and monocytes.  
• We have constructed a novel anti-SLAMF7 CAR  that can specifically recognize SLAMF7 -
expressing target cells and eradicate SLAMF7 -expressing tumor s in mice.  
• This protocol will test genetic modification of autologous T cells with genes encoding  an 
inducible  caspase 9  (IC9) cell-suicide system  plus the anti-SLAMF7 CAR.  
• Administration of the dimerizer drug Rimiducid  (AP1903) is necessary to activate the IC9 
suicide gene and eliminate CAR T cells .  
• In this protocol, the suicide gene system will be used to eliminate CAR -expressing T cells in 
case of severe toxicities caused by the CAR T cells.  
• Possible toxicities include cytokine -associated toxicities such as hypotension, and neurolog ical 
toxicities.  Elimination of NK cells and normal plasma cells  could make patients more 
susceptible to infections . Unknown toxicities are also possible.  
Objectives:  
Primary  
• Determine the s afety , feasibility of administering T cells expressing a n anti -SLAMF7  CAR plus 
IC9 cell-suicide system to patients with MM.  
 
Eligibility:  
• Greater than or equal to 18 years of age and less than or equal to age 73.  
• Patients must have measurable MM defined as  a serum M -protein ≥ 0.6 g/dL or a urine M -protein 
≥200 mg/24 hours or an involved serum free light chain (FLC) level ≥10 mg/dL (provided FLC 
ratio is abnormal) or a biopsy-proven plasmacytoma  of 1.5 cm or more in largest dimension, or 
greater than or equal  to 30% bone marrow plasma cells .  
• Patients must have previously received at least 3 different treatment regimens for MM.  
• Patients must have prior exposure to an immunomodulatory drug (IMiD)  such as lenalidomide, 
and a proteasome inhibitor  
• Patients must ha ve a creatinine level of < 1.5 mg/dL  
• Patients must have a cardiac ejection fraction > 50%.  
• An ECOG performance status of 0 -2 is required.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
3 • Patients on any anticoagulant medications except aspirin are not eligible.  
• No active infections are allowed.  
• Absolute neutrophil count ≥ 1000/ µL, platelet count ≥ 55,000/ µL, hemoglobin ≥ 8g/dL  
• ALT and AST ≤ 2.5 -fold higher than the upper limit of normal.  
• At least 14 days must elapse between the time of any prior systemic treatment (including 
corticosteroids) and the required leukapheresis.   
• At least 14 days must elapse between the time of any prior systemic treatment  and initiation of 
protocol treatment. Systemic therapy in cludes  corticosteroids  at a dose equivalent to more than 
5 mg of prednisone.  
• Bone marrow p lasma cells must make up less than or equal to 50% of total bone marrow cells < 
24 days prior to the start of protocol treatment.  
• The patient’s MM will need to be assessed for SLAMF7 expression by flow cytometry or 
immunohistochemistry performed at the NIH.  The myeloma must express SLAMF7.  If 
unstained, paraffin-embedded bone marrow or plasmacytoma sections are available from prior 
biopsies, these can be used to determine SLAMF7 expression by immunohistochemistry; otherwise patients will need to come to the NIH for a bone marrow biopsy or other biopsy of a 
plasmacytoma to determine SLAMF7 expression.  The sample for SLAMF7 expression can 
come from a biopsy obtained at any time before enrollment.  
Design:  
• This is a phase I dose -escalation trial 
• Patients w ill undergo leukapheresis , and T cells will be modified to express the IC9 -anti-
SLAMF7 CAR construct.  
• The chemotherapy conditioning regimen is cyclophosphamide 300 mg/m
2 daily for 3 days and 
fludarabine 30 mg/m2 daily for 3 days.  The intent of chemotherapy is to enhance CAR T -cell 
activity.  
• After the chemotherapy ends , the patients will have two days with no treatments and then 
receive an infusion of CAR T cells.  
• The initial dose level will be 0. 66x106 Anti-SLAMF7 -CAR + T cells/kg of recipient bodyweight.  
• The cell dose administered will be escalated for up to 4 doses until a maximum tolerated dose is 
determined.  
• Following the T-cell infusion, there will be a mandatory 9-day minimum inpatient hospitalization to monitor for toxicity.  
• Outpatient follow -up is planned for 2 weeks, and 1, 2, 3, 4, 6, 9, and 12 months after the CAR 
T-cell infusion.  Afterwards, follow -up will be every six months up to at least 3 years  af ter 
infusion.  
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
4 TABLE OF CONTENTS  
PRÉCIS ..................................................................................................................................... 2  
TABLE OF CONTENTS .......................................................................................................... 4  
1 INTRODUCTION  ................................................................................................... 10 
1.1 Study Objectives  ..................................................................................................... 10 
1.1.1  Primary Objective  ............................................................................................. 10 
1.1.2  Exploratory Objectives  ..................................................................................... 10 
1.2 Background and Rationale  ....................................................................................... 10 
1.2.1  Introduction  ...................................................................................................... 10 
1.2.2  Multiple myeloma epidemiology and standard treatment  .................................... 11 
1.2.3  Allogeneic transplantation for MM  .................................................................... 12 
1.2.4  T-cell gene therapy  ........................................................................................... 12 
1.2.5  Chimeric antigen receptors  ................................................................................ 13 
1.2.6  Chimeric antigen receptor therapy in Multiple Myeloma  .................................... 14 
1.2.7  SLAMF7  .......................................................................................................... 17 
1.2.8  Suicide Gene  .................................................................................................... 20 
1.2.9  Anti-SLAMF7 CAR development and preclinical testing  ................................... 21 
1.2.10  Anti-SLAMF7 Therapy in MM:  ........................................................................ 27 
1.2.11  Pre-clinical studies utilizing anti-SLAMF7 CAR T cells  .................................... 28 
1.2.12  Summary of risks and potential benefits  ............................................................ 29 
1.2.13  Toxicity ............................................................................................................ 31 
1.2.14  Rationale for immunosuppressive chemotherapy and selection of lymphocyte -
depleting chemotherapy regimen  ....................................................................... 32 
1.2.15  Rationale for dose -escalation and starting dose  .................................................. 33 
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT ............................................. 34 
2.1 Eligibility Criteria .................................................................................................... 34 
2.1.1  Inclusion Criteria  .............................................................................................. 34 
2.1.2  Exclusion criteria:  ............................................................................................. 36 
2.1.3  Recruitment Strategies  ...................................................................................... 37 
2.2 Screening Evaluation  ............................................................................................... 37 
2.2.1  Screening activities performed prior to obtaining informed consent  .................... 37 
2.2.2  Screening activities performed after a consent for screening has been signed  ...... 37 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
5 2.3 Participant Registration and Status Update Procedures  .............................................. 39 
2.4 Treatment Assignment Procedures for the Registration Purposes Only:  ..................... 39 
3 STUDY IMPLEMENTATION  ................................................................................ 40 
3.1 Study Design  ........................................................................................................... 40 
3.1.1  General study plan  ............................................................................................ 40 
3.1.2  Protocol schema  ............................................................................................... 41 
3.1.3  Dose Limiting Toxicity -the dose limiting toxicity assessment period is 28 days.  . 42 
3.1.4  Dose Escalation  ................................................................................................ 43 
3.2 Dose Modifications/Delay  ....................................................................................... 45 
3.3 Drug Administration  ................................................................................................ 45 
3.3.1  Leukapheresis ................................................................................................... 45 
3.3.2  Anti-SLAMF7 -CAR-expressing T -cell preparation  ............................................ 46 
3.3.3  Conditioning chemotherapy and CAR -SLAMF7 T -cell administration -chemotherapy 
administration can be either inpatient or outpat ient ............................................ 46 
3.3.4  Rimiducid administration  .................................................................................. 48 
3.3.5  Potential repeat treatment  .................................................................................. 48 
3.4 Protocol Evaluation  ................................................................................................. 49 
3.4.1  Baseline evaluations and interventions ............................................................... 49 
3.4.2  Studies to be performed on Day 0 and during the mandatory 9-day inpatient 
admission after cell infusion .............................................................................. 51 
3.4.3  Post-infusion outpatient evaluation  .................................................................... 52 
3.5 Study Calendar  ........................................................................................................ 55 
3.6 Gene -therapy- specific follow -up .............................................................................. 61 
3.7 Criteria for Removal from Protocol Therapy and Off Study Criteria  .......................... 61 
3.7.1  Criteria for removal from protocol therapy ......................................................... 61 
3.7.2  Off-Study Criteria  ............................................................................................. 62 
3.8 Protocol Stopping Criteria ........................................................................................ 62 
4 CONCOMITANT MEDICATIONS/MEASURES .................................................... 63 
4.1 Antibiotic prophylaxis  ............................................................................................. 63 
4.2 Blood product support  ............................................................................................. 63 
4.3 Anti-emetics  ............................................................................................................ 63 
4.4 Granulocyte colony-stimulating factor ...................................................................... 63 
4.5 Avoidance of corticosteroids  .................................................................................... 64 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
6 4.6 Toxicity management guidelines  .............................................................................. 64 
5 BIOSPECIMEN COLLECTION .............................................................................. 64 
5.1 CORRELATIVE STUDIES FOR RESEARCH  ........................................................ 64 
5.1.1  Biospecimen collection before the start of the conditioning chemotherapy:  ......... 64 
5.1.2  Biospecimen collection Day 0 and after CAR T -cell infusion during the required 
hospitalization  .................................................................................................. 64 
5.1.3  Biospecimen collection during outpatient follow -up........................................... 65 
5.1.4  Immunological Testing  ..................................................................................... 65 
5.1.5  Biospecimen collection with Rimiducid administration:  ..................................... 66 
5.1.6  Additional biopsies and additional blood draws  ................................................. 66 
5.1.7  Future studies  ................................................................................................... 67 
5.2 Sample Storage, Tracking and Disposition  ............................................................... 67 
5.2.1  Samples Sent to Figg Lab .................................................................................. 67 
5.2.2  Sample Storage, Tracking and Disposition ......................................................... 67 
5.2.3  Sample Storage, Tracking, and Disposition for Surgery Branch  .......................... 69 
5.2.4  Protocol Completion/Sample Destruction  .......................................................... 69 
5.2.5  Samples for Ge netic/Genomic Analysis  ............................................................. 69 
6 DATA COLLECTION AND EVALUATION  .......................................................... 70 
6.1 Data Collection  ....................................................................................................... 70 
6.1.1  Adverse event recording:  .................................................................................. 70 
6.2 Data Sharing Plans  .................................................................................................. 71 
6.2.1  Human Data Sharing Plan  ................................................................................. 71 
6.3 Genomic Data Sharing Plan  ..................................................................................... 71 
6.4 Response Criteria  .................................................................................................... 71 
6.4.1  Important Considerations on response criteria  .................................................... 71 
6.4.2  International Myeloma Working Group uniform response criteria:  ..................... 72 
6.4.3  Minimal residual disease (MRD) criteria (requires complete response as defined 
above)  .............................................................................................................. 74 
6.5 Toxicity Criteria  ...................................................................................................... 75 
7 NIH REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
 75 
7.1 Definitions  .............................................................................................................. 75 
7.2 OHSRP Office of Compliance and Training / IRB Reporting  .................................... 75 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
7 7.2.1  Expedited Reporting  ......................................................................................... 75 
7.2.2  IRB Requirements for PI Reporting at Continuing Review  ................................. 75 
7.3 NCI Clinical Director Reporting  .............................................................................. 75 
7.4 Institutional Biosafety Committee (IBC) Reporting Criteria  ...................................... 75 
7.4.1  Serious Adverse Event Reports to IBC  .............................................................. 75 
7.4.2  Annual Reports to IBC ...................................................................................... 76 
7.5 NIH Required Data and Safety Monitoring Plan  ....................................................... 77 
7.5.1  Principal Investigator/Research Team ................................................................ 77 
7.5.2  Safety Monitoring Committee (SMC)  ................................................................ 77 
8 Sponsor Safety Reporting  ........................................................................................ 77 
8.1 Definitions  .............................................................................................................. 77 
8.1.1  Adverse Event  .................................................................................................. 77 
8.1.2  Serious Adverse Event (SAE)  ........................................................................... 77 
8.1.3  Life-threatening  ................................................................................................ 78 
8.1.4  Severity  ............................................................................................................ 78 
8.1.5  Relationship to Study Product  ........................................................................... 78 
8.2 Assessment of Safety Events .................................................................................... 78 
8.3 Reporting of Serious Adverse Events  ....................................................................... 79 
8.4 Safety Reporting Criteria to the Pharmaceutical Collaborators  .................................. 79 
8.4.1  Reporting by CCR to Bellicum Pharmaceuticals Inc. .......................................... 79 
8.4.2  Reporting by Study Team to Bellicum Pharmaceuticals Inc.  ............................... 80 
8.5 Reporting Pregnancy  ............................................................................................... 80 
8.5.1  Maternal  exposure  ........................................................................................... 80 
8.5.2  Paternal exposure .............................................................................................. 80 
8.6 Regula tory Reporting for Studies Conducted Under CCR -Sponsored IND ................. 81 
9 CLINICAL MONITORING ..................................................................................... 81 
10 STATISTICAL CONSIDERATIONS  ...................................................................... 81 
10.1  Statistical Hypothesis ............................................................................................... 81 
10.2  Sample Size Determination  ...................................................................................... 82 
10.3  Populations for Analyses  ......................................................................................... 83 
10.4  Statistical Analyses .................................................................................................. 83 
10.4.1  General Approach  ............................................................................................. 83 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
8 10.4.2  Analysis of the Primary Endpoints ..................................................................... 83 
10.4.3  Analysis of the Secondary Endpoint(s)  .............................................................. 83 
10.4.4  Safety Analyses  ................................................................................................ 83 
10.4.5  Baseline Descriptive Statistics  ........................................................................... 83 
10.4.6  Planned Interim Analyses .................................................................................. 83 
10.4.7  Sub-Group Analyses  ......................................................................................... 83 
10.4.8  Tabulation of individual Participant Data ........................................................... 83 
10.4.9  Exploratory Analyses  ........................................................................................ 83 
11 COLLABORATIVE AGREEMENTS ...................................................................... 84 
11.1  Clinical Trial Agreement  ......................................................................................... 84 
12 HUMAN SUBJECTS PROTECTIONS .................................................................... 84 
12.1  Rationale For Subject Selection ................................................................................ 84 
12.2  Participation of Children  .......................................................................................... 85 
12.3  Participation of Subjects Unable to Give Consent  ..................................................... 85 
12.4  Evaluation of Benefits and Risks/Discomforts  .......................................................... 85 
12.4.1  Risks of exposure to Ionizing Radiation ............................................................. 87 
12.5  Consent Process and Documentation  ........................................................................ 87 
13 PHARMACEUTICAL INFORMATION ................................................................. 88 
13.1  Retroviral Vector Containing the CAR -SLAMF7 Gene ............................................. 88 
13.1.1  Cells manufacturing  .......................................................................................... 88 
13.1.2  Source  .............................................................................................................. 88 
13.1.3  Toxicities  ......................................................................................................... 88 
13.1.4  Administration procedures:  ............................................................................... 88 
13.2  Commercial Agents: ................................................................................................ 88 
13.2.1  Cyclophosphamide  ........................................................................................... 89 
13.2.2  Fludarabine  ...................................................................................................... 89 
13.3  Rimiducid  ............................................................................................................... 89 
13.3.1  Source  .............................................................................................................. 89 
13.3.2  Toxicity ............................................................................................................ 89 
13.3.3  Formulation  and preparation  ............................................................................. 89 
13.3.4  Administration procedures:  ............................................................................... 91 
14 REFERENCES ........................................................................................................ 92 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
9 15 APPENDICES  ...................................................................................................... 104  
15.1  Appendix A: P erformance Status Criteria  ............................................................... 104  
15.2  Appendix B: Data Collection Elements Required By Protocol................................. 105  
15.3  Appendix C:  Guidelines for management of common toxicities that occur after CAR 
T-cell infusions  ..................................................................................................... 107  
15.4  Appendix D:   Infusion Instructions ........................................................................ 112  
15.5  Appendix E:   CARTOX (Adapted from Neelapu et al, 2018):  ................................ 115  
15.6  Appendix F:   Cytokine Release Syndrome Grading Assessment (Adapted from Lee et 
al, 2019).  ............................................................................................................... 116  
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
10 1 INTRODUCTION 
1.1 STUDY OBJECTIVES  
1.1.1 Primary Objective 
• Determine the safety and feasibility of administering T cells genetically modified to express  
a novel  chimeric antigen receptor (CAR)  targeting signaling lymphocyte activation molecule  
family member  7 (SLAMF7) and an inactivated caspase 9  cell-suicide system  to patients 
with multiple myeloma (MM) .   
1.1.2 Exploratory Objectives  
• Evaluate the in vivo  persistence and phenotype of the CAR T cells .  
• Assess for associations between toxicity and immunologic parameters including blood and 
bone marrow  CAR T-cell and cytokine levels.  
• Assess CAR T cells for anti-MM activity post infusion  by evaluating MM responses by 
standard methods . 
• Assess efficacy of Rimiducid to eliminate CAR T cells in patients with severe  infections  and 
other toxicities  
1.2 BACKGROUND AND RATIONALE  
1.2.1 Introduction 
Multiple myeloma (MM) is a malignancy of plasma cells that is almost always incurable.  New 
therapies are needed for MM.  Regressions of MM occurring in the setting of allogeneic stem cell 
transplantation (alloHSCT), and particularly after allogeneic donor lymphocyte infusions (DLIs), 
provide evidence that cellular immune responses can have a clinically significant anti -myeloma 
effect, but alloHSCT is associated with a significant transplant-related mortality and by chronic graft -versus-host disease. (1, 2
) Many  patients have obtained lengthy complete remissions of 
lymphoma or chronic lymphocytic leukemia after infusions of autologous T cells that were genetically modified to express chimeric antigen receptors (CARs) targeting the B -cell antigen 
CD19. (
3, 4)  Anti-CD19 CARs are now FDA-approved treatments.  Recently, three  phase 1 trials 
have shown that CAR T cells targeting B -cell maturation antigen ( BCMA) are effective and have a 
tolerable safety profile in relapsed multiple m yelom a.(5-8) The lasting complete remissions of MM 
that sometimes occur in the setting of alloHSCT and the encouraging results obtained treating patients with anti-BCMA and anti -CD19-CAR-expressing T cells are rationales f or attempting to 
develop CAR T -cell therapies for MM.  
Signaling lymphocyte activation molecule 7 (SLAMF7), also known as CRACC, CS1 or CD319, is a homophilic, glycosylated cell surface protein that is uniformly expressed at high levels in MM as 
shown by g ene expression studies and immunohistochemical analysis  of whole blood, 
plasmacytomas and bone marrow tissu e.(6, 9-13
) Although SLAMF7 is expressed on a proportion 
of various lymphocyte subsets including NK c ells, NKT cells, some CD8+ T cells, some B cells, 
some monocytes /macrophages  and some dendritic cells, it is not expressed on normal 
nonhematopoietic tissues. (9) The limited expression of SLAMF7 in normal tissues makes it a 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
11 promising targ et for CAR T -cell therapies. However, to mitigate potential toxicities that may occur 
with the depletion of endogenous NK, CD8+ T cells, and other SLAMF7 -expressing leukocytes, we 
have engineered a DNA construct that includes CAR and a suicide gene that can be activated if 
prolonged or severe toxicities occur.  
This protocol describes a novel T -cell therapy for patients with relapsed/refractory MM. This new 
CAR differs from prior anti -myeloma CAR therapies by targeting an antigen that is uniformly and 
highly expressed on MM cells as well as incorporating a suicide gene to limit toxicity of therapy. 
The anti -SLAMF7 CAR will incorporate a CD28 costimulatory domain.  This trial will enroll 
patients with advanced MM persisting or progressing despite at least 3 prior therapies.  Patients 
enrolled on the trial will receive a single cycle of chemotherapy that is designed to decrease endogenous lymphocyte counts because extensive evidence demonstrates that depleting endog enous 
lymphocytes, and possibly other leukocytes, with chemotherapy or total body irradiation 
dramatically increases the anti -tumor activity of adoptively transferred T cells. (14-16
)  Af ter the 
lymphocyte -depleting chemotherapy, patients will receive an infusion of autologous anti-SLAMF7 -
CAR T cells.  The T cell dose will escalate with sequential cohorts of patients until a maximum 
tolera ted dose is determined.  
 
1.2.2 Multiple myeloma epidemiology and standard treatment  
Multiple myeloma (MM) is a neoplasm of monoclonal plasma cells. (17, 18)  For MM to be 
diagnosed, a patient must have a proliferation of monoclonal plasma cells plus other abnormalities 
such as anemia, renal insufficiency, hypercalcemia, and lytic bone lesions. (18, 19)  MM is the second 
most frequently occurring hematologic cancer in the United States (U.S.). (18)  An estimated 22,350 
new cases of MM w ere diagnosed in the U.S. in 2013, and an estimated 10,710 patients died from 
MM in the U.S. in 2 013.(20)  Recent improvements in the therapy of MM have occurred. (17, 18, 
21)  These improved treatments have increased the median survival of patients with newly -
diagnosed MM from 3 years to slightly over 5 years, although the prognosis of newly -diagnosed 
MM patients varies widely. (18, 21)   
Current standard therapies for MM include various combinations of dexamethasone, bortezomib and its analogs, lenalidomide and its analogs, prednisone, melphalan, and cyclophosphamide. (17, 18, 21
, 
22)  Myeloablative doses of chemotherapy followed by autologous stem cell transplantation (ASCT) 
is a standard therapy for MM patients with good performance status, and adequate bone marrow stem cells. (
18, 21)  Compared to standard doses of chemotherapy for first treatme nt of MM, 
administration of myeloablative doses of chemotherapy followed by autologous stem cell 
transplantation improved progression-free survival in most trials and overall survival in some 
trials. (18, 21) Myeloablative chemotherapy followed by autologous transplantation can also be used 
as a treatment for relapsed MM in some cases. (18, 21, 23)   Use of the International Uniform 
Response Criteria for M ultiple Myeloma is the most common approach for assessing clinical 
outcomes in MM. (24)  Despite the recent improvements in treatment, MM remains an almost always 
incurable disease. (21, 25, 26)  Patients obtaining remissions of MM almost always relapse. (21)  The 
median overall survival of patients with relapsed MM is 3 years or less. (25)   Survival is shorter for 
patients trea ted with lenalidomide plus dexamethasone who have received at least 2 prior lines of 
therapy compared to patients who received only one prior line of therapy. (27)  In patients with MM 
that was refractory to bortezomib, the median overall survival was only 9 months when the patient 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
12 was also either ineligible for thalidomide or lenalidomide, or the patient had MM th at was relapsed 
or refractory to thalidomide or lenalidomide. (26)  Utilizing the immune system to treat MM is one 
possible way to improve therapy of MM. Recently published data from two phase 1 clinical trials 
utilizing anti-BCMA CAR T cells to treat relapsed/refractory MM have produced promising results. An NCI trial demonstrated an ORR of was 81% with 63% very good partial remissions or complete 
remission; a multi-center clinical trial of a different anti -BCMA CAR de monstrated ORR of 94% in 
18 patients at 40 weeks. (
5, 6) 
 
1.2.3 Allogeneic transplantation for MM  
Allogeneic stem cell transplantation (alloHSCT) can cure a fraction of patients  with MM. (28, 29)  
Myeloablative alloHSCT can induce long -term complete remissions of MM, but also has a  
transplant -related mortality rate (TRM) of 20% to 50%. (28, 29)  The high TRM of myeloablative 
alloHSCT led investigators to test nonmyeloablative alloHSCT for MM. (28-30 ) A commonly used 
transplantation strategy is to administer myeloablative chemotherapy plus an autologous stem cell 
transplant and then to conduct a nonmyeloablative alloHSCT a short time later. (1, 28, 29)  In some 
studies, this strategy has been shown to yield higher rates of progression-free and overall survival when compared to the strategy of 2 sequential autologous stem cell transplants. (
1, 30) One recent 
trial showed an 8-year progression-free survival rate of 22% for patients receiving an autologous transplant followed by a nonab lative alloHSCT compared to an 8 -year progression -free survival of 
12% for patients receiving sequential autologous transplants. (
1)  These results showed a statistically 
significant advantage for the autologous followed by alloHSCT strategy, but also point out that the 
vast majority of patients are not cured by either approach.   
Because many nonmyeloablative transplant regimens that have been used to treat MM include very 
low doses of radiation or chemotherapy, nonmyeloablative alloHSCTs depend on an immunolog ic 
graft -versus -myeloma effect, and remissions of MM that occur after nonmyeloablative alloHSCT 
provide evidence that immune responses can be effective at eliminating MM. (1, 28, 29)  Direct 
evidence that lymphocytes can eliminate MM comes from donor lymphocyte infusions (DLIs). (2, 
29)  Twenty -two to twenty -eight percent of patients receiving DLIs to treat persisting MM after 
alloHSCT have achieved complete remissions (CRs). (2, 28, 29)  Of note, some of these patients 
obtaining CRs after DLIs did not receive any other therapies aro und the time of their DLI. (2)  These 
results demonstrate the ability of the immune system to eradicate MM.  Unfortunately, both 
alloHSCT and DLIs utilize allog eneic lymphocytes; therefore, they are associated with the 
sometimes fatal complication of graft -versus -host disease (2, 28, 29) in addition most patients 
receiving DLIs for MM do not obtain CRs, so developing of an effective autologous cellular im mune 
therapy for MM would be a major advance.  
 
1.2.4 T-cell gene therapy  
T cells can be prepared for adoptive transfer by genetically modifying the T cells to express receptors 
that specifically recognize tumor -associated antigens. (31-38 )  Genetic modification of T cells is a 
quick and reliable process, and clinical trials of genetically modified T cells targeting a variety of malignancies  have been carried out. (
3-6, 35, 39, 40)  Genetically modified antigen -specific T cells 
can be generated from peripheral  blood mononuclear cells (PBMC) in sufficient numbers for clinical 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
13 treatment within <10 days. (3)  Genetically modifying T cells with gammaretroviruses consistently 
causes high and sustained levels of expression of introduced genes without in vitro selection( 4, 39, 
41, 42), and genetic modification of mature T cells with gammaretroviruses has a long history of 
safety in humans. (43-45)  There are two general approaches for generating antigen -specific T cells 
by genetic modification: introducing genes encoding natural αβ  T cell receptors (TCRs) or 
introducing genes encoding chimeric antigen receptors (CARs). (32, 34, 35, 37)  CARs are fusion 
proteins incorporating antigen recognition moieties and T cell activation domains. (36, 46-48 )  The 
antigen -binding  domains of most CARs currently undergoing clinical and preclinical deve lopment 
are antibody variable regions. (32, 36, 46, 48)  TCRs recognize peptides presented by human 
leukocyte an tigen (HLA) molecules; therefore, TCRs are HLA -restricted, and a particular TCR will 
only be  useful in patients expressing certain HLA molecules (32, 34, 35, 46), which limits the number 
of patients who could be treated with T cells genetically modified to express a TCR.  In contrast, 
CARs recognize intact cell -surface proteins and glycolipids, so CARs are not HL A-restricted, and 
CARs can be used to treat patients regardless of t heir HLA types. (32, 35, 49-51) 
 
1.2.5 Chimeric antigen receptors  
Preclinical experiments evaluating CAR -expressing T cells as cancer therapy were initiated in 
1993. (52, 53)  These experiments led to a clinical trial of CAR -transduced T cells targeting the α-
folate receptor on ovarian cancer cells; no tumor regressions were observed during this clinical 
trial.(54)  CARs that were capable of recognizing a variety of tumor -associated antigens have been 
evaluated in many centers. (32, 46)  Preclinical studies have assessed a wide variety of factors that 
could affect in vivo function of CAR -expressing T cells.  Multiple approaches for inserting  CAR 
genes into T cells by using gammaretroviruses (4, 39, 41-43, 55-57), lentiviruses (3, 58-61 ), or 
transposon systems (62, 63) have been assessed.  Because all methods of T -cell genetic modification 
require a period of in vitro culture, various T -cell culture techniques have been evaluated. (3, 55, 64)  
Different portions of CARs including antigen-recognition moieties, extracellular structural components, costimulatory domains such as the cytoplasmic portion of the CD28 protein, and T -
cell-activation moieties such as the signaling domains of the CD3ζ  protein can all be important to 
the in vivo function of CAR -expressing T cells, and all of these portions of CARs remain the subject 
of intensive investigation. (
46, 55, 59, 65-67 )  Much of the preclinical work evaluating CARs has 
been performed with CARs targeting the B -cell antigen CD19. (15, 55-57, 62, 68, 69) Data 
suggesting that T-cell costimulation played an important role in the activity of CAR -expressing T 
cells in vivo led investigators to add signaling moieties from the costimulatory molecule CD28 to 
CARs.( 57, 66)  These studies showed that adding CD28 moieties to CARs enhanced antigen-specific 
cytokine production and proliferation by anti -CD19 CAR T cells. (66, 70, 71)  T cells expressing 
CARs with CD28 signaling moieties and CD3 ζ signaling domains were more effective than T cells 
expressing CARs without CD28 moieties at eradicating  human leukemia cells from mice. (70, 71)  
Subsequently, CARs  incorporating other signaling domains from costimulatory molecules such as 
4-1BB (CD137) were developed. (58)  Anti-CD1 9 CARs containing the signaling domains of both 
4-1BB and CD3 ζ were superior to CARs containing the signaling domains of CD3ζ  without any 
costimulatory domains at eradicating human malignant cells from mice. (59, 65)   Similar to CD28, 
including 4-1BB signaling moieties in CARs led to increased  CD19-specific proliferation and 
enhanced in vivo persistence. (59)  In contrast to T cells expressing a CAR with a CD28 moiety, the 
increased in vitro proliferation and prolonged in vivo per sistence of T cells expressing a 4 -1BB-
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
14 containing CAR occurred whether or not  the T cells were exposed to the antigen that the CAR 
recognized. (59, 65)   
Results from several clinical trials of anti-CD19 CAR T cells have been reported to date in peer -
reviewed papers. (3, 4, 39, 41, 42, 72-75 )  The first evidence of antigen -specific activity of anti-CD19 
CAR T cells in humans was generated during a clinical trial at the National Cancer Institute in a 
patient who experienced a dramatic regression of advanced follicular lymphoma. (41)  This clinical 
trial utilized a gammaretroviral vector to introduce an anti-CD19 CAR containing the signaling 
domains of the CD28 and CD3ζ  molecules. (41) Subsequent development of this CAR was carried 
out, and it was found that anti -CD19 CAR T cells were an effective therapy for a v ariety of B -cell 
malignancies. (74, 76) Subsequent studies with this same CAR demonstrated the effectiveness of 
anti-CD19 CAR T cells against diffuse large B -cell lymphoma and led to multicenter phase II trials 
and FDA approval. (74) 
 
1.2.6 Chimeric antigen receptor therapy in Multiple Myeloma  
Success of CAR T -cells against leukemia and lymp homa has encouraged development of CAR T -
cell therapies for MM. A critical factor in determining the success or failure of a CAR -T therapy is 
the choice of target antigen. It is important that a selected antigen is uniformly expressed on the 
malignancy tar geted by CAR T cells. (77-80) MM is a clonal malignancy, but over time, multiple 
sub-clones of MM evolve. (81-85) This leads to genetic and phenotypic heterogeneity of the MM 
cells within the same patient. (83, 84, 86) This phenotypic heterogeneity includes differences in cell 
surface antigen expression. (85) To avoid toxicity, the targeted antigen should be absent on essenti al 
normal tissues because CAR T cells might destroy cells expressing the target antigen whether the 
antigen -expressing cells are normal or malignant. Many potential CAR targets in MM have been the 
subject of pre -clinical testing including CD44 variant 6, CD70 and CD56. (87-90) CARs with CD19, 
immunoglobin kappa light chain and BCMA moieties have been tested both in the preclinical and 
clinical trial setting:   
 
CD19:  
Several investigators have reported a population of cells that are distinct from the bulk population of malignant MM plasma cells; these cells phenotypically resemble B -cells and their role might be 
that of a cancer stem cell. (
82, 86, 91-93)  Circulating B -cells that are clonally related to malignant 
plasma cells have been characterized in patients with MM; in -vitro studies suggest that CD138 -
negative cells that express B -cell surface antigens including CD45, CD20 and CD19 can give rise  to 
myeloma colonies. (82, 86, 91, 92, 94) Several studies suggest that the postulated myeloma stem cells 
have intrinsic drug -resistant properties that may promote relapse. (82, 92, 94) Garfall et al. 
hypothesized that CAR -Ts targeting CD19 would deplete myeloma cells with stem cell properties 
after myeloablative chemotherapy and standard ASCT. (95, 96) Ten myeloma patients who had a 
history of progressive MM after a prior ASCT received a second ASCT followed by an i nfusion of 
5x107 anti-CD19 CAR T cells  12-14 days after infusion of stem cells. (95, 96)  The ASCT 
chemotherapy conditioning regimen was 140-200 mg /m2 of melphalan. (96) CD19+ cells were 
detected at low levels among the MM plasma cells of seven of the nine patients evaluated by flow cytometry of pre -ASCT bone marrow; in these 7 patients 0.5-1.5% of MM cells were CD19
+.(96)  
This finding emphasizes that anti -CD19 CAR-Ts are intended to target MM stem cells, not the bulk 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
15 population of MM cells.  All 10 treated patients have progr essed; the median PFS was 185 days 
(range 42 -479). (96)  
 
Immunoglobulin Kappa Light Chain:  
Plasma cells do not generally express cell -surface immunoglobulin, but Ramos et al have employed 
a strategy to target a postulated multiple myeloma stem cell population that expresses surface 
immunoglobulins by generating a CAR targeting kappa light chain. (97) Targeting kappa -expressing 
cells spares lambda-expressing B -lymphocytes. (97) In a phase I study, seven patients with multiple 
myeloma were treated with kappa-targeted CAR -T cells.(97) All seven MM patients had active 
disease at the time of CAR -T infusion and had one or more lines of prior chemotherapy; six out of 
seven patients had an ASCT in the past. (97) Three patients received salvage chemotherapy wit hin 
four weeks prior to infusion of CAR -T.(97) Those who did not have prior chemotherapy within four 
weeks of CAR -T infusion or who did not have an ALC <500 received 12.5 mg/kg cyclophosphamide 
prior to infusion of CAR -T cells. (97) Four patients had SD lasting six weeks to 24 months, and three 
patients had no response to kappa CAR -T infusion. (97)  
 
BCMA:  
B-cell maturation antigen ( BCMA) is expressed by normal and malignant plasma cells but not 
normal essential cells.  BCMA is not expressed by hematopoietic stem cells or nonhematolog ic 
cells. (5, 98, 99) It is uniformly expressed on most cases of MM by IHC. (5)  By flow -cytometry, cell -
surface BCMA was expressed at varying levels by almost all cases o f MM. (5) In pre -clinical work, 
T-cells expressin g anti-BCMA CARs could specifically recognize BCMA, kill primary myeloma 
cells in vitro, and eradicate BCMA+ tumors in mice. (98)   
 This pre -clinical work led to the first in -humans clinical trial of CAR  T cells  targeting BCMA at the 
National Cancer Institute (NCI). (
5) An anti -BCMA CAR containing a murine scFv, a CD8 hing e 
and transmembrane region, a CD28 costimulatory domain, and a CD3ζ T -cell activation domain was 
created by synthesizing the appropriate DNA and ligating it into a gamma -retroviral backbone. (5) 
Patients who had MM with uniform BCMA expression by either  immunohistochemistry ( IHC) or 
flow cytometry were enrolled. (5) All participants received conditioning che motherapy prior to 
infusion of CAR  T cells  with goals of depleting endogenous leukocytes, including depletion of 
regulatory T cells, and increasing s erum cytokine levels of IL -15 and IL -7 to increase CAR -T 
activity. (5, 74, 77, 100)  The chemotherapy regimen used was cyclophosphamide 300 mg/m2 and 
fludara bine 30 mg/m2 given daily on the same 3 days followed by CAR T -cell infusion 2 days after 
the end of the chemotherapy. (5)  Administration of chemotherapy or radiation therapy to deplete 
recipient leukocytes has been shown to enhance the activity of adoptively-transferred T cells. (15, 16, 
101)  
Twenty -six patients with MM were treated on this study at the N CI. Patients were treated at doses 
of 0.3-9x106 CAR+ T cells/kg. Of the patients treated on 0.3 - 3x106 CAR+ T cells/kg, patients had a 
median of 7 prior lines of therapy; of the patients treated on the highest dose level of 9x106 CAR+ T 
cells/kg, patients had a median of 9.5 prior lines of therapy with 63% refractory to their last treatment. (8
) At doses of 0.3-3x106 CAR+ T cells/kg, 2 of 10 patients experienced objective 
responses of PR or better. (8) Of the 16 patients who received BCMA CAR T cells at a dose of 9x106 
CAR+ T cells/kg, 13 patients had responses of PR or better. (5, 8) The overall response rate for these 
patients was 81%. (8) All but one patient on the hig hest dose level had a substantial decrease in their 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
16 serum MM markers. (8) The median even t-free survival for patients treated at a cell dose of 9x106/kg 
was 31 weeks with six patients having ongoing remissions. (8) To date, five responses have lasted 
more than 6 months. (8) In nine of nine patients that were evaluated with bone marrow biopsies and 
immunohis tochemistry staining for CD138 before and 2 months after CAR -BCMA infusion, bone 
marrow plasma cells steeply decreased between these 2 -time points. (8) Of the 16 patients receiving 
9x106 CAR+ T cells/kg, 11 patients were evaluable for minimal residual d isease (MRD), and all 
achieved MRD negative status following CAR -BCMA T -cell infusion. (8) CAR-BCMA T -cell 
toxicity was mild at lower dose levels, with no CRS grades of 3 or 4 at cell doses of 0.3 -3x106 CAR+ 
T cells/kg. (5) At a cell dose of 9x106 CAR+ T cells/kg, CRS related toxicities were substantial. (8, 
102) As the dose of CAR  T cells  escalated, patients began to have more symptoms of cytokine 
release syndrome, including fever and tachycardia. (5) The first two patients treated with 9x106 CAR+ 
T cells/kg experienced substantial cytokine release syndrome (CRS) toxicities. Because of the 
toxicities experienced by these two patients,  the latter 14 patients treated with 9x106 CAR-BCMA 
T cells/kg were required to have lower MM burdens with BM involvement by myeloma of less than 30% prior to cell infusi on.(
8) Six of sixteen patients receiving 9x106 CAR-BCMA T cells/kg (38%) 
required vasopressor support for hypotension for CRS following CAR T -cell infusion, and one 
patient required mechanical ventilation. (8) Five patients (31%) received tocilizumab and 3 patients 
(19%) received corticosteroids for CRS -related toxicities .(8) Two patients received stress -dose 
hydrocortisone for evidence of adrenal insufficiency before or during CRS. (8) Patients with CRS of 
Grade 3 or 4 had higher levels of bone marrow plasma cells compared with patients who had less than Grade 3 CRS, which indicates an increased chance of severe CRS in patients with high MM 
burdens (
8).  
Neurologic toxicities were limited to confusion or delirium in the setting of high fevers during CRS except for one patient who experienced encephalopathy and grade 3 muscle weakness of all 
extremities that was thought due to critical illness polyne uropathy. (8
)  
Most cytopenias occurred early after CAR -BCMA T -cell infusion and were att ributable to 
chemotherapy, but two cases of cytopenias occurred after recovery of blood counts from chemotherapy -related cytopenias. Neutropenia rapidly resolved after filgrastim support in both of 
these cases. (8
) Both patients received the thrombopoietin receptor agonist eltrombopag and 
prednisone. Platelets recovered to greater than 50,000/ µL without platelet transfusions by 63 and 53 
days after CAR -BCMA T -cell infusion in the two patients.  Toxicities were managed without long -
lasting complications. (5, 8)  
A second anti -BCMA CAR T-cell  clinical trial was conducted by bluebird bio  and Celgene Inc.  and 
was a multicenter trial. (6) Twenty -one patients with relapsed/refractory MM were treated with 
bb2121, an anti -BCMA CAR-T that expresses a CAR with the same scFv as the anti -BCMA CAR 
used at the NCI. (5, 6)  In contrast to the NCI anti -BCMA CAR, bb2121 had a 4-1BB costimulatory 
motif, and was encoded by a lentivirus. (6)  Bb2121 wa s administered after cyclophosphamide plus 
fludarabine lymphocyte -depleting chemotherapy and at  planned dose levels of 50, 150, 450, 800, 
and 1,200 x 106 CAR+ T cells .(6) As of May 2017, 21 heavily -pretreated patients were evaluable 
for clinical response. (6) Of these, three patients were treated on the lowest dose level. The lowest 
dose level had minimal anti -myeloma activity and minimal toxicity. Patients had a median of 7 prior 
lines of therapy and all patients had a history of an autologous transplant. (6) Median follow -up after  
bb2121 infusion was 15.4 weeks. (6) There were no reported grade 3 or higher neurotoxicity events  
on the dose -escalation phase of  this trial, but one patient did experience Grade 4 neurologic toxicity 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
17 on the expansion phase of this trial. CRS was primarily Grade 1 or 2 in 15 of 21 patients (71%); 2 
patients had Grade 3 CRS that resolved in 24 hours. (6) Four patients received tocilizumab and one 
patient received steroids to manage CRS. (6) The ORR was 89% and increased to 100% for patients 
treated with doses of 150 x 106 CAR+ T cells or higher. (6) No patients treated with doses of 150 x 
106 CAR+ T cells or higher had disease progression wi th time of follow up between 8 and 54 
weeks. (6) MRD negative results were obtained in all 4 patients evaluable for analysis. (6)  Of the 18 
patients treated at doses above the first dose level, the overall response rate (PR or better) was 94% 
and the CR rate was 56%.  
Cohen et. al have published their initial findings from a phase I trial of anti -BCMA CAR-T without 
conditioning chemotherapy in patients with relapsed or refractory MM. (7) One patient was treated 
with 1.8x108 CAR-Ts, two with 2x108 CAR-Ts and three patients at the highest dose level of 5x108 
CAR-Ts. (7)  Toxicities were similar to those published by Ali et. al, except for an episode of grade 
4 posterior reversible ence phalopathy syndrome (PRES) that manifested as severe delirium, seizures, 
obtundation and cerebral edema. (7) This was treated with steroids, anti-epileptics, and interestingly, 
cyclophosphamide; there was no long -term neurological dysfunction. (7) Reported results show one 
patient has a stringent CR at seven months with an MRD -negative bone marrow by flow 
cytometry. (7) One patient who had pleural and dural MM involvement was  found to have CAR -Ts 
cells in pleural fluid and CSF and achieved VGPR with resolution of extramedullary disease; this 
patient’s VGPR lasted 5 months, and progression was associated with loss of BCMA expression on 
MM cells. (7)  
Currently, a new clinical trial has opened targeting CD38 (clinicaltrials.gov: [STUDY_ID_REMOVED] ).  CD38 
is a transmembrane glycoprotein involved in cell -adhesion, signal transduction and calcium 
regulation. (103, 104) It is normally expressed on precursor B -cells, plasma cells, T -cells, NK -cells, 
and myeloid precursors. (104- 106) Among non-hematologic organs, CD38 is expressed on prostate 
cells, in the nervous system, gut, muscle cells, and on osteoclasts. (104, 105) Two monoclonal 
antibodies against CD38 have been tested clinically, Daratumumab and Isatuximab. (107, 108) 
Although at an early stage of development, CAR T cells have great promise to improve MM 
treatment.  
 
1.2.7 SLAMF7  
Signaling lymphocyte activation molecule 7 (SLAMF7), also known as CRACC, CS1 or CD319, is a homophilic, glycosylated cell surface protein and member of a larger signaling family of receptors involved in the effector functions of hematopoietic cells. (109-112
) Receptors in this family 
modulate function through tyrosine switch motifs and intracellular adaptor proteins. (109, 112-114) 
The SLAMF7 structure is comprised of an extracel lular region containing a single Ig variable -like 
domain and a single C2 domain, a transmembrane domain and a cytoplasmic domain with two tyrosine -based switch motifs. (
111, 115) 
A critical factor for any antigen to be considered as a target for immunotherapy is the antigen’s expression pattern in normal tissues. Although SLAMF7 is highly expressed in almost all cases of MM it has very limited or absent expression on normal tissues  aside from leukocytes such as CD8
+ 
T cells, natural killer (NK) cells, B cells, plasma cells, some monocytes, NKT cells, and some dendritic cells. (9, 10, 110, 112, 113
)  Notably, hematopoietic stem cells do not express 
SLAMF7. (111) SLAMF7 is not expressed on the surface of normal organ epithelial tissue such as 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
18 lung, kidney, stomach, brain, breast, spleen, prostate, skeletal muscle, testis, liver, ovary, heart, 
thymus and small intestine epithelial tissue. (9, 10, 12) In one study by Hsi et al, organs staining 
positive for SLAMF7 were evaluated further by peri -cellular staining to detect infiltrating leukocytes 
and double staining with CD138 to detect plasma cells. Results showed that organs staining positive 
for SLAMF7 were due to the presence of infiltrating  leukocytes and plasma cells, consistent with 
the published expression profile of SLAMF7. (9) Plasma cells and MM cells express higher levels 
of SLAMF7  mRNA and protein than on any other lymphocyte subset. (9)  
In Figure 1, actin cDNA copies and SLAMF7  cDNA copies were measured by qPCR  in all of the 
samples, and the results were expressed as the number of SLAMF7  cDNA copies per 105 actin cDNA 
copies.  
Figure 1 
 
 
We went on to evaluate SLAMF7  protein expression in normal human organs.  Except for plasma 
cells and rare lymphocytes , we did not detect SLAMF7  protein expression by the cells of any of the 
organs that we stained.  We detected plasma cells expressing cell -surface SLAMF7  in 
gastrointestinal organs.  SLAMF7  expression by normal plasma cells probably accounts for the low 
levels of SLAMF7  RNA detected in these organs because we did not detect SLAMF7  expression by PlasmacytomaAdrenal
Bone marrowB rainCervixColon
DuodenumEpididym usEsophagusFat
Heart
Sm all Intestine
Intracranial ArteryK idneyLiverLung
Lymph Node
Blood leucocytesMammary glandM uscle
Nasal MucosaOptic nerveOvary
OviductPancreas0100020003000SLAMF7 copies/105 actin copies SLAMF7 copies/105 actin copies
PlasmacytomaPenis
PericardiumPituitaryPlacentaProstate RectumR etina
Seminal vesiclesSkin
Spinal cordSpleenStomachTestisThymusThyroidTongueTonsil
Trachea UrethraBladderUterusU vulaVagina
Vena cava0100020003000
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
19 any of the other cells  except plasma cells and some lymphocytes  and rare macrophages  in these 
organs.   
Table 1 
 
 
SLAMF7 is highly and uniformly expressed on MM tumor cells in whole blood and in the bone 
marrow detected by both gene expression and IHC; according to studies, 80-95% of primary 
myeloma cells collected from MM patients express SLAMF7. (9-13 ) It is not as strongly or as 
uniformly expressed on NK cells, CD8+ T cells, B cells, monocytes or dendritic cells. (9, 10)  
 
SLAMF7 is expressed on normal leukocytes, including NK cells and CD8+ T cells. A small fraction 
of monocytes and CD4+ T cells also express SLAMF7 ( Figure 2). Figure 2 shows the results of flow 
cytometry analysis on unmanipulated  peripheral blood mononuclear cells (PBMC). The results show 
that CD3-negative, CD56+ NK cells almost all express SLAMF7. Also, a large fraction of 
CD3+CD8+ cells express SLAMF7.  adrenal 
bladder 
bone  
breast 
cerebellum 
cerebral cortex
eye 
fallopian tube 
esophagus 
stomach 
small intestine 
colon 
rectum 
heart 
kidney
liverlung
ovary 
pancreas 
parathyroid 
pituitary 
placenta 
prostate 
skin 
spinal cord 
spleen 
skeletal muscle
testis 
thymus 
thyroid 
tonsil
uterine cervix 
uterine endometriumOrgans stained for SLAMF7 by immunohistochemistry and found to lack SLAMF7 
expression except on plasma cells, some macrophages and some lymphocytes 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
20 Figure 2 
 
 
 
SLAMF7 is expressed on MM cells independent of cytogenetic abnormalities. (116- 118) 
Amplification of chromosome 1q23, the location of SLAMF7 gene family, is associated with more 
aggressive myeloma and unfavorable prognosis. (111) SLAMF7 is strongly  and uniformly expressed 
in extramedullary plasmacytomas, lymphoplasmacytic lymphoma and bone marrow core samples of 
MM patients. Expression in MM persists after disease relapse and after proteasome inhibitor treatment. (
111) Serum levels of soluble SLAMF7 correlate with stage and activity of MM in 
patients. (119) Downregulation of SLAMF7 in MM cells has been associated with reduced MM cell 
survival. (118) SLAMF7 may play a role in MM cell -bone  marrow interactions.(111),(114)  
Under normal conditions, SLAMF7 receptors play a role in regulating immune cell functions, such as cell adhesion, growth and survival; however, the receptor’s full role is incompletely understood. (12, 112, 114
) SLAMF7 receptor signaling may exert activating or inh ibitory actions on 
cells depending on which lymphocyte subset is engaged and which adaptor pr otein is present. ( 9, 10, 
120) For example, SLAMF7 is thought to be important for NK cell-mediated anti -viral activities and 
general tumor surveillance when the EAT -2 adaptor protein is present; however, SLAMF7 signaling 
that occurs in the absence of EAT -2 signaling in CD4 T cells, CD8 T cells and NKT cells leads to 
decreased proliferation and cytokine secretion. (9, 10, 120)  In MM, SLAMF7 signaling lacks EAT-
2 downstream activation, thus MM cells do not proliferat e with receptor engagement. (117) 
1.2.8 Suicide Gene  
The high expression of SLAMF7 on MM cells makes it an attractive target for CARs aimed at MM, but because of the expression of SLAMF7 on normal leukocytes, a mechanism for eliminating anti -
SLAMF7 CAR T cells after infusion into patients is necessary. In on e pre -clinical study, cell line 
experiments from MM patients and healthy donors showed that on average 17.3% of NK cells, 
Gated on CD3 -negative PBMC Gated on CD3 -negative PBMC
Gated on CD3 -positive PBMC Gated on CD3 -positive PBMCSLAMF7
SLAMF7SLAMF7
SLAMF7CD56 CD14
CD4 CD8
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
21 35.4% of CD8+ T cells, 66.5% of B cells and 85% of CD4+ T cells were viable at the end of the 
fratricide assay with an anti -SLAMF7 CAR  T cells. (10).  Thus, to mitigate potential toxicity caused 
by lymphocyte de pletion, the  inducible  caspase 9 system  iCasp9  (IC9) is the preferred safety switch 
for this project because of its proven clinical effectiveness. (121) The IC9 system has been found to 
be safe and well tolerated and is the most clinically -tested of the various suicide gene systems. (121, 
122) 
The IC9 suicide gene system requires that T cells are genetically modified to express the IC9 
gene. (121 ) The IC9 gene contains part of the apoptotic protein human caspase 9 protein fused to a 
drug binding domain derived from human FK -506 binding protein-12 (FKBP12).( 123) Activation 
of the caspase 9 domain of the iCasp9 protein is dependent on dimerization with a small molecule 
drug, Rimiducid (AP1903) which cross -links the FKBP 12 domains, initiating the apoptotic pathway 
of the T cell(122). T lymphocytes trans duced with the IC9 system were shown in -vitro to retain their 
immune potential and can be eliminated with exposure to the dimerizing drug with high specificity and potency(
122). The dimerizer  drug, Rimiducid, has no reporte d effects on cells other than those 
engineered with the suicide gene. (124) The transgene is made from human products thus conferring 
low immunogenicity potential. (121, 124) Maximal killing occurred at about 0.3 ng/ml. (122 ) Pre-
clinical studies with CAR T cells show that T cells engineered with the IC9 transgene were able to be eliminated within 3 days or less of administration; however, in the clinical setting, GVHD was controlled much faster than 3 days in some patients. (
121, 125) An advantage of this system is that 
it utilizes endogenous apoptotic pathways, resulting in rapid elimination of the transduced cells. (121, 
122) 
In the clinical setting, the IC9 system has been shown to be safe and efficacious in a trial to rapidly control graft -versus -host -disease in patients who underwent stem cell transplantation for 
leukemia. (121
) Five patients who had  underg one haploidentical allogeneic stem cell transplantation 
for relapsed acute leukemia were treated with T cells engineered with the IC9 system. ( 121) These 
T cells propagated in vivo showing that the expression of IC9 did not inhibit survival or in vivo 
expansion of the transduced cells. Ski n GVHD (four patients) and liver GVHD  (one patient) 
developed in four patients; a single dose of dimerizing drug eliminated more than 90% of the modified T cells within 30 minutes after administration, which resulted  in the end of GVHD in those 
patients w ithout recurrence. (
121) The dimer izing drug had no effect on the endogenous CD3+CD19 -
negative  untransduced T -cell population or on other blood counts. ( 121) Within 24 hours of infusion, 
GVHD abnor malities began to resolve and normalized within 24-48 hours after infusion. (121) No 
evidence of an immune res ponse to the transgenic T cells was found. (121)  
The four patients who developed GVHD in the clinical trial received 0.4 mg/kg of the dimerizing agent Rimiducid as a 2 -hour infusion. (121
) In a different study, pharmocokinetic data showed that 
the plasma concentration following administration of Rimiducid doses ranging from 0.01 to 1.0 
mg/kg resulted in plasma concentrations of 10 to 1275 ng/ml with plasma levels falling to 18% of the maximum half an hour after infusion and 7% of the maximum 2 hours after the infusion. (
121, 
122) At these concentrations, pre-clinical studies s howed little variation in the induction of apoptosis 
among patients with consistent elimination of more than 90% of IC9-expressing cells.3 The terminal 
half life of Rimiducid is 5 hours (in vivo). ( 121)   
1.2.9 Anti-SLAMF7  CAR developmen t and preclinical testing  
The suicide gene plus anti-SLAMF7  CAR construct  to be assessed in this protocol contains  the IC9 
suicide gene, which is made up the of an FKBP12 dimerization domain and a caspase 9 domain , as 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
22 described in section 1.2.8 , followed by a thosa asigna virus 2A (T2A) ribosomal skip domain 
followed by an anti -SLAM F7 CAR. The antigen recognition domain of the CAR is a single chain 
variable fragment from the murin e Luc90 antibody. The anti -SLAMF7  CAR contains the hing e and 
transmembrane regions of the human CD8α  molecule, the signaling moiety of the CD28  
costimulatory molecule, and the signaling domains of the CD3ζ  molecule.  T he CAR is designated 
Luc90-CD828Z (Figure  3). The clinical gene therapy vector encoding IC9-Luc90-CD8 28Z is 
MSGV 1, which has been used in many prior clinical trials at the NCI. (126 )  
 
Figure  3 
 
 
After transductions, we found high levels of cell surface expression of the Luc90-CD828Z  anti-
SLAMF7  CAR on the transduced T cells as shown in the representative example in  Figure  4. 
Figure  4 
 
Figure 4  shows Luc90-CD828Z  CAR expression on T cells from a multiple myeloma patient 5 day s 
after transduction with gammaretroviruses encoding the Luc90-CD828Z .  Transductions were 
carried out 2 days  after the cultures were started, so the T cells had been in culture for a total of 7 
days at the time of this analysis. Staining of untransduced T cells is also shown.  The plots are gated 
on live, CD3+ lymphocytes.  
We also performed a series of in vitro assays to assess the function of anti -SLAMF7 -CAR-
expressing T cells, and we found that Luc90-CD828Z -CAR-expressing T cells exhibited SLAMF7 -
specific activities including CD107a upregulation and cytokine production in vitro.  These 
experiments showed that anti-SLAMF7 -CAR-expressing T cells are activated in a SLAMF7 -
specific manner.  
 Caspase9 FKBP12               T2A CD3ζ Luc90 scFv CD28 SS CD8α
IC9-Luc90 -CD828Z       Untransduced
CD3CAR+
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
23 Figure 5 
 
Figure 5  shows upregulation of CD107a, which indicates degranulation and correlates with 
cytotoxicity  when Luc90-CD828Z  CAR-expressing CD8+ T cells  (top row)   or CD4+ T cells (bottom 
row) were cultured with the SLAMF7 -expressing cell line MM.1S .  CD107a was not upregulated 
when Luc90-CD828Z -CAR-expressing T cells were cultured for 4 hours with the SLAMF7 -negative 
control cell line NGFR -K562.  Untransduced T cells did not upregulate CD107a when cultured with 
either MM.1S  or NGFR -K562 (not shown).  The plots are gated on live CD3+ lymphocytes.    
T cells transduced with IC9-Luc90CD828Z suicide gene plus CAR construct and T cells 
transduced with the Luc90CD828Z CAR alone both  produced large amounts of IFN γ when they 
were cultured overnight with the SLAMF7 -expressing cell lines SLAMF7 -K562 and MM. 1S 
(Table 2  
).  In contrast, the anti -SLAMF7  CAR-expressing T cells  produced only background levels of IFN γ 
when they were cultured with the SLAMF7 -negative target cell lines NGFR -K562 and CCRF-
CEM.  The anti-SLAMF7 -CAR-transduced T cells also made minimal IFN γ when cultured 
without any target cell.  As expected, untransduced T cells and T cells expressing the anti -CD19 
CAR Hu19 -CD828Z released  only low levels of IFN γ in response to all target cells. The 
experiment depicted in  Table 2  
 consisted of culturing the T cells with the indicated tar get cell lines overnight and then performing 
a standard IFN γ enzyme-linked immunosorbant assay (ELISA) to detect IFN γ in the culture 
supernatant.  IC9-Luc90 -CD828Z
+MM.1SIC9-Luc90 -CD828Z
+NGFR -K562
IC9-Luc90 -CD828Z
+MM.1SIC9-Luc90 -CD828Z
+NGFR -K562CD107a
CD107aCD8 CD8
CD4 CD4
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
24 Table  2 
 
A second ELISA experiment performed in a similar manner utilizing T cells from a different 
patient is shown in Table 3  
.  In t he experimental results s hown in Table 3  
, four different types of effector T cells from the same multiple myeloma patient were evaluated, 
untransduced T cells, T cells expressing the Hu19-CD828Z  anti-CD19 CAR, T cells expressing the 
Luc90-CD828Z anti SLAMF7  CAR, and T cells expressing the IC9 suicide gene  plus Luc90 -
CD828Z plus . The untransduced T cells and T cells expressing the anti -CD19 CAR expressed only 
background levels of IFN γ against all target cells. T cells expressing either Luc90-CD828Z  or IC9-
Luc90-CD828Z specifically recognized SLAMF7  as shown by the high levels of IFN γ released when 
the CAR -expressing T cells were cultured with the SLAMF7+ target cells SLAMF7 -K562; in 
contrast, the CAR -expressing T cells produced much lower levels of IFN γ when cultured with the 
SLAMF7 -negative target cell  lines A431-H9, Panc10.05, U251, COLO205, HEPG2, A549, TC71, 
and 624. T cells alone made low levels of IFN γ for all T cell types evaluated.   
Table 3 
 
Table 4  
 shows ELISA results from an experiment in which effector T cells were cultured in the presence of 
soluble SLAMF7  protein at concentrations ranging from 0 ng/mL to 200 ng/mL.  Effector T cells  
used in this experi ment were T cells from the same patient transduced with one of 2 anti -SLAMF7 
CARs, either  Luc90-CD828Z or Luc63-CD828Z . Untransduced T cells were also assessed.   Target 
cells used in this experiment were either SLAMF7 -RPMI (RPMI8226 cel ls transduced with the 
SLAMF7 gene)  or NGFR -K562 cells, which are SLAMF7 -negative.  The T cells and target cells 
were cultured together overnight, and IFN γ was measured in the culture supernatant by a standard 
ELISA assay.  The presence of soluble SLAMF7  protein did not block recognition of the RPMI8226 
SLAMF+ target cells . SLAMF7  protein also did not cause nonspecific activation of the T cells.  All 
numbers are pg/mL IFN γ. The concentration of soluble SLAMF7 added is shown in ng/mL.  T cellsSLAMF7 -
K562 MM.1SNGFR -
K562 CCRF -CEMT cells 
alone %CAR+
Untransduced 231.4 170.5 138.2 64.7 4.9
Hu19 -CD828Z 57.0 68.6 48.1 39.0 38.6 58.2
Luc90 -CD828Z 90780.1 22519.4 22.9 19.2 18.6 83.0
IC9-Luc90 -CD828Z 76955.3 30188.4 32.9 14.2 21.1 50.2
Target 
cells
T cells SLAMF7 -K562 A431 -H9Panc
10.05 U251 COLO205 HEPG2 A549 TC71 624 T cells %CAR+
Untransduced 598.0 48.4 395.2 165.4 48.4 41.2 17.9 28.8 31.0 44.4 0.3
Hu19 -CD828Z 521.8 129.5 367.3 173.3 74.2 398.4 87.5 247.1 144.6 89.4 29.9
IC9-Luc90 -
CD828Z 77961.3 423.8 390.6 217.1 496.6 212.2 349.0 722.1 662.7 215.7 42.0
Luc90 -CD828Z 104728.5 509.7 526.3 227.5 749.0 196.8 447.9 522.9 823.2 247.5 68.1
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
25 Table 4 
 
Figure  4 presents the results of a 4 -hour cytotoxicity assay in which MM.1S  cells were used as target 
cells for either Hu19-CD828Z anti -CD19 negative -cont rol T cells , or T cells transduced with the 
anti-SLAMF7 CAR Luc90-CD828Z, or T cells transduced with the IC9 suicide gene and Luc90 -
CD828Z CAR (IC9-Luc90-CD828Z) .  MM.1S is SLAMF7+ and CD19-negative. The graph gives 
specific cytotoxicity of MM.1S  cells relative to the negative -control SLAMF7 -negative CCRF -CEM 
cell line.  T cells expressing either Luc90 -CD828Z or IC9 plus Luc90-CD828Z were able to cause 
specific cytotoxici ty of the SLAMF7+ cell line.  
Figure 6 
 
Anti-SLAMF7 -CAR-transduced T cells also proliferated in a SLAMF7 -specific manner. Figure 7 
shows a carboxyfluorescein diacetate,succinimidyl ester ( CFSE) proliferation assay in which anti -
SLAMF7 -CAR-transduced T cells were cultured for 4 days with either SLAMF7 -K562 cells or 
SLAMF7 -negative NGFR -K562 cells.  In a series of experiments, we compared 2 CAR plus suicide 
gene constructs. In Luc90-CD828Z -IC9, the sequence of the CAR is followed by the IC9 suicide 
gene. In IC9 -Luc90-CD828Z, the suicide gene sequence comes first and is followed by the CAR 
gene. CFSE was diluted to a greater degree, indicating more proliferation, when the T cells  
transduced with either of the CAR plus suicide gene constructs  were cultured with SLAMF7 -K562 
target cells (open histogram in  Figure 7) compared to when T cells were cultured with SLAMF7 -
negative NGFR -K562 target cells (solid  red histogram in Figure 7).  The solid red histogram 
representing culture of anti-SLAMF7  CAR T cells with NGFR -K562 cells is smaller than the open Target 
cells
T-cellsSLAMF7 
RPMI
0 ng/mlSLAMF7 
RPMI  
50 ng/mLSLAMF7 
RPMI  
200 ng/mLNGFR
K562 
0 ng/mLNGFR 
K562    
50 ng/mLNGFR K562    
200 ng/mLT cells
0 ng/mLT cells
50 ng/mLT cells
200 ng/mL
Luc90 -CD828Z 23538 23315 21301 267 223 224 172 160 41
Luc63 -CD828Z 3495 2873 3083 191 98 83 20 22 30
Untransduced 504 451 501 564 433 507 23 22 25
Targets alone 5 5 5 5
200 ng/mL soluble SLAMF7 
alone: 6
2 0 :16 .7 :1 2. 2: 1 0 .7 :10255075100
E :T   R a tio%  C y to to x ic ityH u19- C D 828Z
Luc90- C D 828Z
I C 9- Luc90- C D 828Z
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
26 histogram representing culture of anti-SLAMF7  T cells with SLAMF7 -K562 cells because fewer T 
cells that were cultured with NGFR -K562 were left alive at the end of the assay.   The ass ay was 
conducted as described previously. (127)  In multiple experiments, we consistently foun d equivalent 
in vitro proliferation of T cells expressing Luc90-CD828Z -IC9 compared with T cells expressing 
IC9-Luc90-CD828Z . 
Figure 7 
 
We established MM.1S  human multiple myeloma cell line tumors in immunodeficient mice.   We 
allowed sizable tumors to develop over 7  days , and  then we treated the mice with a single 
intravenous infusion of T cells transduced  with either the anti-SLAMF7 CAR Luc90-CD828Z  or T 
cells transduced with Luc90-CD828Z plus the IC9 suicide gene. Control groups included mice 
treated with untransduced T cells or T cells transduced with the anti-CD19 CAR Hu19-CD828Z.  
After infusion of anti -SLAMF7 -CAR T cells, dramatic regressions of all tumors occurred between 
day 6 and day 18 after the T cell infusion . In contrast, tumors continued to increa se in size in all 
untreated mice and mice treated with the T cells expressing the Hu19 -CD828Z anti -CD19 CAR. 
Mice receiving anti -SLAMF7 -CAR T cells survived while untreated mice and mice receiving T cells 
expressing the anti -CD19 CAR Hu19-CD828Z developed large tumors that required that the mice 
be euthanized  (Figure 8 ). In the experiments de picted in Figure 8, anti-SLAMF7 -CAR T cells were 
infused on Day 0, and no other treatments were administered, and  there were 5 mice in all groups.  
Figure 8 
 Luc90 -CD828Z -IC9
IC9-Luc90 -CD828Z
D ays af t er  T cel l  i nf usi onPer cent  Sur vi val
0 6 12 18 24 30 36020406080100
H u19- C D 828Z
I C 9- Luc90- C D 828ZLuc90- C D 828ZU n tre a te d0 3 6 9
12 15 1 8 21 2 4 27 30 3 3 3602004006008001000
D ays af t er  T cel l  i nf usi onTum or  Vol um e i n m m3
U n tre a te d
H u19- C D 828Z
I C 9- Luc90- C D 828ZLuc90- C D 828Z
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
27  
 
We conducted in vitro experiments to demonstrate the activity of AP1903 (Rimiducid) against T 
cells expressing both the Luc90 -CD828Z CAR and the inactivated caspase 9 (IC9) suicide gene. We 
transduced T cells with MSGV -IC9-Lu c90-CD828Z  and then exposed them to graded 
concentrations of AP1903 in vitro for 6 hours prior to performing flow cytometry (Figure 9). 
Application of AP1903 caused a rapid disappearance of CAR+ T cells, and most of the residual T 
cells were apoptotic as indicated by their annexin V+ status  (Figure 9). In a human clinical trial, t he 
mean peak serum concentrations of AP1903 achieved with a single dose of 0.5 mg/kg  of AP1903  
was 626 ng/mL (122 ), so the in vitro concentrations that we assess ed were substantially lower t han 
clinically -achievable concentrations.  
Figure 9 
 
 
1.2.10  Anti-SLAMF7 Therapy in MM:  
Elotuzumab, a humanized IgG1 kappa monoclonal antibody, in combination with lenalidomide and 
dexamethasone is an FDA approved therapy shown to have activity in MM in clinical trials. (117, 
118, 128) Elotuzumab exerts it’s effect through several mechanisms: elotuzumab impairs MM cell 
adhesion and exerts direct effects on primary MM cell survival in vitro; it mediates antibody -
dependent cellular cytotoxicity mediated through NK cell interaction; and it dir ectly activates NK 
cells through SLAMF7 receptor ligation. (9, 10, 129-131) In pre -clinical studies, elotuzumab did not 
exhibit cytotoxicity against NK cells. (9, 10, 129-131 )  
CD3CD3CAR+0 ng/mL                         1 ng/mL                       10 ng/mL                      100 ng/mL
0 ng/mL                           1 ng/mL                      10 ng/mL                      100 ng/mLAnnexin VRimiducid (AP1903) eliminates >90% of IC9 -Luc90 -CD828Z CAR T cells only 6 hours after exposure
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
28 As a single agent, elotuzumab did not result in objective responses in a phase 1 trial in heavily 
pretreated MM. (132 ) At doses of 10 mg/kg and 20 mg/kg elotuzumab, SLAMF7 receptors on bone 
marrow-derived myeloma cells were consistently saturated. (132) Lower dose groups exhibited more 
variation  of target cell saturation. (132) No opportunisti c viral or fungal infections were seen on any 
dose of elotuzumab used in this phase 1 trial. (132) Transient decreases in absolute lymphocyte 
counts were observed after the first elotuzumab infusion only and resolved by day 7 of follow -
up.(132) The transient decrease in lymphocytes (both SLAMF7 positive and negative NK cells, 
CD8+ T cells, CD4+ T cells and B cells) coincided with increase in IP -10 a chemokine that stimulates 
migration of activated T cells and NK cells. (132) There was no evidence of lymphocyte depletion 
associated with repeated dosing of elotuzumab and cytotoxicity was observed against MM cells but 
not against autologous NK cells. (132)  
In a phase 3 trial, the combination of elotuzumab, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed refractory MM, resulted in a 30% decrease in the risk of disease progression or death. (117, 118, 131-133
) The 1 -year PFS rate in the 
elotuzumab cohort was 68% versus 57% in the control group. (117, 118, 131-133 ) The PFS was 
maintained at the 3 year extended follow up with a trend toward improved overall survival. (117, 
118, 131-133 )  
In a phase 2 trial comparing bortezomib plus dexamethasone with the combination plus elotuzumab, PFS was statistic ally significantly longer in the elotuzumab group with a 28% reduction in the risk 
of progression of death. (118
)  
Results from pre -clinical work and clinical trials involving elotuzumab offer proof of principle that 
SLAMF7 may be a suitable target for future targeted T -cell therapy.  
1.2.11  Pre-clinical stud ies utilizing anti-SLAMF7 CAR T cells 
Several pre-clinical studies utilizing an anti-SLAMF7 CAR T -cell have been carried out. (10, 11, 13, 
116) These studies show that T cells engineered to target SLAMF7 can be expanded and have 
activity in eradicating MM cells.  
Several groups shown that MM cells from patients with untreated MM as well as relapsed/refractory 
MM express high, uniform levels of SLAMF7 on their surface despite prior proteasome inhibitor or 
immunomodulatory therapy. (9-11 , 13, 116) Mathur et al and Wang et al report that >90% of MM 
cases they tested uniformly express SLAMF7. (11, 13)  
Chu et al engineered an anti -SLAMF7 CAR with a CD28 costimulatory domain that was able to kill 
SLAMF7+ cells in MM cell lines, primary myeloma cells and mouse models. (116 ) The antigen 
density of SLAMF7+ determined the rate of killing in their experiments; in cell lines where 
SLAMF7 was expressed at low levels (RPMI8226), the anti -SLAMF7 CARs were not as effective 
at killing. (116) However, in cell lines with high expression of SLAMF7 (NCI -H929 and IM9) and 
in primary MM cells from patients with relapsed disease, the anti-SLAMF7 CAR was able to kill 
SLAMF7+ cells with high efficiency. (116) Furthermore, in a mouse model, anti -SLAMF7 CAR T 
cells suppressed growth and prolonged mouse survival; 44 days after treatment, their group observ ed 
a 100% survival rate for IM9 bearing mice receiving anti -SLAMF7 CAR T -cell infusion as 
compared with 28.6% of the control mice receiving mock T cells. (116)  
Gogishvili et al created an d tested anti-SLAMF7 CAR T cells with a CD28 costimulatory domain 
that was able to exert rapid and specific high level cytolysis of all SLAMF7+ myeloma targets in 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
29 vitro with cell lines and primary MM cells from patients with either untreated or relapsed/re fractory 
disease. (10) The anti-SLAMF7 CAR was able to eradicate systemic myeloma in a xenograft mouse 
model that was sustained until the end of the 8-week observation period. (10)  
Hypothesizing that T cells collected from MM patients are associated with anergy, Mathur et al have 
devised a system to engineer allogeneic anti -SLAMF7 CD4+ and CD8+ CAR T c ells.(11) In order 
to decrease the potential for GVHD potentially associated with allogeneic CAR -T cells, Mathur et 
al have used gene editing technology to knock out endogenous TCR genes. (11) To further limit 
toxicity, they have included an elimination gene for safety that is activated by rituximab administration .(
11) In pre -clinical studies, anti-SLAMF7 allogeneic T cells proliferate when co -
cultured with myeloma cell lines and primary myeloma tumors but not i n co-culture with control 
cells. (11) The anti-SLAMF7 allogeneic T cells eradicated established MM and induced durable 
remissions in mouse models. (11)   
Finally, Wang et al sought to enhance the immune functions of anti -SLAMF7 CAR T cells by 
expanding the CAR T cells in the presence of lenalidomide in vitro. (13) Their pre -clinical results 
demonstrate that lenalidomide enhanced antitumor activity and persistence of the adoptively transferred anti -SLAMF7 CAR T cells in vivo mouse model including improving cytotoxicity, 
memory maintenance, Th1 cytokine production and immune synapse formation. (
13)   
Due to the  expression of SLAMF7 on lymphocyte subsets and the toxicity potential with eradicating 
these lymphocytes with anti -SLAMF7 therapy, Gogishvili et al conducted a series of experiments 
aimed at determining the fratricide potential that could occur with anti-SLAMF7 CAR -T 
therapy. (10) They first demonstrated expression of the SLAMF7 protein on a fraction of naive and 
memory CD4+ and CD8+ T cells, NK and NKT cells, monocytes, and B cells that were obtained 
from the peripheral blood of MM patients. (10) After co -culture of autologous anti -SLAMF7 CAR 
T cells, they used flow -cytometry cytotoxicity assays to assess the fratricide potential. (10) They 
found that in each lymphocyte subset, a population of SLAM+high and SLAM-/low cells existed.  
Furthermore, engineered T cells reverted to a SLAMF7-/low state. CD8+ SLAMF7 -negative CAR T 
cells induced fratricide of SLAMF7+high cells but spared the SLAMF7-/low fraction of cells. (10) These 
SLAMF7-/low CD4 and CD8 lymphocytes were viable and functional based on IFN -gamma secretion 
after stimulation. (10) Their experiments demonstr ated that on average 17.3% of NK cells, 35.4% of 
CD8+ T cells, 66.5% of B cells, and 85% of CD4+ T cells were viable at the end of the fratricide 
assay with SLAMF7 -CAR T cells incubated with cell lines and primary MM cells. (10) Furthermore, 
they found that the SLAMF7-/low T cells were able to respond to specific antigens including  CMV 
after incubation with anti-SLAMF7 CAR T cells. (10) Their data suggests that altho ugh anti -
SLAMF7 CAR T -cell therapy may deplete lymphocytes that express high levels of SLAMF7, a 
subset of effector immune cells might  be preserved that will provide protection against common 
pathogens including cytomegalovirus ( CMV ).(10) Similarly, Chu et al demonstrated that although 
their engineered anti -SLAMF7 CAR T cells were able to kill high SLAMF7 expressing MM cell 
lines, the CAR -T cells were unable to effectively kill cell lines that expressed low levels of 
SLAMF7. (116)   
 
1.2.12  Summary of risks and potential benefits  
This clinical trial is being performed to evaluate a genetically -modified T -cell therapy for multiple 
myeloma, which is an almost always incurable disease.  Only pati ents with multiple myeloma who 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
30 have persisting or relapsed myeloma despite at least 3 prior lines of therapy will be enrolled. The 
risks of the study fall into six categories.   
The first category is  chemotherapy -related toxicity that could cause cytopenia s. As with any 
chemotherapy  that causes neutropenia and thrombocytopenia, this chemotherapy could cause 
toxicities such as infections and bleeding.  CAR T cells might also cause cytopenias.  
The second category of toxicity is cytokine -release-type toxicities  such as high fevers, tachy cardia, 
transient abnormalities of liver function and hypotension. These cytokine -release -type toxicities 
have been detected in other clinical trials of CAR T cells during the first two weeks after anti-CD19 
CAR T cells and anti-BCMA CAR T cells were infus ed.(4, 5, 134) 
A third category of potential toxicities are neurological toxicities such as delirium, obtundation, myoclonus, seizures, headache and transient focal neurological toxicities including aphasia and focal 
paresis. In previous anti -CD19 CAR trials, cytokine -release toxicities and neurological toxicities 
have been limited in duration with toxicities generally resolving within 2 days to 3 weeks. (5, 41, 74
, 
135, 136) In the NCI anti -BCMA trial, neurologic toxicities were limited to confusion or deliriu m 
in the setting of high fevers and one case of encephalopathy and muscle weakness of all extremities consistent with critical illness polyneuropathy/polymyopathy. (
5) In most cases, these toxicities have 
been transient with toxicities generally resolving within 2 days to 2 weeks .   
The fourth category of toxicity is direct damage to normal tissues by the CAR T ce lls.  This could 
happen because of unexpected cross -reactivity of the CAR  T cells  with proteins other than SLAMF7 
in vivo. This trial will be one of the first in human trials testing anti-SLAMF7  CAR T cells in 
patients. Although SLAMF7 is highly expressed in almost all cases of MM it has very limited or absent expression on normal tiss ues aside from leukocytes. (9, 10, 110, 112, 113
)  Hematopoietic 
stem cells do not express SLAMF7. (111) SLAMF7 is not expressed on the surface of normal org an 
epithelial tissue such as lung, kidney, stomach, brain, breast, spleen, prostate, skeletal muscle, testis, 
liver, ovary, heart, thymus and small intestine epithelial tissue. (9) We have performed extensive 
testing of the  MSGV -IC9-Luc90CD828Z CAR T cells by culturing t hem with a variety of human 
cell lines and have not seen recognition of cell lines that did not express SLAMF7. In addition, we did not find any evidence of cross -reactivity in our cell line data or immunohistochemistry data from 
the NIH Department of Path ology.  
A fifth category of toxicity that may be caused by anti -SLAMF7 T cells is impairment of normal 
immunity because SLAMF7 is expressed on leukocytes such as CD8+ T cells, natural killer (NK) 
cells, B cells, plasma cells, some monocytes, NKT cells, and  some dendritic cells. (5, 9, 10, 110, 112, 
113) NK cell deficiencies are associated with severe, potentially life-threatening viral infections 
caused typically by members of the Herpesviridae (VZV, HSV, CMV, EBV) and Papillomaviridae (HPV) families. (
137) Additionally, NK cells have potent cytotoxic activity against malignant cells 
and NK cell defects are linked to ineffective tumor surveillance and clearance. We have included a suicide gene in this trial in large part to allow elimination of anti-SLAMF7 CAR T cells in case depletion of recipient immune cells leads to infections.  
Finally, gen otoxicity is a theoretical risk of any type of integrating gene therapy. To our knowledg e, 
genotoxicity, such as occurrence of a replication -competent retroviruses or transformation of T cells 
caused by insertional mutagenesis has never occurred in a clini cal trials of T-cell gene therapies. (43, 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
31 44)  The specific gene therapy vector backbone, MSGV1, proposed for use in this clinical trial has 
been used in hundreds of patients over the past 13+ years by our group and others. (4, 33, 138, 139) 
The potential benefits  to subjects enrolling on this trial include the possibility that the anti-SLAMF7 -
CAR T cells can cause a significant anti -myeloma effect . Many patients enrolled on trials of anti -
CD19 CAR T cells and anti -BCMA CAR T cells obtained complete remissions of their advanced 
malignancies; there is a chance that recipients of the CAR-SLAMF7  T cells that are being evaluated 
in this protocol could derive a direct benefit from participation in this trial. Patients might also derive 
a benefit from knowing that they are contributing to the development of new cellular therapies for 
cancer  that might help future patients.  
1.2.13  Toxicity  
Cytokine Release Syndrom e:  
The primary acute toxicity observed to date with B cell malignancy-targeted and BCMA -targeted 
CAR T cells has been CRS, and this protocol will grade  CRS as defined by Lee et al. (201 9).(102) 
For this protocol, a CRS is defined as a constellation of symptoms which may include (but are not limited to) fever, chills, hy potension, dyspnea, hypoxia, confusion, mental status changes, seizures, 
myalgias, nausea and vomiting, and laboratory abnormali ties including elevated AST, ALT, 
bilirubin, D -dimers, ferritin, urea and/or creatinine. Treatment of a CRS will follow  the guidelines 
in 
Appendix C of th is protocol. (102) Any subject with a fever ≥100.0°F should have a work up for 
CRS. The work -up of a CRS should include hospitalization, evaluation for an infectious etiolog y 
(e.g., blood  cultures, urine culture, chest X -ray, as required), and  have blood drawn for CAR+ T cells 
and cytokine assessments along with study-outlined clinical laboratory tests.  
Immune cell depletion:  
Potential toxicities may arise from the impairment of normal immunity with anti-SLAMF7 CAR T -
cell therapy because SLAMF7 is expressed on leukocytes such as CD8+ T cells, natural killer (NK) 
cells, B cells, plasma cells, some monocytes, NKT cells, and some dendritic cells. (5, 9, 10, 110, 112, 
113)  
NK Cell Depletion: NK cells are lymphocytes of the innate immune system that mediate cytotoxic 
killing via germline encoded activation receptors. (140) SLAMF7 is expressed on all NK cells; 
however, it is expressed on CD56dimNK cells uniformly and at a higher level than on 56brightNK 
cells. (9, 112, 114, 120, 141) CD56dimNK cells comprise about 90% of circulating NK cells and are 
thought to be the mature subset of NK cells; they have the most potent cytotoxic effects. (140, 142) 
CD56brightNK cells are thought to represent immature NK cells that are precursors of the CD56dim 
subset; CD56brightCD16- NK cells cultured in the presence of skin fibroblasts differentiate into and 
have the characteristic phenotype and functional features of peripheral blood CD56dimNK cells. (140, 
142) Gogishvili et al observed that 17% of NK cells were still viable after incubation with anti-
SLAMF7 CAR T cells. (10) Hematopoietic stem cells do not express SLAMF7. Thus,  in the presence 
of peripheral destruction  of NK cells  by anti -SLAMF7 CAR T cells, the bone marrow should be able 
to produce new NK cells. In addition, CD56brightNK cells may differentiate into cytotoxic NK cells 
with appropriate stimulation. (140, 142) 
Although it is unclear to what level NK cell depletion will occur with anti-SLAMF7 CAR T -cell 
therapy, there is a risk of clinically relevant NK cell deficiency occurring with this therapy. NK cells 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
32 are important for protection against viral infections and in tumor cell surveillance; recently, their 
importance in immunoregulation and coordination of immunity has been elucidated. (140) NK cell 
deficiencies are associated with severe, potentially life-threatening viral infections caused by 
typically benign members of the Herpesviridae (VZV, HSV , CMV, EBV) and Papillomaviridae 
(HPV) families. (137) Additionally, NK cells have potent cytotoxic activity against malignant cells 
and NK cell defects are linked to ineffective tumor surveillance and clearance. (143)  During 
malignant transformation of cells, host -stress molecules are upregulated; NK cells can recognize 
these antigens, leading to destruction of the transformed cell. ( 143) 
Therapeutic approaches to NK cell depletion focus on monitoring for viral infections and malig nant transformation as well as prophylactic treatment with antiviral drugs that target the Herpesviruses such as acyclovir, ganciclovir and related agents. (137
) Prior to enrollment, all patients will be 
screened for current HSV/CMV/EBV infections by history and through laboratory work. Once enrolled,  patients will have CMV PCR checked prior to treatment initiation, once a week during 
required hospitalization and at each follow -up appointment.  Patients will be treated with standard 
anti-viral agents.  If a patient were to have a severe infection from a member of either the 
Herpesviridae or Papillomaviridae families associated with NK cell deficiency  the patient will be 
treated with Rimiducid, the dimerizer drug, that will signal apoptosis of the active anti-SLAMF7 CAR T cells.  
CD8+ T -cell depletion :  De pletion of CD8+ T cells may occur with anti -SLAMF7 therapy. 
Gogishvili et al observed that 35.4% of CD8+ T cells were still viable after incubation with anti -
SLAMF7 CAR T cells. (10) In addition, the viable T cells were found to have specificity and able to 
exact killing of viral pathogens such as CMV. (10) Depletion of CD8+ T cells may reduce the capacity 
for cytotoxic killing of pathogens.  
Monocyte and dendritic cell depletion:  A small subset of monocytes and some dendritic cells 
express SLAMF7. We do not anticipate a complete depletion of monocytes from anti -SLAMF7 CAR 
T cell therapy; however, patients will be carefully monitored for signs of infections . Peripheral 
monocytes will be measured daily during hospitalization and at each follow -up visit.  
B cell depletion : A potential toxicity caused by anti -SLAMF7 CAR T cells damaging normal cells 
is hypogammaglobulinemia due to depletion of plasma cells and a subset of matur e B cells. 
Hypogammaglobulinemia has been a complication for many patients on clinical trials of anti -CD19 
CAR-expressing T cells and anti -BCMA T cells. (4, 41)  We do not expect the same level of B cell 
depletion as prior anti -CD19 CAR T -cell trials as only a fraction of B -cells express SLAMF7. 
Hypogammaglobulinemia in patients treated with anti-CD19 CAR T -cell trials were routinely 
infused with  intravenous immunoglobulins. (4)   
1.2.14  Rationale for immunosuppressive chemotherapy and selection of lymphocyte -depleting 
chemotherapy regimen  
We plan to administer a conditioning chemotherapy regimen of cyclophosphamide and fludarabine 
before infusions of CAR-expressing T cells because substantial evidence demonstrates an 
enhancement of the anti -malignancy activity of adoptively -transferred T cells when chemotherapy 
or radiotherapy are administered be fore the T cell infusions. (14, 16, 144)  In mice, administering 
chemotherapy or radiotherapy prior to infusions of tumor -antigen -specific T cells dramatically 
enhanced the anti -tumor efficacy of the transferred T cells. (14, 16, 34, 35, 144, 145)  Administering 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
33 chemotherapy or radiotherapy enhances adoptive T -cell therapy by multiple mechanisms including 
depletion of regulatory T cells and elevati on of T -cell stimulating serum cytokines including 
interleukin -15 (IL -15) and interleukin-7 (IL -7), and possibly depletion of myeloid suppressor cells 
and other mechanisms. (14, 16, 145, 146)  Removal of endogenous “cytokine sinks” by depleting 
endogenous T cell s and natural killer cells caused serum levels of important T -cell stimulating 
cytokines such as IL-15 and IL -7 to increase, and increases in T -cell function and anti -tumor activity 
were dependent on IL -15 and IL -7.(14)  Experiments in a murine xenograft model showed that 
regulatory T cells could impair the anti-tumor efficacy of anti -CD19 CAR T cells. (102)  Myeloid 
suppressor cells have been shown to inhibit anti -tumor responses. (146)  Experiments with a 
syngeneic murine model showed that lymphocyte -depleting total body irradiation (TBI) 
administered prior to infusions of anti -CD19 -CAR-transduced T cells was required for the T cells to 
cure lymphoma. (15)   In these experiments, some mice received TBI, and other mice did not receive 
TBI.  All mice were then challenged with lymphoma and treated with syngeneic anti -CD19- CAR T 
cells.  Mice receiving TBI  had a 100% cure rate and mice not receiving TBI had a 0% cure rate. (15)  
Strong suggestive evidence of enhancement of the activity of adoptively-transferred T cells has been 
generated in humans. (20, 39, 147)  Very few clinical responses have occurred and very little 
evidence of in vivo activity has been generated in clinical trials of anti -CD19-CAR T cells 
administered without lymphocyte -depleting chemotherapy. (39, 42)  In contrast, many regressions 
and evidence of long -term B -cell depletion have occurred in clinical trials in which patients received 
anti-CD19-CAR T cells after lymphocyte -depleting chemotherapy. (3, 4, 41, 60)   The chemotherapy 
regimen that best increases the anti -malignancy efficacy of CAR -expressing T cells is not known, 
but the most commonly used chemotherapy regimens that have been used in cli nical trials and that 
convincing ly demonstrate persistence and in vivo activity of adoptively transferred T cells have 
included cyclophosphamide and fludarabine. (3, 4, 40, 41, 147, 148)  Both cyclophosphamide and 
fludarabine are highly effective at depleting lymphocytes. (147, 148)  One well -characterized and 
commonly used regimen is the combination of 300 mg/m2 of cyclophosphamide administered daily 
for 3 days and fludarabine 30 mg/m2 administered daily for three days on the same days as the 
cyclophosphamide. (149)  Multiple cycles of this regimen can be tolerated by heavily pretreated 
leukemia patients. (74, 149)    
The chemot herapy regimen that will be used in this protocol is cyclophosphamide 300 mg/m2 and 
fludarabine 30 mg/m2 given daily on days -5 to -3 followed by an infusion of CAR T cells on day 
0.(5)  This same chemotherapy regimen has been used in previous clinical trials.  
 
1.2.15  Rationale for dose -escalation and starting dose  
The clinical trial described in this protocol is planned as a dose escalation in which the number of 
anti-SLAMF7 CAR T cells administered to patients will be increased with sequential dose levels.  
The rationale for conduc ting a dose -escalation trial of a cellular therapy is based on two main sources 
of evidence.  First, the anti -tumor efficacy of adoptively-transferred T cell treatments increases as 
the dose of T cells administered to mice increases. (150-152)  Second, in the setting of allogeneic 
transplantation, relapsed malignancy is often treated with infusions of allogeneic donor lym phocytes 
(DLIs).( 153, 154)  The incidence of graft -versus -host disease, which is caused by T cells attacking 
allogeneic antigens on host t issues, increases as  the dose of T cells administered in DLIs 
increases’. (153, 154)  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
34 The starting CAR T-cell dose of 0. 66x106 CAR+ T cells/kg is based on experience in past CAR 
clinical trials.  The 0.75x106 CAR+ T cells/kg dose is considered a dose lower than that at which 
substantial toxicity has been observed.  The following clinical trials were used to guide the starting 
dose of this trial.  Note that it was our goal to use a dose lower than the MTD of prior trials.  NCI protocol 09-C-0082 (Kochenderfer et al Journal of Clinical Oncology, 2017), a trial of anti -CD19 
CAR T cells had an MTD of 2x10
6 CAR+ T cells /kg.(74)  NCI protocol 14-C-0168, a trial of anti -
BCMA CAR T cells had an MTD of 9x106 CAR+ T cells/kg. (5)  NCI protocol number 16-c- 0054, a 
trial of anti-CD19 CAR T cells started at a dose of 0.66x106 CAR T cells/kg, and the maximum dose administered on this trial was 6x10
6 CAR T cells/kg. A multicenter trial of anti-BCMA CAR 
T cells conducted by bluebird bio and Celgene Inc. determined that a flat dose of 150-450 x106 
CAR+ T cells was the optimal dose for the expansion phase of the study (unpublished results).  The 
450 x 106 flat dose of CAR T cells would be 4.5x106 CAR+ T cells/kg for a 100 kg patient.   
 
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT  
2.1 ELIGIBILITY CRITERIA  
Note: if a patient meets an eligibility requirement as outlined below and is enrolled on the protocol 
but then is f ound to no longer meet the eligibility requirement after enrollment but before the start 
of protocol treatment, the treatment will be canceled or delayed until eligibility criteria are met.  
2.1.1 Inclusion Criteria  
2.1.1.1  Multiple Myeloma criteria  
• SLAMF7 expression must be detected on malignant plasma cells from either bone marrow 
or a plasmacytoma by flow cytometry or immunohistochemistry.  A specific quantitative 
level of SLAMF7 expression for eligibility is not specified, but patients with multip le 
myeloma cells that are negative for SLAMF7  by flow cytometry and immunohistochemistry 
will not be enrolled.  These assays must be performed at the National Institutes of Health 
(NIH).  It is not required that the specimen used for SLAMF7  determination c omes from a 
sample that was obtained after the patient’s most recent treatment.  If paraffin embedded unstained samples of bone marrow involved with MM or a plasmacytoma are available, these can be shipped to the NIH for SLAMF7  staining, otherwise new biopsies will need to be 
performed for determination of SLAMF7  expression.  
• SLAMF7  expression will need to be documented on the majority of malignant plasma cells 
by flow cytometry at the NIH at some time after the original CAR-SLAMF7  T-cell infusion 
in all patients undergoing a second CAR-SLAMF7  T-cell infusion  on this clinical trial.   
• Bone marrow plasma cells must make up less than  or equal to 50% of total bone marrow 
cells based on a bone marrow biopsy performed within 24 days of the start of protocol 
treatment.  
• Patients must have received at least 3 different prior treatment regimens for multiple myeloma  
• Must have prior exposure to an immunomodulatory drug  (IMiD ) such as len alidomide and a 
proteasome inhibitor  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
35 • Patients must have measurable MM as defined by at least one of the criteria below.  
 Serum M -protein greater or equal to 0.6  g/dL.  
 Urine M -protein greater or equal to 200 mg/24 h.  
 Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL 
(100 mg/L) provided serum FLC  ratio is abnormal.  
 A biopsy-proven plasmacytoma  at least 1.5 cm in largest dimension  
 Bone marrow core biopsy with 30% or more plasma cells  
 
2.1.1.2  Other inclusion criteria:  
• Greater than or equal to 18 years of age and less than or equal to age 73.  
• Able to understand and sign the Informed Consent Document.  
• Clinical performance status of ECOG 0 -2 
• Patients of both sexes must be willing to practice birth control from the time of enrollment 
on this study and for four months after last day of receiving protocol treatment.  
• Seronegative for HIV antibody.  (The experimental treatment being evaluated in this protocol depends on an intact immune system.  Patients who are HIV seropositive can have decreased 
immune -competence and thus are less responsive to the experimental treatment and more 
susceptible to its toxicities.)  
• A patient with a negative blood PCR test for hepatitis B DNA test can be enrolled. If hepatitis 
B DNA (PCR) testing is not available, patients with a negative hepatitis B surface antigen 
and negative hepatitis B core antibody can be enrolled.  
• Patients must be tested for the presence of Hepatitis C antigen by PCR and be HCV RNA negative in order to be eligible.  Only if Hepatitis C PCR testing is not available in a timely 
manner, pa tients who are Hepatitis C antibody -negative can be enrolled.  
• Absolute neutrophil count greater than or equal to 1000/mm
3 without the support of 
filgrastim or other growth factors within the previous 10 days.   
• Platelet count greater than or equal to 55,00 0/mm3 without transfusion support  in the past 14 
days .  
• Hemoglobin gr eater than  or equal to 8.0 g/dL .   
• Less than 5% plasma cells in the peripheral blood leukocytes  
• Serum ALT and AST less or equal to 2.5 times the upper limit of the institutional normal.  
• Serum creatinine less than or equal to 1. 5 mg/dL.  
• Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert’s Syndrome who must have a total bilirubin less than 3.0 mg/dL.  
• At least 14 days must have elapsed since any prior systemic t herapy at the time the patient 
starts the cyclophosphamide and fludarabine conditioning regimen, and patients’ toxicities 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
36 must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo  or 
cytopenias ).  
• Because this protocol requires collection of autologous blood cells by leukapheresis in order 
to prepare CAR-SLAMF7  T cells, systemic anti-myeloma therapy including systemic 
corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of 
another cortic osteroid are not allowed within 14 days  prior to the required leukapheresis.  
• Normal cardiac ejection fraction (greater than or equal to 50% by echocardiography) and no evidence of hemodynamically significant pericardial effusion as determined by an echocar diogram.  
• For patients with past participation in gene -therapy, cryopreserved PBMC that have not been 
genetically -engineered must be available.  
• Patients receiving prior gene therapy outside of NIH will not be eligible.  Patients who 
previously received CAR T -cell therapy at the NCI will be potentially eligible.  
 
2.1.2 Exclusion criteria:  
2.1.2.1  Patients who are receiving any other  investigational agents.  
2.1.2.2  Patients on any anticoagulants except aspirin 
2.1.2.3  Patients that require urgent therapy due to tumor mass effects or spinal cord compression.  
2.1.2.4  Patients that have active hemolytic anemia.  
2.1.2.5  Patients with second malignancies in addition to multiple myeloma are not eligible if the 
second malignancy has required treatment within the past 3 years or is not in complete 
remission.  There are two exceptions to this criterion:  successfully treated non -metastatic 
basal cell or squamous cell skin carcinoma.    
2.1.2.6  Women of child-bearing potential who are pregnant or breastfeeding because of the 
potentially dangerous effects of the preparat ive chemotherapy on the fetus or infant.   
Women of child bearing potential cannot have a positive  pregnancy test.  Women of child -
bearing potential are defined as all women except women who are post -menopausal or who 
have had a hysterectomy. Postmenopausal  will be defined as women over the age of 55 
who have not had a menstrual period in at least 1 year.  
2.1.2.7  Active systemic infections (defined as infections causing fevers or requiring anti-microbial treatment), active coagulation disorders or other major uncont rolled  illnesses of the 
cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary, neurologic,  
psychiatric, or immune system, history of myocardial infarction, active cardiac 
arrhythmias, active obstructive or restrictive pulmonary di sease.  
2.1.2.8  Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).  
2.1.2.9  Systemic corticosteroid steroid therapy of greater than 5 mg/day of prednisone or equivalent dose of another corticosteroid  (prednisone, dexamethasone, etc. ) is not allowed 
within 14 days  prior to either the required leukapheresis or within 14 days  prior to CAR T -
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
37 cell infusion  (and at any time after the CAR T cell infusion  unless approved by the Principal 
Investigator or an As sociate Investigator ). 
2.1.2.10  History of severe immediate hypersensitivity reaction to any of the agents used in this study.  
2.1.2.11  Patient unwilling to undergo intensive care unit treatment including mechanical ventilation, 
cardiopulmonary resuscitation, vasoactive drugs, and hemodialysis.  
2.1.2.12  History of allogeneic stem cell transplantation  
2.1.2.13  Patients with  current spinal cord compression  (without intradural myeloma involvement . 
2.1.2.14  Patients who have a history (or current evidence) of cerebrospinal fluid multiple myel oma, 
or intra -dural central nervous system masses . 
2.1.2.15  Patients with active autoimmune skin diseases such as psoriasis or other active autoimmune diseases such as rheumatoid arthritis.  
2.1.2.16  Patients must not have required supplemental oxygen within the past month unless it was for a resolved infection.  
2.1.3 Recruitment Strategies  
This protocol may be abstracted into a plain language announcement posted on the NIH 
websites  and on NIH social media  forums , or from other patients through social media  
platforms. Participants will be recruited from the current patient population at NIH, and local 
community physicians .  
2.2 S
CREENING EVALUATION  
2.2.1 Screening activities performed prior to obtaining informed consent  
Minimal risk activities that may be performed before the subject has sign ed a consent include the 
following:  
• Email, written, in person or telephone communications with prospective subjects  
• Review of existing medical records to include H&P, laboratory studies, etc.  
• Review of existing MRI, x -ray, or CT images  
• Review of existin g photographs or videos  
• Review of existing pathology specimens/reports from a specimen obtained for diagnostic  
purposes.  
2.2.2 Screening activities performed after a consent for screening has been signed  
Note: Screening evaluation testing/procedures are conducted under the separate screening protocol, 
01-C-0129 (Eligibility Screening and Tissue Procurement for the NIH Intramural Research 
Program Clinical Protocols) . 
The following assessments must be completed within 30 days  prior to  starting the 
chemotherapy conditioning regimen unless otherwise noted (if not, then the evaluation must 
be repeated):  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
38 • Complete history and physical examination, including weight, vital signs, ECOG, details 
about the exact size and location of any evaluab le lesions that exist.  
• Confirmation of diagnosis of MM by the NCI Laboratory of Pathology and confirmation of SLAMF7  expression on malignant plasma cells from either bone marrow or a plasmacytoma 
by flow cytom etry or immunohistochemistry.  The sample used  for this SLAMF7  expression 
analysis can come from any time prior to enrollment on the protocol.  
• Bone marrow aspirate and biopsy; specifically ask for SLAMF7  immunohistochemistry  
staining of the bone marrow biopsy.  Order cytogenetics with interphase FISH (pretreatment 
aspirate only)  and flow cytometry  on the bone marrow aspirate. Specifically request 2 
separate bone holes for bone marrow aspiration.  The aspirate for hemepath (0.5 mL) and 
flow (2 -2.5 mL) should be done from 1 bone hole and the aspirate for  research (2 -2.5 mL) 
should be done from a second bone hole followed by an aspirate for cytogenetics ( 2-4 mL) 
from the second bone hole. Note: Only bone marrow aspirates done before CAR T -cell 
treatment and 2 weeks after CAR T -cell infusion require aspirates through 2 bone holes.  All 
other aspirates only need to be done through 1 bone hole.     
The bone marr ow biopsy must take place at some time after the patient’s most recent 
myeloma treatment.  If the patient agrees to future use of specimens when screening bone marrow is obtained, reserve one tube of bone marrow aspirate to be sent to the  Surgery 
Branch Ce ll Production Facility SB -CPF. Bldg. 10 , 3W-3808, Phone: 240-858-3755  Bone 
marrow aspirate cells and supernatant will be cryopreserved. As many vials as possible with 10 million cells or less will be cryopreserved, and 2 vials of supernatant with 0.5 to 1 mL each will be cryopreserved. A bone marrow biopsy must be perfor med within 2 4 days of the 
start of the protocol -required conditioning chemotherapy.  If this screening bone marrow 
aspirate and biopsy is performed within 24 days of the start of the conditi oning 
chemotherapy, a second baseline bone marrow biopsy does not need to be performed.  
• Flow cytometry staining of bone marrow or plasmacytoma cells for SLAMF7  should be 
performed by Dr. Stetler -Stevenson’s lab (NCI Laboratory of Pathology).  
• MRI of spine and pelvis (only if clinically indicated in patients with back pain or pelvic pain or a history of plasmacytomas of spine or pelvic)  
• MRI of the brain  
• CT scans  of areas with possible lesions/plasmacytomas . This may include areas such as the 
head, neck, che st, abdomen and pelvis.  (performed only if necessary,  to document 
measurable malignancy in the event of no other miserable disease in blood, urine and bone marrow). 
• Venous assessment  for apheresis (Valid for up to 6 months before apheresis collection, does  
not need to be performed if cells have been previously collected)  
• DNA (PCR) for Hepatitis B and C; antibody testing for HIV, HTLV -I/II, T. cruzi (Chagas 
agent), West Nile, and syphilis (RPR), only if DNA testing is not available, order  Hepatitis 
C antibody, order Hepatitis B core antibody, and hepatitis B surface antigen.  
• EKG  
• Echocardiogram  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
39 • (Sodium (Na), Potassium (K), Chloride (Cl), Total CO2 (bicarbonate), Creatinine, Glucose, 
Urea nitrogen (BUN), Albumin, Calcium total, Magnesium total (Mg), Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Total CK, Uric Acid)  
• CBC with differential and platelet count 
• Serum immunofixation electrophoresis  
• Serum immunoglobulin free light chains  
• 24-hour urine collection with immunofixation electrophoresis as clinically indicated  
• Glucose -6-phosphate dehydrogenase (G6PD) deficiency screening  
• TSH, T4, and T3 
• Serum Cortisol  
• PT/PTT 
• β-HCG pregnancy test (serum or urine) on all women of child-bearing potential  
2.3 PARTICIPANT REGISTRATION AND STATUS UPDATE  PROCEDURES  
Registration and status updates (e.g. w hen a participant is taken off protocol therapy and when a 
participant is taken off -study) will take place per CCR SOP ADCR -2, CCR Participant 
Registration & Status Updates found here. 
2.4 TREATMENT ASSIGNMENT PROCEDURES  FOR THE REGISTRATION PURPOSES ONLY: 
Cohorts:   
Number  Name  Description  
1 Cohort 1 Subjects enrolled to determine the MTD  
2 Cohort 2 Subjects enrolled after the MTD has been 
identified  
 
Arms:   
Number  Name  Description  
1 Conditioning 
chemotherapy plus CAR T-cells dose escalation  Patients will receive escalating doses (up to 4 planned) of Anti -
SLAMF7 -CAR+ T cells infused on day 0 + Cyclophosphamide: 
300 mg/m
2 IV infusion over 30 minutes on days -5, -4 and -3 + 
Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered 
immediate ly following the cyclophosphamide on days -5, -4, and  -
3 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
40 Number  Name  Description  
2 Conditioning 
chemotherapy plus CAR T-cells expansion phase  MTD dose of Anti-SLAMF7 - CAR T Cells + Cyclophosphamide: 
300 mg/m
2 IV infusion over 30 minutes on days -5, -4 and -3 + 
Fludarabine: 30 mg/m2 IV infusion over 30 minutes administered 
immediately following the cyclophosphamide on days -5, -4, and  -
3 
Arm Assignment:  
Patients in cohort 1 will be directly assigned to arm 1  
Patients in cohort 2 will be directly assigned to arm 2  
 
3 STUDY IMPLEMENTATION 
3.1 STUDY DESIGN  
3.1.1 General study plan   
This protocol is a phase I dose -escalation study of autologous T cells that are genetically modified 
to express an  anti-SLAMF7  CAR. 
The protocol will enroll patients with multiple myeloma previously treated with  at least 3 prior lines 
of therapy.  Patients will be evaluated for general health, and multiple myeloma staging will be 
carried out.  An assessment of SLAMF7  expression will be an important part of the eligibility 
screening.  Patients enrolled on the study will undergo leukapheresis, and anti -SLAMF7 -CAR-
expressing T cells will be generated by transducing the patient’s T cells with a gamma retrovirus  
encoding the anti-SLAMF7  CAR.  Pa tients will receive a conditioning chemotherapy regimen of 
cyclophosphamide 300 mg/m2 daily for 3 days and fludarabine 30 mg/m2 IV daily for 3 days on the 
same days.  This is an extensively used  chemotherapy regimen  that can be easily administered on an 
outpatient basis.  Two days after the end of the conditioning chemotherapy, patients will receive a single infusion of anti -SLAMF7 -CAR-expressing T cells.  A minimum 9 -day hospitalization will be 
required after the cell infusion to monitor closely for acute toxicities.   It is expected that some 
patients will need to be hospitalized for up to 30 days to allow all toxicities to resolve to the point 
that discharge from the hospital is prudent.  Patients are required to stay within 60 minutes driving 
time from the Clinical Center until day 14 after the CAR T-cell infusion.    Patients will then be 
evaluated for toxicity and multiple myeloma will be staged 2 weeks and 1, 2, 3, 4, 6, 9, and 12 
months after the infusion.   They will be followed every 6 months aft erwards for at least 3 years.  
A small number of subjects may be eligible for re -enrollment if a patient is removed from the 
protocol before completing protocol treatment; or the patient is going to receive a second treatment.  
These patients would be requi red to meet all eligibility criteria at the time of re -enrollment.  Patients 
will be assigned a new sequential study number for the reenrollment study period.  Any 
cryopreserved anti -SLAMF7  CAR T cells produced from a patient who was removed from the study 
can be used to treat that patient after re-enrollment.   We do not anticipate changes in the risk profile 
for the initial versus re -enrollment . 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
41 3.1.2 Protocol schema  
 
  
               
Leukapheresis  
In vitro generation of  
Anti-SLAMF7 -expressing  
T cells (7 -9 days); cryopreservation  
Pretreatment staging/Baseline  
Infusion of recipient with  
Anti-SLAMF7 -CAR-expressing T -Cells  
(Inpatient for 9-days minimum post 
infusion)  
Potential repeat treatments for patients with 
persistent myeloma  Follow -up 2 weeks and 1, 2, 3, 4, 6, 9, and 12 
months post -infusion.  Then every 6 months 
up to 3 years post -infusion.  Outpatient or inpatient 
cyclophosphamide plus fludarabine 
conditioning chemotherapy Patient Eligibility evaluation  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
42 3.1.3 Dose Limiting Toxicity -the dose limiting toxicity assessment period is 28 days.  
DLTs are defined as follows (Note that DLTs will not occur in patients who do not receive CAR T -
cell infusions but do receive the conditioni ng chemotherapy):  
o Non-cardiac and non -neurologic Grade 3 toxicities  possibly or probably or definitely 
related to the CAR T cells and lasting more than 9 days  with exceptions below.  
o Grade 4 toxicities possibly or probably or definitely related to the CAR T  cells.  
o Grade 5 toxicities possibly or probably or definitely related to CAR T cells.  
o Grade 3 hypotension or hypoxia  (Appendix F) occurring in the setting of grade 3 CRS  (as 
graded according to  Appendix F) and lasting more than 72 hours will be a DLT for the 
first 2 subjects on study.  
o Grade 3 cardiac and neurologic adverse events lasting more than 72 hours will be DLTs 
except for those included in the list below.  
 
The following grade 3 and 4 toxicities will not be DLTs: 
o Neutropenia (ANC ≤500/µL) lasting 10 days or less is not a DLT 
o Neutropenia with an ANC>500/mL is not a DLT  
o Anemia (Hgb<8 g/dL) lasting 10 days or less is not a DLT  
o Anemia with Hgb greater than or equal to 8 g/dL is not a DLT  even if blood transfusions 
are required  
o Transfusion-dependent thrombocytopenia lasting 28 days or less is not a DLT 
o Thrombocytopenia that is not transfusion -dependent is not a DLT  
o Hypotension requiring continuous treatment with 3 µg/minute or less of norepinephrine 
for 72 hours or less is not a DLT.   
o Grade 3 hypotension or hypoxia occurring in the setting of CRS ( Appendix F) lasting 
more than 72 hours in patients treated after the first two patients on study will not be a 
DLT.  
o Fever is not a DLT.  
o All cytopenias except neutropenia, anemia, and thrombocytopenia are not DLTs  
o Asymptomatic  electrolyte disturbances  regardless of grade are not DLTs  
o Prolonged QT interval as long as ventricular arrhythmias do not occur is not a DLT 
o Grade 3 creatine kinase elevation is not a DLT  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
43 o Infections controlled by antibiotics are not DLTs  
o Grade 3 concentration impairment is not a DLT  
o Grade 3 dysesthesia is not a DLT  
o Grade 3 dysphasia is not a DLT  
o Grade 3 headache is not a DLT  
o Grade 3 memory impairment is not a DLT  
o Grade 3 paresthesia is not a DLT  
o Grade 3 syncope (only 1 uncomplicated resolved event) is not a DLT  
o Grade 3 atrial fibrillation is not a DLT  
o Grade 3 s inus bradycardia is not a DLT  
o Grade 3 sinus tachycardia is not a DLT  
3.1.4 Dose Escalation  
The trial will be a dose -escalation with 4 dose levels based on the patient’s actual  bodyweight.  Each 
dose will be limited to the number of cells that would be administered up to a 120 kg patient.  
 
Dose Escalation Schedule  
Dose Level  Dose of IND Agent  
Level -1 0.3x106 Anti-SLAMF7 -CAR + T cells per kg of recipient 
bodyweight  
Level 1  0.66x106 Anti-SLAMF7 -CAR + T cells per kg of recipient 
bodyweight  
Level 2  2.0x106 Anti-SLAMF7 -CAR + T cells per kg of recipient 
bodyweight  
Level 3  6.0x106 Anti-SLAMF7 -CAR + T cells per kg of recipient 
bodyweight   
Level 4 12.0x106 CAR+ T cells per kg of recipient bodyweight  
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
44 A minimum of 3 patients  will be enrolled at each dose level.   There will be a minimum of 9 days 
between the CAR T -cell infusion of a patient and the  start of the conditioning chemotherapy regimen 
for the next  patient.   
There will be a 28-day  interval between the first and second patient treated on study. A minimum of 
14 days will elapse between the second and third patient on the first dose level. After com pleting the 
1st dose level, we will contact the FDA about  potentially  having a  14-day interval between the first 
and second patient on subsequent dose levels on a case by case basis.   
If sufficient cells cannot be grown to meet the criteria for the assigned dose level , the treatment will 
be cancelled .  A second attempt will be made to prepare cells for the patient , if the patient agrees 
and if the patient still meets all eligibility criteria. If insufficient cells are  left over from the first cell 
production attempt, a second apheresis will be needed.  
Should none of the first 3 patients treated on a dose level experience a DLT, the first patient can be 
infused on the next higher dose level after a 28 -day delay following CAR T -cell infusion of the third 
patie nt.  Should 1 of 3 patients experience a dose limiting toxicity at a particular dose level, three 
more patients would be treated at that dose level. If 1/6 patients have a DLT at a particular dose 
level, the first patient can be infused on the next higher dose level after a 28 -day delay following 
CAR T -cell infusion of the 6th patient.  If a level with 2 or more DLTs in 3 -6 patients has been 
identified, 3 additional patients will be accrued at the next-lowest dose for a total of 6, in order to 
further characterize the safety of the  MTD .   
Any dose level with 3 treated patients and no DLTs can be expanded to 6 patients at the PI’s discretion to better understand toxicity of this dose level prior to proceeding to the next higher dose 
level.  After the 6 patients  are treated, the dose can be escalated to the next higher dose level if 0/6 
or 1/6 DLTs occur. If 2 or more DLTs occur, the cell dose must be reduced to the next lower dose 
level.  
If 2 of 3 patients on Dose level 1 experience DLTs, accrual will proceed on  dose level -1.  
The MTD  is the dose at which a maximum of 1 of 6 patients has a DLT.  After an  MTD  is defined, 
additional patie nts can be treated at the MTD .  Up to 12 total additional recipients can be treated 
after an MTD is established  to more completely characterize toxicity of the MTD .  If cell growth 
limitations preclude administration of the MTD , the patient will receive as many cells as possible up 
to the MTD .  If it proves to be technically impossible or impractical to achieve the higher dose levels 
due to cell production constraints and an  MTD has not been reached, the highest achievable dose 
level will be declared the maximum feasible dose.   
Dose escalation  will follow the rules outlined in the Table below : 
 
Number of Patients with 
DLT 
at a Given Dose Level  Escalation Decision Rule  
0 out of 3  Enter up to 3 patients at the next dose level  
> 2 Dose escalation will be stopped.  This dose level will 
be declared the maximally administered dose (highest 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
45 Number of Patients with 
DLT 
at a Given Dose Level  Escalation Decision Rule  
dose administered).  Up to three (3) additional patients 
will be entered at the next lowest dose level if only 3 
patients were treated previously at  that dose.  
1 out of 3  Enter up to 3 more patients at this dose level.  If 0 of 
these 3 patients experience DLT, proceed to the next 
dose level.  If 1 or more of this group suffer DLT, then 
dose escalation is stopped, and this dose is declared 
the maximally  administered dose.  U p to three (3) 
additional patients will be entered at the next lowest 
dose level if only 3 patients were treated previously at that dose.  
<1 out of 6 at the highest 
dose or 1 level below the 
maximally administered 
dose  This is the MTD and is generally the recommended 
phase 2 dose.  At least 6 patients must be entered at 
the recommended phase 2 dose.  
 
 
3.2 DOSE MODIFICATIONS /DELAY  
Other Toxicity: 
o Patients may have a delay in planned treatment  if they have a ctive infections defined as 
infections causing fevers or infections requiring intravenous anti-microbial therapy that arise 
while patients are on -study but before the CAR T -cell infusion; however , such patients are 
eligible for treatment if they meet all eligibility criteria after the infection resolves.   
o If a patient experiences a grade 3 or greater toxicity (with the exception of cytopenias 
including neutropenia, lymphopenia, anemia, or thrombocytopenia) while on -study before 
the CAR T -cell infusion, the CAR T-cell infusion must be delayed until the toxicity improves 
to a grade 2 or less.  Exceptions to this w ould be if the grade 3 toxicity was present at baseline 
or related to progressing disease.  
3.3 DRUG ADMINISTRATION  
3.3.1 Leukapheresis  
The patient will undergo a 15 to 20 - liter leukapheresis will be processed in the Department of 
Transfusion Medicine (DTM) Dowling Apheresis Clinic according to DTM standard operating 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
46 procedures.  The procedure requires dual venous access and  takes approximately 3-4 hours to 
complete.  A central line will be placed if peripheral venous access is not sufficient.  
3.3.2 Anti-SLAMF7 -CAR-expressing T -cell preparation  
After cells are obtained by apheresis, further cell processing to generate CAR -expressing T cells will 
occur in the DTM according to standard operating procedures (SOPs).  Either freshly collected  cells 
or cryopreserved cells can be used to initiate the cell -preparation process.   Peripheral blood 
mononuclear cells will be isolated. Sufficient cells for a complete cell production will be retained in 
the Department of Transfusion Medicine; the excess cells will be sent to the Surgery Branch Cell 
Production Facility (SB-CPF), Bldg. 10, Room:  3W-3808, Phone: 240-858-3755  for 
cryopreservation at 100 to 300 million PBMC per vial.   These cells will be us ed in research.    The 
anti-CD3 monoclonal antibody OKT3 will be used to stimulate T -cell proliferation. Two  days after 
the start of the T-cell cultures, the cells will be transduced by exposing them to a supernatant 
containing replication -incompetent gamm a retroviruses  encoding the CAR.  The cells will continue 
to proliferate in culture .  The total cell production process will take 7 to 9 days before cells are 
cryopreserved.  Ten vials of the infused cells will be cry opreserved and stored in the Surgery Branch 
Cell Production Facility SB -CPF.  Each vial will contain  10- 20 million cells.  
Before infusion, the percentage of T cells expressing the CAR will be determined by flow cytometry, 
and this percentage of CAR T cells will be used in calculating the total number of cells to be infused 
to meet the dose requirements of the dose -escalation plan described in 3.1.4 .  In addition to flow 
cytometry , further testing of the cells will take place prior to infusion to evaluate for microbial 
contamination, replication -competent retroviruses, and viability.  Details of this testing can be found 
in the appropriate DTM SOPs.  When a patient is no longer eligi ble for retreatment on this protocol 
due to meeting any of the off -study criteria listed in section 3.7.2 , any remaining cryopreserved 
pretreatment  PBMC collected on this protocol will either be disposed of or transferred from the 
Department of Transfusion Medicine to the Principal Investigator of this protocol for storage in the Surgery Branch Cell Production Facility (SB -CPF) and possible use in re search.   
3.3.3 Conditioning chemotherapy and CAR-SLAMF7  T-cell administration -chemotherapy 
administration can be either inpatient or outpatient  
3.3.3.1  Overall summary of the treatment plan  
 
Drug  Dose  Days  
Cyclophosphamide  300 mg/m2 IV infusion over 
30 minutes  Daily x 3 doses  on days -5, -
4, -3 
Fludarabine  30 mg/m2 IV infusion over 
30 minutes administered 
immediately following the 
cyclophosphamide on day -
5, -4, -3 Daily x 3 doses  on days -5, -
4, -3 
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
47 Anti-SLAMF7 -CAR T cells  Variable.  One-time dose  on day 0 
 
3.3.3.2  Detailed treatment plan  
Note that patients must meet still meet protocol enrollment criteria with the exception that a 
platelet count as low as  50,000/ µL is allowed based on laboratory results from 7 days or less 
and physical examination within 3 days or less before chemotherapy starts. 
Day -5, -4, and -3:  Patients will receive pre -hydration with 1000 mL 0.9% sodium chloride I.V. 
over 1 to 3 hours.  
Patients will receive anti-emetics following NIH Clinical Center guidelines, but dexamethasone 
will not be administered .  One sugges ted regimen is ondansetron 16 to 24 mg orally on days -5, -
4, and -3 before chemotherapy (I.V. ondansetron can be substituted).    Patients should be provided with anti-emetics such as lorazepam and prochlorperazine to use at home.   
On days -5, -4, and -3, cyclophosphamide at a dose of 300 mg/m2 I.V. will be diluted in 100 mL  5% 
dextrose solution and infused over 30 minutes.  After the cyclophosphamide on days -5, -4, and - 3, 
patients will receive 30 mg/m2 I.V. fludarabine in 100 mL 0.9% sodium chloride over 30 minutes.  
Note: in patients with an estimated  creatinine clearance of 30-70 m L/minute /1.73m2, the daily 
dose of fludarabine will be reduced by 20%  (see 11.3.6 ).  Creatinine clearance will be estimated 
by the Chronic Kidney Disease  Epidemiology Collaboration ( CKD-EPI) formula.  
Following the fludarabine infusion, patients will receive 1000 mL 0.9% so dium chloride I.V. over 
1-2 hours.   Furosemide will be given if needed.    
Days -2 and -1:  No interventions except as needed for general supportive care such as anti -emetics.  
To minimize bladder toxicity, patients should increase normal oral fluid intake to at least 2 L/day.  
Day 0:  CAR T cells will be administered.  Premedication for the cell infusion will be given approximately 30 minutes prior to the infusion.  The premedi cations are acetaminophen 650 mg 
orally and diphenhydramine 12.5 mg IV.  Cells are  delivered to the patient care unit from the 
Department of Transfusion Medicine.  Prior to infusion, the cell product identity label is double -
checked by two authorized staff (MD or RN), and identification of the product and documentation of administration  are entered in the patient’s chart as is done for blood banking protocols.  The cells 
are to be infused intravenously over 20 to 30 minutes via a central line with non-filtered tubing   using 
an infusion pump, gently agitating the bag during infusion to prevent cell clumping.  Cells may 
arrive on the unit in a syringe instead of a bag.  In this case, the cells can be administered to the patient by pushing the cells through a free-flowing  normal saline line per  nursing SOP, but still must 
be infused over 20-30 minutes.  Details of the infusion procedure are included in 
Appendix D .  
Days 1 to 9: Mandatory minimal hospitalization for observation and treatment as necessary.   Note:  
hospitalization for CAR T-cell patients is routinely extended; extension of hospitalization beyond 
the required 9 days is anticipated for CAR T -cell toxicity management.  In addition, patients are 
required to stay within 60 minutes driving time from the Clinical Center until day 14 after the CAR 
T-cell infusion.    
Guidelines for dealing with toxicities that often occur after CAR T cell infusions including hypotension, fever and tachycar dia are given in Appendix C
. 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
48 A CBC with differential will be obtained daily.  If the absolute neutrophil count becomes less than 
500/microliter , filgrastim will be initiated at a dose of 300 micrograms daily subcutaneously for 
patients under 70 kg in weight and at a dose of 480 micrograms daily for patients over 70 kg in 
weight.  Filgrastim will be  given daily and then discontinued as soon as the absolut e neutrophil count 
recovers to 2000/microliter.  
3.3.4 Rimiducid administration  
Rimiducid  may be administered a  under the following conditions  at the discretion of the Princip al 
Investigator : 
• Significant herpes virus infections such as cytomegalovirus infections, herpes zoster, or other 
significant viral infections in the setting of a peripheral blood NK cell count less than the 
lower limit of normal as determined on lymphocyte phenotyping (TBN K) performed at the 
NIH Department of Laboratory Medicine. “Significant” will be determined by the Principal  
Investigator.  
• Significant organ damage possibly, probably or definitely attributable to CAR T cells . 
“Significant” will be determined by the Princi pal Investigator.  
• Severe cytokine -release syndrome not responsive to high-dose corticosteroids of 200 mg of 
methylprednisolone within 1 hour . If a participant has Cytokine  Release Syndrome  that 
improves  after  the Rimiducid  is given,  methylprednisolone  will be discontinued.  
• Neutrophil count <500/ µL lasting 7 to 9 days (Rimiducid can be given anywhere from 7 to 
9 days of neutrophil count<500/ µL) 
• Transfusion-dependent thrombocytopenia lasting 21 to 23 days (Rimiducid administered anytime between 21 an d 23 days of transfusion dependence)  
• Bleeding due to thrombocytopenia or life -threatening infections in the setting of neutropenia.  
Infusion of Rimiducid: 0.4 mg/kg of Rimiducid is infused in 100 mL of normal saline over 2 hours.  
Patients <50 kg or >150 kg, may have different volume than 100 mL but will still be infused over 2 
hours.  
A second  dose of Rimiducid  will be given  when  2 criteria  are met: 1. An indication  for a 1st dose of 
Rimiducid  persists  at least 48 hours  after the first dose.  2. CAR T cells are still detected  in the 
patient’s  blood 1 day after the first dose of Rimiducid . 
 
Premedication for Rimiducid Infusion:  Patients will receive acetaminophen 650 mg orally and 
diphenhydramine 12.5 mg IV  approximately 30-60  minutes prior to  start of Rimiducid infusion.  
3.3.5 Potential repeat treatment  
Retreatment will only be considered on a case by case basis after consultation w ith the IRB and FDA 
and after the maximum tolerated or maximum administered dose is determined.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
49 3.4 PROTOCOL EVALUATION  
3.4.1 Baseline evaluations and interventions  
Bone marrow aspirate and biopsy must be performed within 24 days prior to the start of the 
conditioning chemotherapy.  If the screening bone marrow aspirate and biopsy were done within 24 
days of the start of conditioning chemotherapy, the baseline bone marrow aspirate and biopsy should not be done unless clinically indicated.  Specifically ask for SLAMF7 , BCMA , CD3, CD8, and CD4  
immunohistochemistry  staining of the bone marrow biopsy.  Order cytogenetics with interphase 
FISH  (pretreatment only) and flow cytometry  on the bone marrow aspirate. Specifically request 2 
separate bone holes for bone marrow aspiration.  The aspirate for hemepath (0.5 mL) and flow (2 -
2.5 mL) should be done from 1 bone hole and the aspirate for research (2-2.5 mL) should be done from a second bone hole followed by an aspirate for cytogenetics (1-2 mL) from  the second bone 
hole. Note:  Only bone marrow aspirates done before CAR T -cell treatment and 2 weeks after 
infusion require aspirates through 2 bone holes.  All other bone marrow aspirates only need to be 
done through 1 bone hole. For all bone marrow aspirates, bone marrow supernatant must be collected and frozen in the same manner as serum is collected and frozen.  
SLAMF7  immunohistochemical staining is performed in the NIH Dept. of Laboratory Medicine 
with the anti-SLAMF7 antibody clone 3B3, LSBio part number LS -C340266.  
 
The following tests must be completed within 14 days prior to the start of the conditioning 
chemotherapy regimen:  
Patients must have a central venous access before the time of cell infusion.  This might require placement of a non-valved  P.I.C.C line or another  device.  
• Physical exam with vital signs and oxygen saturation 
• PET scan in all patients  to measure boney disease and soft tissue plasmacytomas  for safety 
reason .  
• CT scans of neck, chest, abdomen and pelvis  in all patients . CT scans of other locations will 
be performed clinically  to image only areas of previously known plasmacytomas.  If area of 
known plasmacytoma was imaged at the NIH within 14 days, CT scan of that area will not 
be repeated.  
• MRI only if needed to define measurable multiple myeloma plasmacytomas  staging  or spine 
lesions that not evaluable completely  by CT)  
• 250 microgram cosyntropin stimulation test if suspicious for adrenal insufficiency based on 
low serum sodium or high serum potassium or h ypotension or a history of adrenal 
insufficiency or low serum cortisol or other clinical indications  (This may be performed 
after start of chemotherapy as long it is performed before the cell infusion)  
• 24-hour urine collection with immunofixation electrophoresis  
• 24-hour urine collection for urine protein 
• Serum immunofixation electrophoresis  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
50 • Blood CMV PCR 
• Serum immunoglobulin free light chains  
• Anti CMV antibody titer, HSV serology, and EBV panel, T cruzi serology, toxoplasmosis 
serology (Note: patients who are known to be positive for any of the above do not need to be 
retested; may be performed within 3 months of chemotherapy start date)  
• Blood will be collected for research purposes.  Draw 12 CPT tubes (8 mL each of blood will be collected prior to initiation of the conditioning chemotherapy regimen. This is a total of 
96 mL of blood. Some of this blood will be used for immunology assays and some will be used for RCR assays. This blood can be collected on different days as long as a total of 12 
CPT tubes are collected prior to cell initiation of the chemotherapy.  Send to the Surgery 
Branch Cell Production Facility (SB-CPF), Bldg. 10, Room:  3W-3808, Phone: 240-858-
3755. 
• In addition to the CPT tubes, draw 16 mL of blood to obtain serum for research purposes (2 SST tubes, 8 mL per tube) within 3 days prior to the start of the chemotherapy.  Send to the Figg lab; For sample pick -up, page 102 -11964 . 
The following tests must be completed within 7 days of the start of the conditioning chemotherapy regimen : 
• TBNK  
• Sodium (Na), Potassium (K), Chloride (Cl), Total CO2 (bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium total (Mg), Phosphorus, Alkaline 
Phosphatase, ALT, AST, Tota l Bilirubin, Direct Bilirubin, LDH, Total Protein, Total CK 
(creatine kinase), Ur ic Acid (to be repeated on  the first day of the chemotherapy at the 
discretion of the PI)  
• β2-microglobulin  
• ABO typing  
• Ionized calcium  
• CBC with differential and platelet count  
• PT/PTT 
• Fibrinogen 
• Urinalysis; if results are abnormal, send for urine culture  
• β-HCG pregnancy test (serum or urine) on all women of child-bearing potential 
• C-reactive protein (CRP) 
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
51 3.4.2 Studies to be performed on Day 0 and during the mandatory 9-day inpatient admission 
after cell infusion  
• Vital signs including pulse oximetry will be monitored q1h x 4 hours after completion of the CAR T cell infusion and every 4 hours otherwise unless otherwise clinically indicated.  
• Daily physical exam  
• CBC twice a day  from day 0 until day 9 with differential every 24 hours. After day 9 do a 
CBC with differential daily until discharge. ( In the case of a later day infusion or early 
discharge, this may be only once a day. ) 
• TBNK on the day of CAR T -cell infusion (day 0), day 7 and day 14 after infusion  
• Immunoglobulin free light chains day 9 (+/- 1 day)  after infusion  
• Serum immunofixation electrophoresis (if patient had a measurable M -protein prior to 
treatment) day 9 (+/- 1 day)  after infusion  
• Chemistries twice a day starting from day 0 to day 9 .  After day 9 do chemistries once a day 
until discharge: (Sodium (Na), Pot assium (K), Chloride (Cl), Total CO
2 (bicarbonate), 
Creatinine, Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium total (Mg), Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total 
Protein, Uric Acid, creatine kinase. (In the case of a later day infusion or early discharge, this 
may be only once a day.)  All twice daily labs can be reduced to once daily after 9 days 
following CAR T-cell infusion.  
• PT/PTT and  fibrinogen daily while hospitalized  
• Day 0 Research Blood: 1 SST tube will be drawn on the morning of CAR cell infusion prior to infusion of CAR T cells.  Send to the Figg lab; for sample pick-up, page 102 -11964.  
• Post-infusion Research blood:   Every Monday, Wednesday, and Friday during 
hospita lization , starting on the first Monday, Wednesday, or Friday after the day of CAR T -
cell infusion and lasting  up to 14 days  after infusion of CAR-SLAMF7  -transduced T cells, 
56 mL of patient peripheral blood will be obtained (6 CPT tubes 8 mL each and 1 SST tube 
8 mL ). Send CPT tubes to the Surgery Branch Cell Production Facility SB -CPF. Bldg. 10 
3W-3808.   Phone: 240 -858-3755 . Send SST tubes to the Figg lab;  for sample pick -up, page 
102-11964  
• Additional Post -infusion research blood: 1 SST tube will be dr awn on the first Sunday 
after CAR T -cell infusion.  This tube may  be stored refrigerated on the nursing unit and 
processed first thing Monday morning at the latest.  Send to the Figg lab;  For sample pick -
up, page 102-11964. 
• Rimiducid Administration Research Blood:   Draw the below samples immediately before 
Rimiducid administration, 1 day post Rimiducid , and 3 days post Rimiducid  
• 6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for 
immunological testing. Send to the Surgery Branch Cell  Production Facility (SB -
CPF), Bldg. 10, Room:  3W-3808,  Phone: 240-858-3755   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
52 • 1 SST tube (8 mL) of Research Blood will be obtained for serum collection.  Send 
to the Figg lab; For sample pick -up, page 102-11964.  
 
3.4.3 Post-infusion outpatient evaluation 
After completion of therapy the patient will be followed for potential complications related to CAR- 
T-cell infusion. The patient will be seen at the NIH in follow -up to evaluate disease status and late 
problems related to a  CART-cell infusion at days +14  (+/- 1 day) , +30  (+/- 5 days) , +60 (+/- 7 days) , 
+90(+/ - 7 days), and +120(+/ - 7 days) ; and at 180(+/ - 14 days) , 270 (+/ - 14 days), and 365 (+/ - 30 
days)  months  after CART-cell infusion. After 12 months, the patient will be seen every 6 months 
(+/- 30 days) up to three  years. After 3 years  total follow -up, patients will be , transferred to the long -
term follow -up protocol 15-C-01 41. All of these time points have allowable ranges (see Table in 
section 3.5). At these times patients will have the following tests performed to determine clinical 
response:  
• 6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for immunological 
testing. Send to the Surgery Branch Cell Production Facility (SB-CPF), Bldg. 10, Room:  
3W-3808, Phone: 240 -858-3755   
 
• 1 SST tube (8 mL) of Research Blood will be obta ined for serum collection.  Send to the 
Figg lab; For sample pick -up, page 102-11964. Note: after the first year  of follow -up, 
research blood will be reduced to 4 CPT tubes (32 mL total) during required protocol 
visits . 
• Rimiducid Administration Research Blo od:  Draw the below samples immediately before 
Rimiducid administration, 1 day post Rimiducid, and 3 days post Rimiducid  
 6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for immunological testing. Send to the Surgery Branch Cell Production Facility (SB -
CPF), Bldg. 10, Room: 3W -3808, Phone: 240 -858-3755 .  
 1 SST tube (8 mL) of Research Blood will be obtained for serum collection.  Send 
to the Figg lab; For sample pick -up, page 102-11964.  
• PET scans will be performed at 3 and 12, 24 and 36 months  after cell -infusion .  
• CT scans of areas with tumors /plasmacytomas  will be performed  at 1, 2, 4, 6, 9, 12, 18, 24, 
30 and 36 months  after CAR T -cell infusion (only to evaluate known soft -tissue 
plasmacytomas  ). This may include areas such as the head, neck, chest, abdomen and pelvis. 
CT scans will NOT be performed in areas where there are no known tumor plasmacytomas at baseline unless clinically indicated or if there is concern for a new plasmacytoma that 
would constitute progressive disease.  
• MRIs will be performed  to evaluate tumors not evaluable completely by CT, especially to 
follow measurable myeloma staging  or spine lesions   
• Physical exam with vital signs and oxygen saturation 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
53 •  Sodium (Na), Potassium (K), Chloride (Cl), Total CO2 (bicarbonate), Creatinine, Glucose, 
Urea nitrogen (BUN), Albumin, Calcium total, Magnesium total (Mg), Phosphorus, Alkaline 
Phosphatase, ALT, AST, Total Bilirubin, Direct Bilirubin, LDH, Total Protein, Total CK, Uric Acid  
• PT/PTT, fibrinogen  
• TBNK  
• Ionized calcium  
• CBC with differential 
• C-reactive protein (CRP) 
• Blood for serum β 2-microglobulin  
• Blood for immunoglobulin free light chains  
• Blood for serum immunofixation electrophoresis  
• 24-hour urine collection w ith immunofixation electrophoresis timed urine (can be omitted if 
not needed for staging after day 30).  
• 24-hour urine collection with  protein timed urine  (can be omitted if not needed for staging 
after day 30 ). 
• Urinalysis: if results are abnormal, send for urine culture  
• At the 2-week  follow -up, bone marrow aspirate and biopsy must be performed.  Aspirate 
must be sent for flow cytometry to the lab of Dr. M aryalice Stetler -Stevenson.  SLAMF7  and 
BCMA staining must be requested for the flow cytometry.  Also, request flow cytometry for 
anti-SLAMF7 CAR T cells.   SLAMF7 , BCMA immunohistochemistry should also be 
requested on the bone marrow biopsy.  Specifically as k for SLAMF7 , BCMA, CD3, CD8, 
and CD4 immunohistochemistry  staining of the bone marrow biopsy.  Specifically request 2 
separate bone holes for bone marrow aspiration.   The aspirate for hemepath (0.5 mL) and 
flow (2 -2.5 mL) should be done from 1 bone hole a nd the aspirate for research (2 -2.5 mL) 
should be done from a second bone hole.   
• At the 2-month follow -up, a bone marrow aspirate and biopsy will be collected.  Aspirate 
must be sent for flow cytometry to the lab of Dr. Maryalice Stetler -Stevenson.  SLAMF7  and 
BCMA staining must be requested for the flow cytometry.  Also, request flow cytometry for 
anti-SLAMF7 CAR T cells.   SLAMF7  and BCMA immunohistochemistry should also be 
requested on the bone marrow biopsy.  This may also be performed at day +30 if clinicallyindicated.Specifically ask for SLAMF7 , BCMA, CD3, CD8, and CD4 
immunohistochemistry  staining of the bone marrow biopsy.   The aspirate for hemepath (0.5 
mL), flow (2 -2.5 mL) and research ( 2-2.5 mL ) can  be done from 1 bone hole.  
• At the 6 -month follow -up appointment, a bone marrow aspirate and biopsy will be 
performed.  Aspirate must be sent for flow cytometry to the lab of Dr. Maryalice   Stetler -
Stevenson.  SLAMF7  and BCMA staining must be requested for the flow cytometry. Also, 
request flow cytometry f or anti -SLAMF7 CAR T cells.  SLAMF7  and BCMA 
immunohistochemistry should also be requested on the bone marrow biopsy.  Specifically 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
54 ask for SLAMF7 , BCMA, CD3, CD8, and CD4 immunohistochemistry staining of the bone 
marrow biopsy.   The aspirate for hemepath (0.5 mL) , flow (2 -2.5 mL) and research ( 2-2.5 
mL) can  be done from 1 bone hole.  
• At all time -points, bone marrow biopsies might be done to evaluate for MM progression or 
to investigate cytopeni as. 
• For each bone marrow aspirate performed, send one tube of bone marrow aspirate to the 
Surgery Branch Cell Production Facility (SB -CPF), Bldg. 10, Room: 3W-3808, Phone: 240 -
858-3755 .  Bone marrow cells should be cryopreserved,  and the liquid bone marrow 
supernatant should also be saved at -80 degrees.  As many vials as possible with 10 million 
cells or less will be cryopreserved, and 2 vials of supernatant with 0.5 to 1 mL each will be cryopreserved.  
• Gene -therapy -specific follow -up must be carried out as d escribed in section  3.6 
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
55  
3.5 STUDY CALENDAR  
  Inpatient  Follow up  
Proceduresa  
Screening  
Baseline  Day 
0 Post 
Cell
s 
whil
e 
inptc Day+
14 (+ - 
1 
day) Day+
30 
(+/- 5 
days)  Day 
+60 
(+/- 7 
days)  Day 
+90 
(+/- 7 
days)  Day 
+120 
(+/- 7 
days)  Day 
+180 
(+/- 
14 
days)  Day 
+270 
(+/- 14 
days)  Day 
+365 
(+/- 
30 
days)  Every 6 
months after  
day 365(+/ - 
30 days) up to 
3 years post 
CAR cells .  
Clinical Assessments   
History and PE  X Xb Xc Xc X X X X X X X X X 
Vital signs, O2 
saturation  X X Xc Xc X X X X X X X X X 
Weight  X             
Performance Score 
(ECOG)  X             
Lesion Location  
(If applicable)  X             
Pathology 
Confirmation  X             
Laboratory 
Assessments  
CBC with differential  X X Xc Xc X X X X X X X X X 
Sodium, Potassium 
Chloride, CO2, 
Creatinine, Glucose, 
BUN, Albumin, Calcium, Magnesium, 
Phosphorus, 
Alkaline 
Phosphatase, ALT, X X Xc Xc XX X X X X X X X X 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
56   Inpatient  Follow up  
Proceduresa  
Screening  
Baseline  Day 
0 Post 
Cell
s 
whil
e 
inptc Day+
14 (+ - 
1 
day) Day+
30 
(+/- 5 
days)  Day 
+60 
(+/- 7 
days)  Day 
+90 
(+/- 7 
days)  Day 
+120 
(+/- 7 
days)  Day 
+180 
(+/- 
14 
days)  Day 
+270 
(+/- 14 
days)  Day 
+365 
(+/- 
30 
days)  Every 6 
months after  
day 365(+/ - 
30 days) up to 
3 years post 
CAR cells .  
AST, T. Bilirubin, D. 
Bilirubin, LDH, 
Total Protein, CK, 
Uric Acid  
Serum C -reactive 
protein   X Xc Xc X X X X X X X X X 
PT/PTT  X X Xc Xc X X X X X X X X X 
Fibrinogen   X Xc Xc X X X X X X X X X 
Ionized calcium   X   X X X X X X X X X 
TBNK   X X Xd 
(D7
) X X X X X X X X X 
Urinalysis (culture 
prn)  X   X X X X X X X X X 
CMV PCR (Blood)   X            
Anti-CMV, HSV, 
EBV, T.cruzi, 
toxoplasmosis  X Xe            
PCR for HCV and 
HBV; antibody test 
for HIV, HTLV -I/II, 
T.cruzi, West Nile, 
RPR Xf             
TSH, T4, T3  X             
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
57   Inpatient  Follow up  
Proceduresa  
Screening  
Baseline  Day 
0 Post 
Cell
s 
whil
e 
inptc Day+
14 (+ - 
1 
day) Day+
30 
(+/- 5 
days)  Day 
+60 
(+/- 7 
days)  Day 
+90 
(+/- 7 
days)  Day 
+120 
(+/- 7 
days)  Day 
+180 
(+/- 
14 
days)  Day 
+270 
(+/- 14 
days)  Day 
+365 
(+/- 
30 
days)  Every 6 
months after  
day 365(+/ - 
30 days) up to 
3 years post 
CAR cells .  
G6PD  X             
Serum Cortisol  X             
ABO typing   X            
B2-HCG (serum or 
urine in women of 
childbearing 
potential)  X X            
MM Lab Assessments   
β2-microglobulin   X   X X X X X X X X X 
24 hr urine with 
immunofixation 
electrophoresis and 
urine 24 hour 
protein  X X   X X Xg Xg Xg Xg Xg Xg Xg 
Serum 
immunoglobulin free 
light chains  X X  Xh 
(D9
) X X X X X X X X X 
Serum 
immunofixation 
electrophoresis X X  Xh 
(D9
) X X X X X X X X X 
Radiological 
Assessments   
CT scan of disease 
affected areas Xz Xy    Xi Xi      Xi Xi Xi    Xi               Xi 
PET scan  Xw
,        Xv               X w  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
58   Inpatient  Follow up  
Proceduresa  
Screening  
Baseline  Day 
0 Post 
Cell
s 
whil
e 
inptc Day+
14 (+ - 
1 
day) Day+
30 
(+/- 5 
days)  Day 
+60 
(+/- 7 
days)  Day 
+90 
(+/- 7 
days)  Day 
+120 
(+/- 7 
days)  Day 
+180 
(+/- 
14 
days)  Day 
+270 
(+/- 14 
days)  Day 
+365 
(+/- 
30 
days)  Every 6 
months after  
day 365(+/ - 
30 days) up to 
3 years post 
CAR cells .  
Brain MRI  X             
 MRI Xi Xi     Xj Xj Xj  Xj   Xj  Xj  Xj  Xj 
Other Specific 
Assessments   
250 microgram 
cosyntropin test  Xk            
EKG, 
echocardiogram  X             
RCR, Gene Therapy 
Follow Up   X      X  X  X Xl 
Central Venous 
catheter placement   X            
Venous Assessment 
for Apheresis  X
m             
Response Evaluation   
Bone marrow 
aspirate/biopsyn, o, p    Xq   X Xx X   X    
Research Blood   Xr Xs,, t Xs,  t Xt, u Xt, u Xt,, u Xt,, u Xt,, u Xt,, u Xt,, u  Xt, u Xt,, u 
Adverse Events    X X X X X X X X X X X 
Concomitant 
Medications   X X X X X X X X X X X X 
a. see section  2.2 and section 3.3.1  for details  
b. Medical history not required at baseline 
c. see section 3.4.2  for details of testing during hospitalization  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
59 d. TBNK is performed on D7 
e. Patients who are known to be positive for any of these tests do not need to be retested; may be performed within 3 months of 
chemotherapy start date 
f. only if DNA testing is not available, order Hepatitis C antibody, order Hepatitis B core antibody, and hepatitis B surface an tigen. 
g. Urine electrophoresis can be omitted after D30 if not needed for staging  
h. Draw immunoglobulin free light chains and serum immunofixation electrophoresis on day 9 after CAR T -cell infusion 
(electrophoresis  if M-protein at baseline ). 
i. if useful for response assessment  to evaluate known multiple myeloma  plasmacytomas  that identified at screening or baseline  clinically 
except for day 30 and 120 .Note: only day 30 and day 120 CT scan will be done on patients who had known plasmacytoma 1.5 cm.  
j. MRIs will be done only to evaluate tumors not evaluable completely by CT, especially to establish measurable myeloma   
k. only if clinical suspicion of adrenal insufficiency  
l. see section 3.4.3  for details  
m. Venous assessment valid for 6 months before cell collection  
n. bone marrow biopsy will include flow cytometry, SLAMF7 expression, cytogenetics (pretreatment bone marrow aspirate only), amyloid staining (pretreatment bone marrow biopsy only), res earch samples, and molecular studies of each sample.   Note that 2 
separate bone holes will be required for the pretreatment and 2-week follow -up bone marrow aspirates. All other bone marrow 
aspirates will only require 1 bone hole.  
o. Additional  bone marrow biopsies and aspirates might be needed if clinicallyindicated due to low blood counts or for myeloma 
response assessment.  
p. A bone  marrow aspirate and biopsy with flow cytometry will also be performed to confirm suspected complete remission.  
q. Bone marrow biopsy does not need to be repeated for baseline if done previously within 24 days 
r. Baseline  Research Blood (See section 3.4.1 ) 
s. Inpatient Research Blood  (See section 3.4.2 ) 
t. Rimiducid Administration  Research Blood  (See section 3.4.2  and 3.4.3 ) 
u. Follow up Research Blood (See section 3.4.3 ) 
v. PET research scan to evaluate MM in all patients  
w. To measure boney disease and soft tissue plasmacytomas  for safety reason    
x. Only if clinicallyindicated  
y. CT scan of neck, chest, abdomen and pelvis in all patients  for to measure plasmacytoma  staging   will not be repeated if done within 
14 days of protocol treatment start  
z. CT scan of areas with possible lesions/plasmacytomas ( this research scan only be done p erfo rm edper   if needed to establish measurable 
disease ). If outside CT scans of plasmacytomas are available within 30 days, we can use these images to establish measurable 
disease.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
60  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
61 3.6 GENE-THERAPY -SPECIFIC FOLLOW -UP  
• Long -term follow up of patients recei ving gene transfer  is required by the FDA and must 
continue even after the patient comes off the treatment protocol .  Physical examinations 
will be performed and documented annually for 5 year s following cell infusion to evaluate 
long-term safety.  After 3 years , patients who are still on this study will be transferred to 
the long -term gene therapy protocol NCI protocol 15-c-01 41 to complete long -term gene -
therapy follow -up. 
• Persistence of CAR transduced cells will be assessed by quantitative PCR and/or flow 
cytometry at 1, 2, 3, 4, 6 and 12 months after cell infusion, or until CAR -expressing cells 
are no longer detectable or <0.1% of PBMC (whichever is higher) .  If any patient shows a 
high leve l of persistence of CAR gene transduced cells or an increasing population of CAR 
gene transduced T cells at month 6 or later (by FACS staining or qPCR), the previously 
archived samples will be subjected to techniques that would allow the identification of predominant clonal populations of transduced cells.  
• Patients’ blood samples will be obtained and undergo analysis for detection of replication competent retroviruses (RCR) by PCR prior to cell infusion and at 3, 6, and 12 months post 
cell administration .   
• S+L- culture -based replication -competent retrovirus testing will be conducted on the 
infusion CAR T cells of all patients  
3.7 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA  
Prior to removal from study, effort must be made to have all subjec ts complete a safety visit 
approximately 30 days after  the last dose of study therapy . 
3.7.1 Criteria for removal from protocol therapy  
Note that the treatment consists of a conditioning chemotherapy regimen followed by a T -cell 
infusion. O ff-treatment criteria applies  to eligibility for potential repeat treatments ; and also, 
cancellations of treatment for toxicity arising any time before the cell infusion.  
Patients will be taken off treatment for the following : 
• Any DLT  makes patients  ineligible for repeat treatments.  
• The patient started chemotherapy but cannot complete the entire treatment (ending with 
completed cell infusion) for any reason specified in the protocol or PI discretion.  If the reason that the patient is no longer eligible can be rapidly resolved  within 1 day , the patient  
can proceed on treatment, otherwise the patient must come off treatment.   
• The patient receives any other treatment for multiple myeloma except bisphosphonates and 
treatment  on this protocol.  Bisphosphonates are allowed when administered to prevent 
osteopenia more than 2 months after the CAR T-cell infusion.   
• General or specific changes in the patient’s condition render the patient unacceptable for 
further treatment on this study in the judgment of the investigator.  
• Participant requests to be withdrawn from active therapy  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
62 • Investigator discretion  
• Positive pregnancy test  
3.7.2 Off-Study Criteria  
Patients will be taken off study for the following  (all patients coming off study must enroll on the 
long-term gene therapy follow -up protocol 15-c-0041) : 
• The patient completes the study  upon reaching 3 years after CAR T -cell infusion.  
• The patient completes a safety visit 30 day after last administration of study treatment  (only 
for patients who have received chemotherapy but will not receive a cell infusion)  
• The patient voluntarily withdraws  
• There is significant patient noncompliance  
• PI discretion  
• Death  
• Development of progressive or relapsed multiple myel oma after CAR T cell infusion.  
• The patient receives any anti -myeloma therapy except bisphosphonates.  Bisphosphonates 
are allowed 2 months or more after the CAR T -cell infusion.  
• The patient no longer meets the eligibility criteria for the protocol after en rolling but before 
start of the chemotherapy conditioning regimen.  In this case, treatment will be delayed 
until the patient meets eligibility criteria, or if the patient will never likely meet eligibility 
criteria, the patient will be removed from the study. An exception to this is that a platelet 
count of 50,000 or more is considered adequate to start chemotherapy. This platelet level 
is slightly lower than that required for initial protocol enrollment.  
3.8 PROTOCOL STOPPING CRITERIA  
• If no responses of PR or CR occur after 2 patients are treated on the highest dose level , the 
protocol will be stopped.  
• Instructions for how to proceed when toxicity occurs will be as instructed by the dose escalation 
section of the protocol. 
• A death on study not attributable  to progressive malignancy within 30 days of a cell infusion 
for the initial 5 subjects will be a cause for a pause to accrual pending amendment  of the 
protocol approved/reviewed by the FDA and NIH Intramural  IRB.  
• If 3 or m ore of the f irst 9 treated patients experience grade 4 toxicity  possibly or probably 
attributable to CAR T cells within 30 days of cell infusion, this will be a cause for a pause 
to accrual to reassess the safety of the product pending amendment of the protocol 
approved/reviewed by the FDA and NIH Intramural  IRB. 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
63 4 CONCOMITANT MEDICATIONS/MEASURES  
4.1 ANTIBIOTIC PROPHYLAXIS  
• Patients with a CD4 T-cell count less than 200 will be maintained on pneumocystis 
prophylaxis with atovaquone or inhaled pentamidine.  Patients with a CD4 T-cell count less than 200 will also be maintained on acyclovir or valacyclovir.    
Patients with serum IgG level less than 400 mg/dL will receive intravenous immunoglobulin replacement as needed to maintain an IgG level above 400 mg/dL.  An example of an intravenous immunoglobulin infusion to be used for this purpose would be 
Gammunex 500 mg/kg given as a single dose.  Intravenous immunoglobulin infusions 
should be preceded by premedication with diphenhydramine and acetaminophen, and rate of infusion should be started at low rates and escalated in a step -wise manner.  
• Neutropenic patients will start on broad spectrum antibiotics with a first fever of 38.3  C or 
greater or two fevers of 38.0 separated by at least 1 hour and concomitant ANC < 500/ mL.  
• Aminoglycosides will be avoided unless clear evidence of sepsis.  
4.2 B
LOOD PRODUCT SUPPORT  
• Leukocyte filters will be utilized for all blood and platelet transfusions with the exception of the CAR -transduced T cell infusions to decrease sensitization to tr ansfused WBC and 
decrease the risk of CMV infection.  
• Patients who are seronegative for CMV should receive CMV -negative blood products 
whenever possible.  
• Using daily CBC’s as a guide, the patient will receive platelets and packed red blood cells 
(PRBC’s) as  needed.  Attempts will be made to keep Hgb >8.0 gm/dL, and platelets 
>10,000/mm3.  All blood products with the exception of the CAR -transduced T cells will 
be irradiated.  Leukocyte filters will be utilized for all PRBC and platelet transfusions to 
decrease sensitization to transfused WBC’s and decrease the risk of CMV infection.  
4.3 A
NTI-EMETICS  
Anti-emetics will follow NIH Clinical Center Guidelines  (except that corticosteroids will be 
avoided).  
4.4 GRANULOCYTE COLONY -STIMULATING FACTOR  
A CBC will be obtained daily while the patient is inpatient.  If the absolute neutrophil count  
becomes less than 500/microliter , Filgrastim will be initiated at a dose of 300 micrograms daily 
for patients under 70 kg in weight and a dose of 480 micrograms daily for patients over 70 kg in weight only in patients with absolute neutrophil counts less than 500/microliter.  Filgrastim will 
be discontinued as soon as the absolute neutrophil count recovers to 2000 /microliter.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
64 4.5 AVOIDANCE OF CORTICOS TEROIDS  
Patients should not take corticosteroids including prednisone, dexamethasone or any other 
corticosteroid at a dose equivalent to 5 mg/day or more of prednisone for any purpose without 
approval of the Principa l Investigator.  
4.6 TOXICITY MANAGEMENT G UIDELINES  
Guidelines for managemen t of common CAR toxicities including cytokine release syndrome 
(CRS) and neurologic toxicity are in section Appendix C . Rimiducid will be given as des cribed in 
Section 3.3.4 . 
5 BIOSPECIMEN COLLECTI ON 
Biospecimen collection on this protocol will consist of blood draws and acquisition of bone marrow aspirates and possible biopsies of plasmacytomas for research purposes.  Blood and bone 
marrow collection is described above in Sections  2.2, 3.4, and 3.5
. 
5.1 CORRELATIVE  STUDIES  FOR  RESEARCH  
5.1.1 Biospecimen collection before the start of the conditioning chemotherapy:  
• One heparinized syringe containing 2-2.5 mL  of bone marrow aspirate  to be sent to the 
Surgery Branch Cell Production Facility (SB -CPF), Bldg. 10 , 3W-3808, Phone: 240- 858-
3755. It will be used in functional assays to see if CAR-SLAMF7  T cells can recognize the 
patient’s multiple myeloma cells .  
• Blood will be collected for research purposes.  A total of 1 2 CPT tubes (8 mL each of blood 
will be collected prior to initiation of the conditioning chemotherapy regimen. This is a 
total of 96 mL of blood. Some of this blood will be used for immunology assays and some 
will be used f or RCR assays. This blood can be collected on different days as long as a 
total of 12 CPT tubes are collected prior to the start of the chemotherapy and within 14 
days of the start of the chemothe rapy.  Surgery Branch Cell Production Facility (SB -CPF) , 
Bldg. 10 ,  3W-3808, Phone: 240-858-3755  
• 16 mL of blood will be drawn to obtain serum for research purposes (2 SST tubes, 8 mL 
per tube) within 14 days prior to the start of the chemotherapy.  Send to the SST tubes will 
be sent to  Figg lab; For sample pick -up, page 102 -11964 An apheresis is required to obtain 
cells used to prepare the CAR  T cells that are administered on this protocol.  After sufficient 
cells are processed for all possib le clinical needs, the left-over  apheresis cells can be 
cryopreserved for re search use.   Note that these cells would simply be discarded if not used 
for research.   
• Specimens will be cryopreserved,  and assays will be performed retrospectively . 
5.1.2 Biospecimen collection Day 0 and after CAR T -cell infusion during the required 
hospitaliz ation  
Every Monday, Wednesday, and Friday during hospitalization, starting on the first Monday, Wednesday, or Friday after the CAR T -cell infusion and lasting up until 14 days after infusion of 
CAR-transduced T cells, 56 mL of patient peripheral blood will  be obtained (6 CPT tubes 8 mL 
each and 1 SST tube 8 mL). Also,  1 SST tube (8 mL) will be drawn on the morning of CAR cell 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
65 infusion prior to infusion of CAR T cells. 1 SST tube (8 mL) will be drawn on the first Sunday 
after CAR T -cell infusion.   The 1 SST tube will be sent tto the Figg lab; For sample pick -up, pag e 
102-11964. The 6 CPT tubes sent to Surgery Branch Cell Production Facility SB -CPF, Bldg. 10 
3W-3808, Phone: 240 -858-3755 .   
Additional research blood may be collected at any time during the c linical course at the discretion 
of the PI  (within the volume restriction limits)  allowing for the research studies already outlined 
in this protocol  to be performed at the time of an unanticipated clinical event, if necessary to 
address the  objectives of the study.  
5.1.3 Biospecimen collection during outpatient follow -up 
• Patients will return for outpatient follow -up clinic visits 2 weeks, 1 month, 2 months , 3 
months, 4 months, 6 months, 9 months and 12 months after CAR T -cell infusion. After the 
12-month follow -up appointment patients will return for follow -up every 6 months  up until 
3 years after infusion.  The specimens listed below will be performed at each outpatient 
clinic visit during the first year of follow up.  
 6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for immunological testing. Send CPT tubes to Surgery Branch Cell Production Facility SB-CPF, Bldg. 10 3W -3808, Phone: 240 -858-3755 .  
 1 SST tube (8 mL) of Research Blood will be obtained for serum collection.  The 
SST tubes will be sent to Figg lab . For sample pick -up, page 102 -11964 . 
NOTE: After 1-year  research blood collected will be reduced  to 4 CPT tubes at each visit.  
• At the 2-week , 2 months  and 6- month follow -ups, bone marrow aspirate and biopsy will 
be performed and the as pirate will be cryopreserved.   
5.1.4 Immunological Testing  
• T-cell assays: Direct immunological monitoring will consist of quantifying CD3+ T cells 
that express the CAR by quantitative PCR, and/or  by flow cytometry.  These assays will 
be performed to measure the persistence and estimate the proliferation of the infused CAR+ 
T cells.  A quantitative PCR assay  or a flow cytometry assay  will be used to quantitate 
CAR+ T cells at all post-infusion t ime-points up to at least 3  months after infusion, and 
CAR+ T cell analysis will continue until the CAR+ T cell level drops to undetectable levels  
or levels reach <0.1% of PBMC.  The absolute number of CAR+ PBMC will be estimated 
by multiplying the percentage of CAR+ PBMC by the absolute number of lymphocytes 
plus monocytes  per microliter of blood.  Ex vivo immunological assays might  be used to 
measure the SLAMF7 -specific functional activity of the CAR+ T cells and will consist of 
assays such as intracellular c ytokine staining and anti -CD107a degranulation assays. 
Immunological assays will be standardized by the inclusion of pre -infusion recipient 
PBMC and in some cases an aliquot of the engineered T cells cryopreserved at the time of infusion.  
• Serum cytokine l evels will also be measured by enzyme-linked immune sorbent  or similar  
assays.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
66 • A human anti -mouse ELISA assay will be performed retrospectively on serum collected 
before administration of anti-SLAMF7 CAR T cells and 2 to 3 months after anti -SLAMF7 
CAR T -cell administra tion for all patients who previously received treatment involving 
any CAR derived from a murine antibody including previous treatment with the IC9-
Luc90-CD828Z CAR used in this study.  
• Patients’ blood samples will be obtained and undergo analy sis for detection of replication 
competent retroviruses (RCR) by PCR prior to cell infusion and at 3 and 6 months, and 
at one-year  post cell administration . Blood does not need to be banked for gene -therapy 
monitoring after the 12-month post -infusion time -point.  If any post -treatment samples are 
positive, further analysis of the RCR and more extensive patient follow -up will be 
undertaken, in consultation with the FDA.  RCR PCR assays detect the Gibbon Ape Leukemia Virus (GALV) envelop gene and are performed under contract by the National 
Gene Vector Laboratory at Indiana University . The results of these tests are maintained by 
the contractor performing the RCR tests and by the SB  research team.  
• Due to nature of these studies, it is expected that expansion of specific T -cell clones will 
be obser ved as T -cell proliferate in response to the targeted antigen.  Therefore, care will 
be taken to track T -cell persistence, but presence of an oligoclonal T cell population does 
not indicate an insertional mu tagenesis event.    If any patient shows a high level of 
persistence of CAR gene transduced cells or an increasing population of CAR gene transduced T cells at month 6 or later (by FACS staining or qPCR), the previously archived 
samples will be subjected to techniques that would allow the identification of predominant 
clonal populations of transduced cells.  Such techniques may include T cell cloning or LAM -PCR.  If a predominant or monoclonal T cell clone derived from CAR gene 
transduced cells is identifie d during the follow -up, the integration site and sequence will 
be identified and subsequently analyzed against human genome database to determine whether the sequences are associated with any known human cancers.  If a predominant integration site is observed, the T cell cloning,  or LAM -PCR test will be used at an interval 
of no more than three months after the first observation to see if the clone persists or is 
transient.  In all instances where monoclonality is persistent and particularly in instances 
where there is expansion of the clone, regardless of whether  the sequence is known to be 
associated with a known human cancer, the subject should be monitored closely for sig ns of malignancy, so that treatment, if available, may be initiated early.  
5.1.5 Biospecim en collection with Rimiducid  administration:  
If Rimiducid is infused, we will collect research blood (6 CPT tubes and 1 SST tube)  for 
monitoring CAR T -cell levels immediately before the infusion and 1 day and 3 days after the 
infusion. 
 
5.1.6 Additional biopsies and additional blood draws  
Patients might be asked to undergo biopsies or additional blood draws for research purposes. Additional blood draws might be necessary to investigate T cell responses and serum cytokine levels in cases of clinical events such as rapid regressions of malignancy or toxicity.  These 
research biopsies are optional,  and patients can participate in this trial whether or not they agree to 
undergo biopsies for research purposes.  These biopsies will only be performed if minimal 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
67 morbidit y is expected based on the procedure performed and the granulocyte and platelet count.  
Biopsy tissue will be processed in the NCI Laboratory of Pathology. Studies will be performed to 
evaluate the antigen expression by the tumor and to evaluate the reacti vity of lymphocyte from 
these biopsies. In addition,  the presence of transduced cells may be quantitated.  
5.1.7 Future studies  
Blood and tissue specimens collected during  this research project may be banked and used in the 
future to investigate new scientific questions related to this study the patient provides consent for 
this. However, this research may only be done if the risks of the new questions were covered in 
the consent document. If new risks are associated with the research (e.g. analysis of germ line 
genetic mutations) a  protocol amendment will be required, and informed consent will be obtained 
from all research subjects to whom these new studies and risks pertain.   
5.2 SAMPLE STORAGE , TRACKING AND DISPOSITION  
5.2.1 Samples Sent to Figg Lab  
• Venous blood samples will be collected in either a 4 -mL or an 8-mL SST tube to be 
processed for serum and stored for future research.  
o Record the date and exact time of draw on the tube. Blood tubes may be kept in the 
refrigerator until pick -up.  
o For sample pick -up, page 102-11964.  
o For immediate help, call 240 -760-6180 (main Blood Processing Core number) or, if 
no answer, 240-760 -6190 (main clinical pharmacology lab number).  
o For questions regarding sample processing, contact the Blood Processing Core (BPC) at NCIBloodcor e@mail.nih.gov  or 240 -760-6180 . 
o The samples will be processed, barcoded, and stored in the Figg lab until requested by the investigator.  
After delivery to the SB -CPF, peripheral blood mononuclear cell samples will be sent to the 
Head, Clinical Support Laboratory Clinical Services Program, Applied/Developmental Directorate Frederick National Laboratory for Cancer Research for processing and 
cryopreservation. They will be stored long -term at the NCI Frederick Repository.  
5.2.2 Sample Storage, Tracking and Disposition  
 
Samples will be ordered in CRIS and tracked through a Clinical Trial Data Management system. Should a CRIS screen not be available, the CRIS downtime procedures will be followed. All samples will be sent to Blood Processing Core (BPC) and/or SB -CPF for processing and/or and 
storage until they are distributed to the designated place of analysis as described in the protocol. 
A b bre vi ate d  Titl e:  A nti -S L A M F 7  C A R  T  c ells  f or  M M  
V ersi o n D at e:  A pril  1 4,  2 0 2 0  
 
6 8  Sa m ples will n ot b e s e nt o utsi d e NI H wit h o ut a p pr o priate a p pr o vals a n d/ or a gre e m e nts, if 
re q uire d .  
5. 2.2.1  Sa m ples Ma n a ge d b y Dr. Fi g g’s Bl o o d Pr o c essi n g  C ore ( B P C)  
5. 2.2.1. 1  B P C C o nta ct I nf or m ati o n  
Ple as e e -m ail N CI Bl o o d c ore @ m ail. ni h. g o v  at le ast 2 4 h o urs b ef ore tra ns p orti n g  s a m ples  (t h e 
Fri d a y b ef ore is pref erre d).  
F or s a m ple pic k u p,  p a ge 1 0 2 -1 1 9 6 4.  
F or i m m e diate h el p, c all 2 4 0 -7 6 0 -6 1 8 0  ( m ai n bl o o d  pr o cessi n g  c ore n u m ber) or, if n o a ns w er, 
2 4 0 -7 6 0 -6 1 9 0 ( m ai n cli nic al p h ar m ac ol o g y la b n u m ber).  
F or q u esti o ns re gar di n g  s a m ple pr oc essi n g, c o nta ct N CI Bl o o d c ore @ m ail. ni h. g o v.  
5. 2.2.1. 2  Sa m ple D ata C olle cti o n  
All s a m ples s e nt t o t h e Bl o o d Pr o c essi n g  C ore ( B P C) ( Dr. Fi g g’s  la b) will b e b arc o d e d, wit h data 
e ntere d a n d st ore d i n t h e L A Bra d or (a k a La b Sa m ples) utiliz e d b y t h e B P C. T his is a s e c ure 
pr o gra m ,  wit h  a c c ess  t o  L A Bra d or  li mite d  t o  d efi n e d  Fi g g  la b  p ers o n n el,  w h o  are  iss u e d  i n di vid ual  
us er a c c o u nts. I nstallati o n of L A Bra d or is  li mite d t o  c o m p uters s p e cifie d b y Dr.  Fi g g.  T h ese 
c o m p uters  all  h a v e  a  p ass w or d  restricte d  l o gi n  s cre e n.  All  Fi g g   la b  p ers o n n el  wit h a c c ess t o p atie nt  
i nf or m ati o n c o m plete t h e NI H o nli n e Pr ote cti o n of H u m a n S u bje cts c o urs e , i n t h e re q uire d ti me 
fra m e .  
L A Bra d or cre ates a u ni q u e b arc o d e  I D f or e v er y s a m ple a n d s a m ple  b o x, w hic h  c a n n ot b e trace d 
b a c k t o p atie nts wit h o ut L A Bra d o r a c cess. T h e d ata re c or de d  f or e a c h s a m ple i n cl u des t h e p atie nt 
I D, n a m e, trial n a m e/ pr ot o c ol n u m b er,  ti m e dra w n, c y cle ti m e p oi nt, d os e, m aterial t y p e, as w ell 
as b o x a n d fre e z er l o c ati o n. Patie nt d e m o gra p hics ass o ciate d wit h t h e cli nic al c e nter p atie nt 
n u m b er  are  pr o vi d e d  i n  t h e  s yste m.  F or  e a c h  s a m ple,  t h ere  are  n otes  ass o ciate d  wit h  t h e  pr o c essin g  
m et h o d ( d ela y i n s a m ple pr o cessi n g, st ora ge c o n diti o ns o n t h e w ar d, etc.).  
Sa m ple b ar -c o d es are li n k e d t o p atie nt d e m o gra p hics a n d li mite d cli nic al i nf or m at i o n. T his 
i nf or m ati o n will o nl y b e pr o vi de d t o i n v esti gat ors  liste d o n t his pr ot o c ol, via re gistere d us e of the 
L A Bra d or. It  is  critic al  t h at t h e  s a m ple re m ai ns li n k e d t o p atie nt i nf or m ati o n s u c h as ra c e, a ge, 
d ates of dia g n osis a n d d e at h, a n d hist ol o gic al  i nf or m ati o n  a b o ut t h e t u m or, i n  or d er t o  c orrelate 
ge n ot y p e wit h t h es e v aria bles.  
5. 2.2.1. 3  Sa m ple St ora ge  
Barc o d e d s a m ples  are  st ore d i n  b arc o d e d b o x es i n  a  l o c k e d fre e z er at  eit h er -2 0 or -8 0 C 
a c c or di n g  t o  sta bilit y  re q uire m e nts.  T h es e  fre ez ers  are  l o c ate d  o ns ite i n t h e B P C  a n d off site at  N CI  
Fre d eric k Ce ntral Re p osit or y Ser vic es i n Fre d eric k, M D. Visit ors t o t h e la b orat or y  are re q uire d to 
b e a c c o m p a nie d  b y la b orat or y  staff at all ti m es.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
69 Access to stored clinical samples is restricted. Samples will be stored u ntil requested by a 
researcher named on the protocol. All requests are monitored and tracked in LABrador. All 
researchers are required to sign a form stating that the samples are only to be used for research purposes associated with this trial (as per the IRB-approved protocol) and that any unused samples must be returned to the BPC. It is the responsibility of the NCI Principal Investigator to ensure that the samples requested are being used in a manner consistent with IRB approval.  
Following completion of this study, samples will remain in storage as detailed above. Access to 
these samples will only be granted following IRB approval of an additional protocol, granting the rights to use the material.  
If, at any time, a patient withdraws from the study and does not wish for their existing samples to be utilized, the individual must provide a written request. Following receipt of this request, the samples will be destroyed.  
5.2.3 Sample Storage, Tracking, and Disposition for Surgery Branch  
Samples received by the Surgery Branch research lab will be tracked using password protected 
web-based NCI database Lab  matrix. All specimens will be tracked for date of receipt in the 
Surgery Branch lab, date analyzed, date returned to the originating hospital and/or date destro yed. 
Specimens will be stored in a locked laboratory cabinet or refrigerators in a locked research lab. 
All specimens will be entered into Lab  matrix with identification and storage location. Access to 
the stored specimens will be restricted. Access to Lab  matrix will be granted upon PI approval 
only. It is the responsibility of the NCI PI to ensure that the specimens are being used and stored 
in a manner consistent with IRB approval. All samples are stored in monitored 
freezers/refrigerators in 3NW NCI-SB laboratories at specified temperatures with alarm systems 
in place.  
5.2.4 Protocol Completion/Sample Destruction  
All specimens obtained in the protocol are used as defined in the protocol.  
If the patient withdraws consent, the participant’s data will be excluded from future distributions, 
but data that have already been distributed for approved research use will not  be able to be 
retrieved.  
The PI will record any loss or unanticipated destruction of samples as a deviation. Reports will 
be made per the requirements of section 7.2 . 
 
5.2.5 Samples for Genetic/Genomic Analysis  
No genetic/genomic analysis will be performed.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
70 6 DATA COLLECTION AND EVALUATION  
6.1 DATA COLLECTION  
The PI will be responsible for overseeing entry of data into an in-house password protected 
electronic system, C3D and ensuring data accuracy, consistency and timeliness. The principal investigator, associate investigators/research nurses and/or a contracted data manager will assist with the data management efforts.  All data obtained during the conduct of the protocol will be kept in secure network drives or in approved alternative sites that comply with NIH security 
standards. Primary and final analyzed data will have identifiers so that research data can be 
attributed to an individual human subject participant.  
All ongoing AEs, including clinically significant abnormal findings on laboratory evaluations, 
regardless of severity, will be followed until return to baseline or stabilization of event. Document AEs from the first study intervention, Study Day 1, through the end of treatment.  Beyond 30 days 
after the last intervention, only adverse events which are serious and related to the study 
intervention need to be recorded . 
An abnormal laboratory value will be considered an AE if the laboratory abnormality is characterized by any of the following:  
• Results in discontinuation from the study  
• Is associated with clinical signs or symptoms  
• Requires treatment or any other therapeutic intervention  
• Is associated with death or another serious adverse event,  including hospitalization.  
• Is judged by the Investigator to be of significant clinical impact 
• If any abnormal laboratory result is considered clinically significant, the investigator will 
provide details about the action taken with respect to the test drug and about the patient’s outcome.  
End of study procedures: Data will be stored according to HHS , FDA regulations and NIH 
Intramural Records Retention Schedule as applicable.  
Loss or destruction of data: Should we become aware that a major breach  in our plan to protect 
subject confidentiality and trial data has occurred, this will be reported expeditiously per 
requirements in section 7.2.1 .  
6.1.1 Adverse event recording:  
• Grade 1 adverse events will not be recorded.  
• Grade 2 adverse events that will be recorded:  
a. Adverse events regardless of attribution will be recorded for the first year after the infusion.
 
b. Unexpected events that are possibly,  probably, or definitely related to the research  
will be recorded after the first year . 
• All grade 3, 4, and 5 adverse events will be recorded regardless of attribution.  
• All serious events regardless of attribution  
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
71 6.2 DATA SHARING PLANS  
6.2.1 Human Data Sharing Plan  
What data will be shared?  
I will share human data generated in this research for future research as follows:  
  x__ Coded, linked data in an NIH -funded or approved public repository.   
_x__ Coded, linked data in BTRIS (automatic for activities in the Clinical Center)  
_x__ Coded, linked or identified data with approved outside collaborators under appropriate 
agreements.  
 
How a nd where will the data be shared?  
Data will be shared through:  
  x__ An NIH -funded or approved public repository.  Insert name or names:  ClinicalTrials.gov . 
_x__ BTRIS (automatic for activities in the Clinical Center)  
_x__ Approved outside collaborators under appropriate individual agreements.  
_x__ Publication and/or public presentations.  
 
When will the data be shared 
_x__ Before publication.  
_x__ At the time of publication or shortly thereafter.  
6.3 GENOMIC DATA SHARING PLAN 
Genomic data will not be generated.  
6.4 RESPONSE CRITERIA  
Responses will be categorized by using the International Uniform Response Criteria for Multiple 
myeloma  2016 updated version. (155)  Multiple  myeloma staging will be conducted at the 2 week 
follow -up appointment and at each subsequent follow -up appointment.  The appropriate staging 
studies will need to be determined for each patient because  of the variability in multiple myeloma.    
6.4.1 Important Considerations on response criteria  
• Response criteria for all categories and subcategories of response except CR  and sCR  are 
applicable only to patients who have ‘measurable’ disease by at least one of the three measurements as defined below  
• All responses must be confirmed to be stable in two evaluation s made at any time.  
6.4.1.1  Definition of measurable disease(24
) 
Any one or combination of these abnormalities defines measurable disease:   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
72 • Serum M -protein greater or equal to  0.6 g/dL (6 g/L).  
• Urine M -protein greater or equal to 200 mg/24 h.  
• Serum FLC assay: involved FLC level greater or equal to10 mg/dL (100 mg/ L) provided 
serum FLC ratio is abnormal.  
• Presence of a biopsy -proven plasmacytoma  
6.4.1.2  Laboratory tests for measurement of M -protein  
• Serum M -protein level is quantitated using densitometry on SPEP except in cases where 
the SPEP is felt to be unreliable such as in patients with IgA monoclonal proteins migrating 
in the beta region.  If SPEP is not available or felt to be unreliable (e.g., in some cases of 
IgA myeloma) for routine M-protein quantitation during therapy, then quantitative 
immunoglobulin levels on nephelometry or urbidometry can be accepted.  However, this must be explicitly reported, and only nephelometry can be used for that patient to assess response and SPEP and ne phelometric values cannot be used interchangeably.  
• Urine M -protein measurement is estimated using 24 -h UPEP only.  (Random or 24 h urine 
tests measuring kappa and lambda light chain levels are not reliable and are not 
recommended)  
6.4.1.3  Suggested follow -up to me et response criteria  
• Patients with  measurable disease by both SPEP and UPEP need to be followed by both 
SPEP and UPEP for response assessment and categorization;  
• Except for assessment of sCR, CR, and VGPR, patients with “measurable disease” restricted to the SPEP will need to be followed routinely only by SPEP;  
• Patients with “measurable disease” restricted to the UPEP will need to be followed routinely only by UPEP;  
• Patients with “measurable disease” in either SPEP or UPEP or both will be assessed for response only based on these two tests and not by the FLC assay;  
• FLC response criteria are only applicable to patients without measurable disease in the serum or urine, and to fulfill the requirements of the category of sCR;  
• Bone marrow is required only for  categorization of CR   
• For good clinical practice patients should be periodically screened for light chain escape with UPEP or serum FLC assay.  
• Plasmacytomas can be staged at baseline and followed for response with CT scans  or MRI 
scans  by measuring target lesions with the sums of the products of the diameters method. 
For purposes of defining CR, masses greater than 1.5 cm will be considered abnormal.  
6.4.2 International Myeloma Working Group uniform response criteria:  
6.4.2.1  Stringent Complete Remission (sCR)  
• CR as d efined below  plus 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
73 o Normal FLC ratio and  
o Absence of clonal cells in bone marrow by immunohistochemistry or 
immunofluorescence  or flow cytometry  (only1 bone marrow  evaluation  is needed).  
6.4.2.2  Complete Remission (CR)  
• Negative immunofixation on the serum and urine and  
• Disappearance of any soft tissue plasmacytomas and 
• 5% or less plasma cells in bone marrow (only 1 bone marrow evaluation is needed) 
• No evidence of progressive or new bone lesions if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)  
Comments: To  be considered a CR,  
• Both  serum and urine immunofixation must be carried out and be negative regardless of 
the size of baseline M -protein in the serum or urine;  
• Patients with negative UPEP values pretreatment still require UPEP testing to confirm CR 
and exclude light chain or Bence– Jones escape  
6.4.2.3  Very Good Partial Remission (VGPR)  
• Serum and urine M -protein detectable by immunofixation but not on electrophoresis or  
• 90% or greater reduction in serum M -protein plus urine M -protein level <100mg per 24 h  
• No evidence of progressive or new bone lesions if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)  
• 90% decrease in the sum of the products of the diameters of soft tissue plasmacytomas is required.  
6.4.2.4  Partial Remission (PR)  
• 50% or greater reductio n of serum M -protein and  
• 90% or greater reduction in 24-h urinary M -protein (or to less than 200mg per 24 h)  and 
• 50% or greater reduction in the size of soft tissue plasmacytomas, if present at baseline  
•  No evidence of progressive or new bone lesions if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)  
Only  if the serum and urine M -protein are not measurable (as per definition in section  6.4.1.1 ), 
• 50% or greater decrease in the difference between involved and uninvolved FLC levels is required (in lieu of the serum and urine M -protein criteria).  
• If serum and urine M -protein are not me asurable and serum FLC assay is also not 
measurable, 50% or greater reduction in plasma cells is required in lieu of M -protein 
evaluation (provided baseline bone marrow plasma cell percentage was 30% or greater)  
6.4.2.6  Stable Disease (SD)  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
74 • Not meeting criteria for CR, VGPR, PR or progressive disease  
(Not recommended for use as an indicator of response; stability of disease is best described by 
providing the time to progression estimates)  
• All response categories require two consecutive assessments made at any time before the 
institution of any new therapy;  
• Confirmation with repeat bone marrow biopsy not needed.  
• Presence/absence of clonal cells is based upon the κ/λ ratio.  An abnormal κ/λ ratio by immunohistochemistry and/or immunofluorescen ce requires a minimum of 100 plasma cells 
for analysis.  An abnormal ratio reflecting presence of an abnormal clone is κ/λ ration of greater 
than 4:1 or less than 1:2.  
6.4.2.7  Progressive Disease (PD)
a 
Requires one or more of the following:  
• Increases of greater or equal to 25%  from the lowest post -treatment (nadir) value  in 
o Serum M -component (minimum absolute increase of 0.5g/ dL) or 
o Urine M -component (minimum absolute increase of 200mg/24h) or  
o Only in patients without measurable M -protein, percentage of bone marrow plasma 
cells (minimum absolute percentage of 10%)  
o Only in patients without measurable serum and urine M -protein levels:  The 
difference between involved and uninvolved FLC levels.  The absolute increase must be >10 mg/dL.   The FLC ratio must be  abnormal.  
• Definite development of new bone lesions  or clear increase in size of on e or more bone 
lesion(s) (must be 50% or greater increase of a lesion at least 1 cm in longest length at nadir)  on CT scan or new lesion  1.5 cm or larger on CT scan.  
• 50% or more increase in the sum of the products of the diameters of multiple soft tissue plasmacytomas or 50% or more increase in the size of a single soft tissue plasmacytoma.  
• Development of hypercalcemia solely attributable to the disease  (corrected serum 
calci um >11.5 mg/dL)   
aAll relapse categories require 2 consecutive assessments made at any time before 
classification as relapse or progression or institution of a new therapy.  
 
6.4.3 Minimal residual disease (MRD) criteria (requires complete response as defined 
above)  
Flow MRD -negative -Absence of aberrant clonal plasma cells in the bone marrow by f low 
cytometry  using EuroFlow standard operating procedures or equivalent  (which includes NCI 
Dept. of Pathology multicolor flow); must have sensitivity of one in 105 nucleated cells.  
Sequencing MRD -negative -absence of clonal plasma cells by next generation sequencing  on 
bone marrow aspirate with a method with sensitivity of 1 in 105 nucleated cells.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
75 Imaging plus MRD -negative -MRD negativity as defined by NGF or NGS plus 
disappearance of every area of increased tracer uptake found at baseline or a preceding 
PET/CT or decrease to less than mediastinal blood pool SUV or decrease to less than that of surrounding normal tissue.  
6.5 T
OXICITY CRITERIA  
The following adverse event management guidelines are intended to ensure the safety of each patient while on the study.  The descriptions and grading scales found in the revised NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 5 .0 will be utilized for AE 
repor ting.  All appropriate treatment areas should have access to a copy of the CTCAE version 
5.0.  A copy of the CTCAE version 5 .0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ).  
7 NIH  REPOR TING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN 
7.1 D
EFINITIONS  
Please refer to definitions provided in Policy 801: Reporting Research Events found here . 
7.2 OHSRP  OFFICE OF COMPLIANCE AND TRAINING / IRB  REPORTING  
7.2.1 Expedited Reporting  
Please refer to the reporting requirements in Policy 801: Reporting Research Events and Policy 802 Non-Compliance Human Subjects Research found here
. Note: Only IND Safety Reports that 
meet the definition of an unanticipated problem will need to be reported per these policies.  
7.2.2 IRB Requirements for PI Reporting at Continuing Review  
Please refer to the reporting requirements in Pol icy 801: Reporting Research Events found here .  
7.3 NCI  CLINICAL DIRECTOR REPORTING  
Problems expeditiously reported to the OHSRP in iRIS will also be reported to the NCI Clinical 
Director.  A separate submission is not necessary as reports in iRIS will be available to the 
Clinical Director.  
In addition to those reports, all deaths that occur within 30 days after receiving a research 
intervention should be reported via email to the Clinical Director  unless they are due to 
progressive disease.    
To report these deaths, please send an email describing the circumstances of the death to  Dr. 
Dahut  at NCICCRQA @mail.nih.gov  within one business day of learning of the death.  
7.4 INSTITUTIONAL BIOSAFETY COMMITTEE (IBC)  REPORTING CRITERIA  
7.4.1 Serious Adverse Event  Reports to IBC 
The Principal Investigator (or delegate) will notify  IBC of any unexpected fatal or life -threatening 
experience associated with the use of CAR-SLAMF7  T cells  as soon as possible but in no event 
later than 7 calendar days of initial receipt of the information.  Serious adverse events  that are 
unexpected and associated with the use of the CAR-SLAMF7  -expressing T cells , but are not fatal 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
76 or life -threatening, must be reported to the NIH IBC as soon as possible, but not later than 15 
calendar days after the investigator’s  initial receipt of the information.  Adverse events may be 
reported by using the FDA Form 3500a.  
7.4.2 Annual Reports to IBC  
Within 60 days after the one -year anniversary of the date on which the  IBC approved the initial 
protocol , and after each subsequent anniversary until the trial is completed, the Principal 
Investigator (or delegate) shall submit the inform ation described below.  Alternatively, the IRB 
continuing review report  can be sent to IBC in lieu of a separate report.  Please include the IBC 
protocol number on the report.  
7.4.2.1  Clinical Trial Information   
A brief summary of the status of the  trial in progre ss or completed during the previous year. The 
summary is required to include the following information:  
• the title and purpose of the trial   
• clinical site  
• the Principal Investigator  
• clinical protocol identifiers  participant population (such as disease indication and general 
age group, e.g., adult or pediatric);  
• the total number of participants planned for inclusion in the trial; the number entered into 
the trial to date  whose participation in the trial was completed; and the number who 
dropped out of the t rial with a b rief description of the reasons   
• the status of the trial, e.g., open to accrual of subjects, closed but data collection ongoing , 
or fully completed,  
• if the trial has been completed, a brief description of any study results.  
7.4.2.2  Progress Report a nd Data Analysis  
Information obtained during the previous year's clinical and non-clinical investigations, 
including:  
• a narrative or tabular summary showing the most frequent and most serious adverse experiences by body system  
• a summary of all serious adverse events submitted during the past year  
• a summary of serious adverse events that were expected or considered to have causes not associated with the use of the gene transfer product such as disease progression or concurrent medications  
• if any deaths have occurred, the number of participants who died during participation in 
the investigation and causes of death  
• a brief description of any information obtained that is pertinent to an understanding of the 
gene transfer product’s actions, including,  for example, information about dose -response, 
information from controlled trials, and information about bioavailability.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
77 7.5 NIH  REQUIRED DATA AND SAFETY MONITORING PLAN 
7.5.1 Principal Investigator/Research Team  
The clinical research team will meet on a regular weekly basis when patients are being actively 
treated on the trial to discuss each patient. Decisions about dose level enrollment and dose 
escalation if applicable will be made based on the toxi city data from prior patients.  
All data will be collected in a timely manner and reviewed by the principal investigator.  Events 
meeting requirements for expedited reporting as described in section 7.2.1  will be submitted within 
the appropriate timelines.  
 The principal investigator will review adverse event and response data on each patient to ensure 
safety and data accuracy. The principal investigator will personally conduct or supervise the invest igation and provide appropriate delegation of responsibilities to other members of the 
research staff.  
7.5.2 Safety Monitoring Committee (SMC) 
This protocol will require oversight from the Safety Monitoring Committee (SMC).  Initial review 
will occur as soon as  possible after the annual NIH Intramural IRB continuing review date.   
Subsequently, each protocol will be reviewed as close to annually as the quarterly meeting schedule permits or more frequently as may be required by the SMC.   For initial and subseque nt 
reviews, protocols will not be reviewed if there is no accrual within the review period. Written outcome letters will be generated in response to the monitoring activities and submitted to the Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.  
8 SPONSOR SAFETY REPORTING  
8.1 D
EFINITIONS  
8.1.1 Adverse Event  
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this 
treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related t o the medicinal (investigational) 
product (ICH E6 (R2)) 
8.1.2 Serious Adverse Event (SAE)  
An adverse event or suspected adverse reaction is considered serious if in the view of the 
investigator or the sponsor, it results in any of the following:  
• Death,  
• A life -threatening adverse event (see 8.1.3 ) 
• Inpatient hospitalization or prolongation of existing hospitalization  
o A hospitalization/admission that is pre -planned (i.e., elective or scheduled surgery 
arranged prior to the start of the study), a planned hospitalization for pre -existing 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
78 condition, or a procedure required by the protocol, without a serious deterioration i n 
health, is not considered a serious adverse event.  
o A hospitalization/admission that is solely driven by non -medical reasons (e.g., 
hospitalization for patient convenience) is not considered a serious adverse event.  
o Emergency room visits or stays in observation units that do not result in admission to 
the hospital would not be considered a serious adverse event. The reason for seeking 
medical care should be evaluated for meeting one of the other serious criteria.  
 
• Persistent or significant incapacity or substantial disruption of the ability to conduct norma l 
life functions  
• A congenital anomaly/birth defect.  
• Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition.  
8.1.3 Life-threatening  
An adverse event or suspected adverse reaction is considered "life-threatening" if, in the  view of 
either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death. It does not include an adverse event or suspected adverse reaction that, had it occurred in a 
more severe form, might have caused death. ( 21CFR312.32)  
8.1.4 Severity  
The severity of each Adverse Event will be assessed utilizing the CTCAE version 5 .0. 
8.1.5 Relationship to Study Product  
All AEs will have their relationship to study product assessed using the terms:  related or not 
related.   
• Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the study product and the adverse event.  
• Not Related  – There is not  a reasonable p ossibility that the administration of the study 
product caused the event.  
8.2 ASSESSMENT OF SAFETY EVENTS  
AE information collected will include event description, date of onset, assessment of severity and relationship to study product and alternate etiology (i f not related to study product), date of 
resolution of the event, seriousness and outcome. The assessment of severity and relationship to 
the study product will be done only by those with the training and authority to make a diagnosis 
and listed on the For m FDA 1572 as the site principal investigator or sub-investigator.  AEs 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
79 occurring during the collection and reporting period will be documented appropriately regardless 
of relationship.  AEs will be followed through resolution.  
SAEs will be: 
• Assessed for severity and relationship to study product and alternate etiology (if not related 
to study product) by a licensed study physician listed on the Form FDA 1572 as the site 
principal investigator or sub-investigator.  
• Recorded on the appropriate SAE report form, the medical record and captured in the clinical database.  
• Followed through resolution by a licensed study physician listed on the Form FDA 1572 as the site principal investigator or sub -investigator.  
For timeframe of recording adverse events, please refer to section 6.1 . All serious adverse events 
recorded from the time of first investigational product administration must be reported to the 
sponsor.  
8.3 R
EPORTING OF SERIOUS ADVERSE EVENTS  
Any AE that meets a protocol -defined serious criterion or meets the definition of Adverse Event 
of Special Interest that require expedited reporting must be submitted immediately (within 24 
hours of awarene ss) to OSRO Safety using the CCR SAE report form.  
All SAE reporting must include the elements described in  section  8.2. 
SAE reports will be submitted to the Center for Cancer Research (CCR) at: OSROSafety@mail.nih.gov
 and to the CCR PI and study coordinator.  CCR SAE report form and 
instructions can be found at:   
https://ccrod.cancer.gov/confluence/pages/viewpage.action?pageId=157942842   
Following the assessment of the SAE by OSRO, other supporting documentation of the event may 
be requested by the OSRO Safety and should be provided as soon as possible.  
8.4 SAFETY REPORTING CRITERIA TO THE PHARMACEUTICAL COLLABORATORS  
8.4.1 Reporting by CCR to Bellicum Pharmaceuticals Inc.  
All events listed below must be reported in the defined timelines to CCRsafety@mail.nih.gov .  
The CCR Office of Regulatory Affairs will send all reports to the manufacture r as described below.  
Rimiducid is provided under NCI CTA# 01096-18 with Bellicum Pharmaceuticals Inc. Data 
sharing with Bellicum Pharmaceuticals Inc. must be carried out as follows:  
• An annual report of all patients receiving Rimiducid. This report will consist of a brief summary of each patient’s Grade 2 or greater adverse events and multiple myeloma 
responses after the date of Rimiducid administration (report to Paul Woodard, MD of Bellicum, Inc. at pwoodard@bellicum.com).  
• Communications with the FDA related to Rimiducid must be shared within 10 c alendar 
days. Report to this email address: BellicumSafety@pharmalex.com
. Also send to Paul 
Woodard, MD of Bellicum, Inc. at pwoodard@bellicum.com.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
80 • Pregnancies must be reported to BellicumSafety@pharmalex.com . Also send a copy to 
Paul Woodard, MD of Bellicum, Inc. at pwoodard@bellicum.com.  
8.4.2 Reporting by Study Team to Bellicum Pharmaceuticals Inc.  
• SAEs possibly or definitely related to Rimiducid must be reported within 24 hours of 
the sponsor becoming aware of the SAE. Study team will report to this email address: BellicumSafety@pharmalex.com
. Back -up reporting is to this phone number: 1-617 -
315-4825. Also, report to Paul Woodard, MD of Bellicum, Inc. at pwoodard@bellicum.com.  
• Any use of Rimiducid must be reported within 3 calendar days and must include the following (report to Paul Woodard, MD of B ellicum, Inc. at 
pwoodard@bellicum.com.) by
 Principal Investigator: 
o Patient age, sex, malignancy, brief history including indication for Rimiducid  
o Dose of CAR T cells received by the patient and percentage of infused cells expressing the CAR  
o Blood CAR T -cell levels before and after Rimiducid administration (may take 
longer than 3 days to obtain these results).  
o Blood cytokine levels before and after Rimiducid administration (may take longer than 3 days to obtain these results).  
o Timing and nature of Grade 2 or greater AEs within the first 3 days after Rimiducid administration.     
 
8.5 R
EPORTING PREGNANCY  
8.5.1 Maternal  exposure  
If a patient becomes pregnant during the study, the study treatment should be discontinued 
immediately, and the pregnancy reported to the Sponsor no later than 24 hours of when the 
Investigator becomes aware of it. The Investigator should notify the Sponsor no later than 24 hours 
of when the outcome of the Pregnancy become known,  
Pregnancy itself is not regarded as an SAE. However, congenital abnormalities or birth defects 
and spontaneous miscarriages that meet serious criteria ( section 8.1.2 ) should be reported as SAEs.  
The outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital abnormality) should be followed up and documented.  
8.5.2 Paternal exposure 
Male patients shou ld refrain from fathering a child or donating sperm during the study and for 4 
months after the last dose of receiving protocol treatment.  
Pregnancy of the patient’s partner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
81 congenital abnormality) occurring from the date of the first dose until ( 120 days)  after the last dose 
should, if possible, be followed up and documented.  
8.6 REGULATORY REPORTING FOR STUDIES CONDUCTED UNDER CCR-S PONSORED IND 
Following notification from the investigator, CCR, the IND sponsor, will report any suspected 
adverse reaction that is both serious and unexpected in expedited manner to the FDA in accordance 
to 21 CFR 312.32.  CCR will report an AE as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the study product and the adverse event.  CCR will notify 
FDA and all participating investigators (i.e., all investigators to whom the sponsor is providing 
drug under its INDs or under any investigator’s IND) in an IND safety report of potential serious risks from clinical trials or any other source, as soon as possible, in accordance to 21 CFR Part 312.32.  
All serious events will be reported to the FDA at least annually in a summary format.  
9 CLINICAL MONITORING  
As a sponsor for clinical trials, FDA regulations require the CCR to maintain a monitoring program. The CCR’s program allows for confirmation of: study data, specifically data that could affect the interpretation of primary and secondary study endpoints; adherence to the protocol, regulations, ICH E6, and SOPs; and human subjects protection. This is done through independent 
verification of study data with source documentation focusing on:  
• Informed consent process  
• Eligibility confirmation  
• Drug administration and accountability  
• Adverse events monitoring  
• Response assessment.  
The monitoring program also extends to multi -site research when the CCR is the coordinating 
center.  
This trial will be monitored by personnel employed by a CCR contractor. Monitors are qualified 
by training and experience to monitor the progress of clinical trials. Personnel monitoring this 
study will not be affiliated in any way with the trial conduct.  
10 STATI STICAL CONSIDERATIONS    
10.1 S
TATISTICAL HYPOTHESIS  
The primary endpoint of this trial is to determine the safety of administering CAR-expressing T cells to patients with multiple myeloma.  The primary approach for assessing this endpoint will be through a dose  escalation.   
Exploratory objectives of this trial are to measure any anti -malignancy effect that might occur, to 
assess the feasibility of administering CAR-expressing T cells, and to measure persistence, 
function, and gene expression of CAR -expressing T  cells. In addition, the efficacy of Rimiducid 
at inducing apoptosis of the SLAMF7 expressing  CAR T cells and mitigating toxicity including 
severe infections will be assessed.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
82 10.2 SAMPLE SIZE DETERMINATION  
The sample size of this clinical trial will be determ ined by the requirements of the dose -escalation 
scheme.  A maximum of 24 treated patients will be needed to complete the dose escalation scheme, 
and an additional 12-patient expansion group will be treated at the MTD.  The 12 -patient expansion 
group to bet ter characterize the MTD is needed because of the substantial variability between 
patients receiving infusions of CAR T cells.  The total number of treated patients will be a 
maximum of 36. The trial uses a dose -escalation design, with 4 dose levels and a -1 dose level if 
needed.  The number of CAR+ T cells transferred for each dose level  is as follows:  
 
Dose level -1 0.3x106 CAR+ T cells per kg of recipient bodyweight  
Dose level 1  0.66x106 CAR+ T cells per kg of recipient bodyweight  
Dose level 2  2.0x106 CAR+ T cells per kg of recipient bodyweight  
Dose level 3  6.0x106 CAR+ T cells per kg of recipient bodyweight  
Dose level 4  12.0x106 CAR+ T cells per kg of recipient bodyweight  
 If sufficien t cells cannot be grown to meet the criteria for the assigned dose level , the patient will 
receive the dose of cells called for by one dose level lower than the assigned dose level .  If  
sufficient cells cannot be grown to meet the dose requirement called f or one dose level lower than 
the assigned dose level , the treatment will be aborted.  If a DLT occurs in an additional patient 
entered at a lower dose due to cell growth limitations, accrual will continue at this level as 
described in the dose -escalation s cheme in section 3.1.4
.  Accrual will be halted at the higher level 
until accrual at the lower level is complete as described above.  
Should none of the first 3 patients treated on a dose level experience a DLT, the first patient can be infused on the next higher dose level after a 28 -day delay following CAR T -cell infusion of the 
third patient.  Should 1 of 3 patients experience a DLT at a particular dose level, three more patients 
would be treated at that dose level. If 1/6 patients have a DLT at a particular dose level, the first patient can be infused on the next higher dose level after a 28-day delay following CAR T -cell 
infusion of the 6
th patient. If a level with 2 or more DLTs in 3 -6 patients has been identified, 3 
additional patients will be accrued at the next-lowest dose for a total of 6, in order to further 
characterize the safety of the MTD .  The MTD  is the dose at which a maximum of 1 of 6 patients 
has a DLT.  After a MTD  is defined, additional patients can be treated on this trial: up to 12 total 
additional recipients can be treated after a MTD is established in order to better define safety and 
toxicity at that dose level.  If cell growth limitations preclude administration of the maximum 
tolerated dose to a patient in the expansion group, the patient will receive as many cells as possible 
up to the MTD .  
DLTs that occur in patients receiving a repeat treatment will not affect the dose  escalation because 
no retreatments will be allowed until the optimal CAR T-cell dose is established.  Use of Rimiducid 
will be recorded and used in descriptive statistics.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
83 10.3 POPULATIONS FOR ANALYSES  
Toxicity Analysis: All patients will be evaluable for toxicity from the time of Anti-SLAMF7 -CAR  
T cell infusion.  Toxicity data will be collected for all patients.  
Response Analysis - Intention to treat: any subjects who enroll onto the trial and provide consent 
and who receive at least one cycle of treatment wil l be included in analyses  dataset . 
10.4 STATISTICAL ANALYSES  
10.4.1  General Approach  
This is a standard 3+3 dose escalation study. Toxicity data will be obtained and used to determine 
the MTD of the treatment.  
10.4.2  Analysis of the Primary Endpoints  
The toxicity obtained on each patient will be determined and used to report the number of patients at each dose level who experience a DLT, following standard phase I procedures.  
10.4.3  Analysis of the Secondary Endpoint(s)  
There are no secondary endpoints.  
10.4.4  Safety Analyses  
The study will determine the toxicity experienced on each patient enrolled on the trial and report this by dose level.  
10.4.5  Baseline Descriptive Statistics  
None will be provided in a formal manner; brief descriptions may be incorporated in a final report.  
10.4.6  Planned Interim A nalyses  
Toxicity will be evaluated at each dose level as the patients accrue to the trial. Stopping criteria are described in section 3.8
. 
10.4.7  Sub-Grou p Analyses  
None  
10.4.8  Tabulation of individual Participant Data  
None  
10.4.9  Exploratory Analyses  
The degree of persistence of CAR -transduced T cells will be evaluated by a quantitative measure 
(flow cytometry and/or quantitative PCR) in all patients.  Serum cytokine levels are other important exploratory assessments.  Anti -malignancy effects will be measured by clinical response 
and categorized according to the International Uniform Response Criteria for Multiple Myeloma 
(Section 6.4
). The clinical multiple myeloma responses will be interpreted cautiously in the context 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
84 of a pilot study which may be used to guide parameters for study in future protocols if warranted.  
Efficacy of Rimiducid will be assessed by resolution of clinical toxicity and by evaluating 
elimination of CAR+ T cells by monitoring blood CAR T -cell levels by qPCR and/or flow 
cytometry.  
All other evaluations of exploratory objectives will be performed using exploratory techniques. No formal adjustment for multiple comparisons will be used since the evaluations are being done to generate hypotheses.  Exploratory assessments will include analysis for associations between 
clinical outcomes suc h as severity of toxicity and serum cytokine levels or severity of toxicity and 
blood CAR T -cell levels.  Parametric and nonparametric tests will be used as appropriate.   
11 COLLABORATIVE AGREEMENTS  
11.1 C
LINICAL TRIAL AGREEMENT  
Rimiducid is provided under a Clinical Trial Agreement (CTA) NCI CTA# 01096 -18 with 
Bellicum Pharmaceuticals Inc.  
12 HUMAN SUBJECTS PROTE CTIONS  
12.1 RATIONALE FOR SUBJECT SELECTION  
• The patients to be entered in this protocol have multiple myeloma which is an almost 
always incurable disease; m oreover, patients will have progressive or relapsed myeloma 
despite at least 3 prior therapies.  These patients have limited life expectancies.  Subjects 
from both sexes  and all racial/ethnic groups are eligible for this study if they meet the 
eligibility criteria.  To date, there is no information that suggests that differences in disease 
response would be expected in one group compared to another.  Efforts will be made to extend accrual to a representative population, but in this preliminary study, a bala nce must 
be struck between patient safety considerations and limitations on the number of individuals exposed to potentially toxic and/or ineffective treatments on the one hand and the need to explore gender and ethnic aspects of clinical research on the other hand.  If differences in outcome that correlate to gender or to ethnic identity are noted, accrual may 
be expanded,  or a follow -up study may be written to investigate those differences more 
fully.  
• MM remains an incurable disease despite recent advances in therapy . 
• Over the last 40 years and throughout the most recent era of improved therapy with novel 
agents, the depth of the disease response to therapy (including T- cells targeting B -cell 
maturation antigen ) has remained the single most predictive factor for event free and 
overall survival in MM 
• Therefore, improving the rate and depth of responses remains a high priority for clinical research in MM. 
• This justifies the enrollment of all subjects with MM eligible for T- cells targeting B -cell 
maturation antigen  in this phase I/II study in an attempt to improve the clinical outcome 
while feasibility and safety are being evaluated.  
• The upper age limit of this protocol will be 73 years of age. CAR T -cell therapies  often 
result in patients being admitted to intensive care units due to cytokine -release syndrome. 
These critically ill patients often need vasopressor drugs and occasionally need mechanical 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
85 ventilation among other intensive care interventions. The mortality of critically -ill patients 
progressively increases with age above 20 years  as shown in the Acute Physiol ogy and 
Chronic Health Evaluation (APACHE) IV: Hospital mortality assessment for today’s 
critically ill patients. (156 ) Because mortality of critically -ill patients reaches >10% at age 
70 (Table 6 of the cited paper). Because CAR toxicity is very unpredictable and based on 
my extensive past experience treating patient with CAR T cells on phase I clinical trials, I 
choose to not enroll patients over the age of 73.  
12.2 PARTICIPATION OF CHILDREN  
Children will not be enrolled on this study.  Multiple myeloma is extremely uncommon in children; moreover, since the efficacy of this experimental procedure is unknown, it does not se em 
reasonable to expose children to this risk without further evidence of benefit.   
12.3 P
ARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT  
Adults unable to give consent are excluded from enrolling in the protocol.  However,  re-consent 
may be necessary and there is a possibility, though unlikely, that subjects could become 
decisionally impaired. For this reason and because there is a prospect of direct benefit from 
research participation (section 10.4  ), all subjects will be offered the opportunity to fill in their 
wishes for research and care, and assign a substitute decision maker on the “NIH Advance 
Directive for Health Care and Medical Research Participation” form so that another person can 
make decisions about their medical care in the event that they become incapacitated or cognitively 
impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent 
Assessment  Team  (ACAT) for evaluation  as needed for the following:  an independent assessment 
of whether an individual has the capacity to provide consent; assistance in identifying and assessing an appropriate surrogate when indicated; and/or an assessment of the ca pacity to appoint 
a surrogate .  For those subjects that become incapacitated and do not have pre -determined 
substitute decision maker, the procedures described in NIH HRPP SOP 14E  for appointing a 
surrogate decision maker for adult subjects who  are (a) decisionally impaired, and (b) who do not 
have a legal guardian or durable power of attorney, will be followed.   
12.4 EVALUATION OF BENEFITS AND RISKS/DISCOMFORTS  
The experimental treatment has a chance to provide clinical benefit though this is unknown.  A goal o f this study is to improve upon the number of patients who may benefit from adoptive cell 
therapy by using genetically modified  T-cells.  This clinical trial is being performed to evaluate a 
genetically -modified T -cell therapy for multiple myeloma, which i s an almost always incurable 
disease. (21
)  Only patients with multiple myeloma who have persisting or relapsed myeloma 
despite at least 3 prior lines of therapy will be enrolled. The risks of  the study fall into six  
categories.   
The first category is  chemotherapy -related toxicity that could cause cytopenias. As with any 
chemotherapy that causes neutropenia and thrombocytopenia, this chemotherapy could cause toxicities such as infections and bleeding.  
The second category of toxicity is cytokine -release -type toxicities such as high fevers, tachycardia, 
transient abnormalities of liver function and hypotension. These cytokine -release -type toxicities 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
86 have been detected in other clinical trials of CAR T cells during the first two week s after anti -
CD19 CAR T cells and  anti-BCMA CAR T cells were infused. (4, 5, 134) 
A third category of potential toxicities are neurological toxicities such as delirium, obtundation, 
myoclonus, seizures, headache and transient focal neurological toxicities including aphasia an d 
focal paresis. In previous anti -CD19 CAR trials, cytokine -release toxicities and neurological 
toxicities have been limited in duration with toxicities generally resolving within 2 days to 3 
weeks. (5, 41, 74, 135, 136) In the NCI anti -BCMA trial, neurologic toxicities were limited to 
confusion or delirium in the setting of high fevers and one case of encephalopathy and muscle weakness of all extremities consistent with critical illness polyneu ropathy/polymyopathy .(
5) In 
most cases, these toxicities have been transient with toxicities generally resolving within 2 days to 2 weeks .   
The fourth category of toxicity is direct damag e to normal tissues by the CAR T cells.  This could 
happen because of unexpected cross -reactivity of the anti-SLAMF7 CAR with proteins other than 
SLAMF7 in vivo. This trial will be  one of the first in human trials testing anti-SLAMF7 CAR T 
cells in patients with multiple myeloma who have failed at least three previous lines of therapy. Although SLAMF7 is highly expressed in almost all cases of MM it has very limited or absent expression on normal tissues aside from leukocytes. (9, 10, 110, 112, 113
)  Hematopoietic stem 
cells do not express SLAMF7.( 111) SLAMF7 is not expressed on the surface of normal organ 
epithelial tissue such as lung, kidney, stomach, brain, breast, spleen, prostat e, skeletal muscle, 
testis, liver, ovary, heart, thymus and small intestine epithelial tissue. (9) We have performed 
extensive testing of the  MSGV -iCasp9 -Luc90CD828Z CAR T  cells by culturing them with a 
variety of human cell lines and have not seen recognition of cell lines that did not express SLAMF7. In addition, we did not find any evidence of cross -reactivity in our cell line data or 
immunohistochemistry data from the N IH Department of Pathology.  
A fifth category of toxicity that may be caused by anti -SLAMF7 CAR T cells is impairment of 
normal immunity because SLAMF7 is expressed on leukocytes such as CD8+ T cells, natural killer 
(NK) cells, B cells, plasma cells, some monocytes, NKT cells, and some dendritic cells. (5, 9, 10, 
110, 112, 113) NK cell deficiencies are associated with severe, potentially life-threatening viral 
infections caused typically by benign members of the Herpesviridae (VZV, HSV, CMV, EBV) and Papillomaviridae (HPV) families. (
137) Additionally, NK cells have potent cytotoxic activity 
against malignant cells and NK cell defects are linked to ineffective tumor surveillance and 
clearance. We have included a suicide gene in this trial in large part to allow elimination of anti-SLAMF7 CAR T cells in case depletion of recipient immune cells lea ds to infections. Greater 
detail about the depletion of leukocyte subsets is provided below.  
Finally, genotoxicity is a theoretical risk of any type of integrating gene therapy. To our knowledge, genotoxicity, such as occurrence of a replication-competent retroviruses or 
transformation of T cells caused by insertional mutagenesis has never occurred in a clinical trials 
of T-cell gene therapies. (43, 44
)  The specific gene therapy vector backbone, MSGV1, proposed 
for use in this clinical trial has been used in hundreds of patients over the past 13+ years by our  
group and others. (4, 33, 138, 139) 
The potential benefits  to subjects enrolling on this trial include the possibility that the CAR T cells 
can cause a significant anti -myeloma effect. Many patients enrolled on trials of anti-CD19 CAR T 
cells and anti -BCMA CAR T cells obtained complete remissions of their advanced malignancies ; 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
87 there is a chance that recipients of the CAR T cells that are being evaluated in this protocol could 
derive a direct benefit from participation in this trial. Patients might also derive a benefit from 
knowing that they are contributing to the development of new cellular therapies for cancer by 
aiding in the development of new therapies might help future pat ients.  
Because all patients in this protocol have advanced multiple myeloma and limited life expectancies the potential benefit is thought to outweigh the potential risks.  It is also anticipated that this study will provide scientific information relevant to tumor immunotherapy.    
The risks associated with biopsies are pain and bleeding at the biopsy site. In order to minimize pain, local anesthesia will be used. Rarely, there is a risk of infection at the sampling site.  
12.4.1  Risks of exposure to Ionizing Radi ation  
    The procedures for performing the CT  scans will follow clinical policies, no special 
procedures apply to these additional assessments for research purposes.  In summary, subjects 
may receive additional radiation exposure from up to s even (7) CT neck  +CAP, two (2) CT -
Guided biopsies  and three (3)18F DG-PET/CT scans  in the first year of the study . 
The total additional radiation dose for research purposes will be approximately 15.6  rem in the 
first year of the study. Being exposed to too much radiation can cause harmful side effects such 
as an increase in the risk of cancer.  
Most patients will obtain much less than the maximum levels of radiation exposure since CT scans will only be carried out in patients who have measurable plasmacytomas after baseline assessment. 
In addition, CT imaging will be modified based on plasmacytoma locations. For example, many 
patients will not receive any post -infusion neck CTs since many patients do not have baseline neck 
involvement with myeloma. Most activity of CAR T cells occurs in the first 3 months after infusion, so we need to assess the onset of myeloma responses carefully during this time -period. 
Note that our imaging practices are similar to those in the largest multicenter anti-BCMA CAR study, the bb2121 trial . (157
) The radiation exposure on this study is in fact, less than what is 
outlined in the Raje et al. study.  
 
12.5 CONSENT PROCESS AND DOCUMENTATION  
The informed consent document will be provided to the participant or consent designee(s) (e.g., 
the parent/guardian i f participant is a minor, legally authorized representative [LAR] if 
participant is an adult unable to consent) for review prior to consenting.  A designated study 
investigator will carefully explain the procedures and tests involved in this study, and the  
associated risks, discomforts and benefits. In order to minimize potential coercion, as much time as is needed to review the document will be given, including an opportunity to discuss it with friends, family members and/or other advisors, and to ask questions of any designated study 
investigator. A signed informed consent document will be obtained prior to entry onto the study.  
The initial consent process as well as re -consent, when required, may take place in person in a 
private area (e.g., clinic consul t room) or remotely (e.g., via telephone or other NIH approved 
remote platforms) per discretion of the designated study investigator and with the agreement of 
the participant/consent designee(s).   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
88 Permission for additional biopsies for research will be obt ained from patients at the time of the 
biopsy procedure.  The research nurse, Principal Investigator  or his designee  is responsible for 
obtaining written informed consent from the patient.  
13 PHARMACEUTICAL INFORMATION   
Note: The commercial drugs used in this  study will not alter labelling of the FDA approved drug s 
and nor does the investigation involve a route of administration or dosage level in use in a patient 
population or other factor that significantly increases the risks (or decreases the acceptability  of 
the risks) associated with the use of the drug product.  
13.1 RETROVIRAL VECTOR CONTAINING THE CAR-SLAMF7  GENE  
13.1.1  Cells manufacturing  
The retr oviral vector supernatant  (MSGV1 -IC9-Luc90CD828Z)  (encoding a CAR directed against 
SLAMF7  with the iCasp9 suicide gene  system  was prepared and preserved following cGMP 
conditions in the University of Cincinnati Medical Center  Vector Production Facility . The 
retroviral vector utilizes the MSGV retroviral vector backbone including the 5' LTR from the 
murine stem cell virus (promoter), packaging  signal including the splicing donor (SD) and splicing 
acceptor sites,  the anti -SLAMF7   CAR protein containing a signal peptide from human CD8 -
alpha signal sequence, a single -chain variable fragment antigen recognition domain de rived from 
the murine Luc90 antibody , CD8 -alpha  (hinge and transmembrane  domains ), CD28 (cytoplasmic 
region), and CD3-zeta (cytoplasmic region), followed by the murine stem cell virus 3'LTR.    
The supernatant will be stored at – 80oC or shipped on dry ice and stored in the Dept. of Transfusion 
Medicine, NIH or at Fisher Biosciences , Rockville, MD. Both storage facilities are equipped with 
around-the -clock temperature monitoring. There will be no re -use of the same unit of supernatant  
for different patients. Retroviral titer has been shown to be stable after immediate thawing and 
immediate use. Handling of the vector should follow the guidelines of Biosafety Level -2 (BSL -
2).   The specific guidelines for Biosafety Level -2 (BSL -2) can b e viewed at 
http://bmbl.od.nih.gov/sect3bsl2.htm   
13.1.2  Source  
After cells are obtained by apheresis, further cell processing to generate CAR -expressing T cells 
will occur in the DTM according to standard oper ating procedures (SOPs).  Either freshlycollected 
cells or cryopreserved cells can be used to initiate the cell -preparation process.  
13.1.3  Toxicities  
Please refer to section 1.2.13 . 
13.1.4  Administration procedures :  
Please see section  3.3 3.1.4 .Potential Drug Interactions  
There are no known drug interactions.  
13.2 COMMERCIAL  AGENTS : 
Please refer to the US approved package insert for the full prescribing information here: 
http://www.accessdata.fda.gov/scripts/cder/drug satfda/index.cfm?fuseaction=Search.DrugDetails  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
89 13.2.1  Cyclophosphamide  
13.2.1.1  Source  
Cyclophosphamide will be purchased by the NIH Clinical Center Pharmacy Department from 
commercial sources and is supplied as a lyophilized powder in various vial sizes.  
13.2.1.2  Administration procedures  
The cyclophosphamide used in this regimen will be given as Intravenous infusion over 3 0 minutes.  
13.2.2  Fludarabine  
13.2.2.1  Source  
Fludarabine monophosphate will be purchased by the NIH Clinical Center Pharmacy Department from commercial sources and is supplied as a white, lyophilized powder. Each vial contains 50 mg of fludarabine phosphate, 50 mg of mannitol, and sodium hydroxide to adjust pH.  Fludara bine is 
stored at room temperature.  
13.2.2.2  Administration procedures  
Fludarabine is administered as  an IV infusion in 100 mL  0.9% sodium chloride, USP over 30 
minutes.   
13.3 R
IMIDUCID  
13.3.1  Source  
Rimiducid  will be  supplied by a CTA from Bellicum Inc.  
13.3.2  Toxicity  
No serious adverse events occurred during the Phase 1 study in volunteers. (122) The incidence of 
adverse events was very low following each treatment, with all adverse events being mild in 
severity. Only one adverse event was considered possibly related to AP1903. This was an episode 
of vasodilatation, described as “facial flu shing” for 1 volunteer at the 1.0 mg/kg AP1903 level. 
This event occurred at 3 minutes after the start of infusion and resolved after 32 minutes’ duration. All other adverse events reported during the study were considered by the investigator to be 
unrelat ed or to have improbable relationship to the study drug. These events included chest pain, 
flu syndrome, halitosis, headache, injection site pain, vasodilatation, increased cough, rhinitis, 
rash, gum hemorrhage, and ecchymosis. (
122) 
13.3.3  Formulation and prepa ration  
This information is from the Rimiducid “Guidance for Investigators” from Bellicum, Inc. The 
Rimiducid for Injection is packaged in 3 ml Type 1 clear glass serum vials. The contents of each 
vial are composed of the labeled content 10 mg (2 ml) of Rimiducid drug substance dissolved in a sterile, endotoxin free, 25% Solutol HS 15/Water for Injection solution at an Rimiducid concentration of 5 mg/ml and at pH 5.0 – 7.5. Each vial is stoppered with a Teflon© coated serum 
stopper and a yellow flip-off sea l.  
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
90 The primary product label (applied directly to the vial) for Rimiducid for Injection will contain the 
following information: product name, Rimiducid for Injection; the manufacturer’s lot number; 
product concentration, 5 mg/ml; volume of solution avail able in the vial; total Rimiducid contents 
of the vial (10 mg); a statement, “For IV Infusion Following Dilution, contains no preservatives” and the IND notation, “Caution: New Drug -Limited by Federal Law to Investigational Use”. The 
product will be labele d according to the requirement of each competent authority.  
 
Rimiducid is formulated in 25% Solutol HS 15, a non- ionic surfactant. Prior to administration, 
rimiducid is diluted in normal saline, which may lead to the formation of micro -micelles. Micelles of 
polyethoxylated pharmaceutical surfactants, such as Solutol, are known to activate complement, leading to anaphylactoid- like reactions or pseudoallergy. Such responses may be the result of the 
activation of mast cell and subsequent degranulation (Szebeni 2001).  
 
Bellicum recommends that patients are pre -medicated using standard procedures for the prevention of 
infusion reactions prior to administration of rimiducid. Such pre -treatment regimens would typically 
be administered thirty minutes to one hour prior to the infusion of rimiducid.  
Rimiducid for Injection must be warmed to room temperature prior to dilution.  
 
Drug interactions : Rimiducid is an investigational new drug and while there are no known verified 
drug interactions, investigators should be  aware that potential unknown interactions and adverse effects 
may occur. It should be noted that rimiducid is an inhibitor of CYP3A4 and CYP2C8 and therefore, co-administration of rimiducid with other substrates of CYP3A4 and CYP2C8 could lead to elevated  
concentrations of these concomitant medications. However, a drug/drug interaction study was 
conducted to evaluate the potential interaction of rimiducid with substrates of CYP3A4 using the probe 
midazolam. This study indicated that following a single IV dose of 0.5 mg/kg or less, rimiducid is 
unlikely to alter the clearance of co -administered CYP3A4 substrates.  
 
Rimiducid was tested in normal, healthy people at doses 2.5-fold greater than those used in the 
clinical trials using gene modified cells (Covance  Study No. 1711 -1). A side effect noted was facial 
flushing (redness) in one person. Although not observed in patients to date, rimiducid was associated with modest elevations of hepatic transaminases, bilirubin and alkaline phosphatase in the acute and su bacute non-human primate study. It is possible that other side effects may occur.  
In the Bellicum BP -PC-001 trial, one patient exhibited an adverse event of cytokine mediated release 
or hypersensitivity like reaction upon infusion of rimiducid and one pat ient experienced  urticaria and 
flushing, which resolved with antihistamine administration. None of these AEs were considered 
serious.  
Rimiducid for Injection is incompatible with materials containing plasticizer or DEHP and materials 
sterilized with ethylene oxide.  
 
Rimiducid (AP1903) with iCasp9 Swi tch suspected  unexpected serious adverse reaction 
(SUSARs) : Currently, no SUSARs have been reported under this program. For regulatory reporting 
purposes, there are currently no adverse events expected.  
The Rimiducid for Injection vials must be stored at 5°C ± 3°C (41°F ± 5°F) in a limited access, qualified refrigerator, preferably without l ight (but not required to protect from light). 
Prior to 
administration, the calculated dose will be diluted to 100 mL in 0.9% normal saline for 
infusion. (121, 122) 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
91 13.3.4  Administration procedures :  
For use, the Rimiducid will be diluted prior to administration. Rimiducid is administered via I.V. 
infusion at the target dose diluted in normal saline with volume as appr opriate for age of patient to 
be administered over 2 hours, using a DEHP -free saline bag and solution set.  
 
Rimiducid  for Injection (0.4 mg/kg) in a total volume of 100 ml  of Rimiducid plus normal saline  
will be administered via IV infusion over 2 hours, using a non-DEHP, non -ethylene oxide 
sterilized infusion set and an infusion pump.  For patients <50 kg or >150 kg, a volume of 
administration of Rimiducid different than 100 mL is allowed  (121, 122) 
Note: Recommendations include premedication per institutional standards (acetaminophen and 
antihistamine) 30 min utes prior to infusion for prevention of potential hypersensitivity to the 
Solutol HS 15 or rimiducid.   
Dose reduction for renal impairment: Rimiducid is thought to be cleared by non-renal means. Dose adjustments for hepatic or renal insufficiency have not been established.  
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
92 14 REFERENCES 
 
1. Gahrton G, Iacobelli S, Björkstrand B, Hegenbart U, Gruber A, Greinix H, et al. 
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation 
in multiple myeloma: long -term results of the EBMT-NMAM2000 study. Blood. 
2013;121(25):5055-63.  
2. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, et al. Donor leukocyte 
infusions for multiple myeloma. Bone Marrow Transplantation. 2000;26(11):117 9-84. 
3. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric 
antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine. 2011;3(95).  
4. Koche nderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B -
cell depletion and remissions of malignancy along with cytokine -associated toxicity in a clinical 
trial of anti-CD19 chimeric -antigen -receptor -transduced T cells. Blood. 2012;119(12 ):2709-20.  
5. Ali SA, Shi V, Maric I, Wang M, Stroncek DF, Rose JJ, et al. T cells expressing an anti –
B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688-700.  
6. Berdeja JG, Lin Y, Raje NS, Siegel DSD, Munshi NC, Liedtke M, et al. First-in -human 
multicenter study of bb2121 anti -BCMA CAR T -cell therapy for relapsed/refractory multiple 
myeloma: POSTER Updated results. Journal of Clinical Oncology. 2017;35(15_suppl):3010-. 
7. Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. B -Cell 
Maturation Antigen (BCMA) -Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for 
Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study ABSTRACT. Blood. 
2016;128(22):1147-. 
8. Brudno JN, Maric I, Hartman SD, Rose JJ, Wang M, Lam N, et al. T cells Modified to 
Express an Anti -B-cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of 
Poor -prognosis Relased Multiple Myeloma. Journal of Clinical Oncology. 2018;In Pres s. 
9. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential 
new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer 
Research. 2008;14(9):2775 -84. 
10. Gogishvili T, Danhof S, Prommersberger S,  Rydzek J, Schreder M, Brede C, et al. 
SLAMF7 -CAR T -cells eliminate myeloma and confer selective fratricide of 
SLAMF7&lt;sup&gt;+&lt;/sup&gt; normal lymphocytes. Blood. 2017.  
11. Mathur R, Zhang Z, He J, Galetto R, Gouble A, Chion-Sotinel I, et al. Univers al 
SLAMF7 -Specific CAR T -Cells As Treatment for Multiple Myeloma. Blood. 2017;130(Suppl 
1):502-. 
12. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CSl humanized 
monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibo dy-dependent 
cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329 -37. 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
93 13. Wang X, Walter M, Urak R, Weng L, Huynh C, Lim L, et al. Lenalidomide Enhances the 
Function of CS1 Chimeric Antigen Receptor -Redirected T Cells Against Multiple M yeloma. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 
2018;24(1):106 -19. 
14. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. 
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor -specific CD8+ T cells. J Exp Med. 2005;202(7):907-12.  
15. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Adoptive transfer of 
syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can 
eradicate lymphoma and normal B cells. Blood. 2010;116(19):3875 -86. 
16. North RJ. Cyclophosphamide -facilitated adoptive immunotherapy of an established 
tumor depends on elimination of tumor -induced suppressor T ce lls. J Exp Med. 
1982;155(4):1063 -74. 
17. Palumbo A, Anderson K. Multiple myeloma. New England Journal of Medicine. 
2011;364(11):1046-60.  
18. Munshi NC, Anderson KC. Plasma Cell Neoplasms. In: DeVita VT, Lawrence TS, 
Rosenberg SA, editors. Cancer:  Principles and Practice of Oncology 9th ed 2011.  
19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. 
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. 
The Lancet Oncology. 2014;15(12):e538-e48.  
20. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. 
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology. 
2005;23(10):2346 -57. 
21. Rajkumar SV. Treatment of multiple myeloma. Nature Reviews Clinical Oncology. 
2011;8(8):479-91.  
22. Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O. Evolving therapeutic 
paradigms for multiple myeloma: Back to the future. Leukemia and Lymphoma. 2013;54(3):451 -
63. 
23. Gonsalves WI, Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. 
Second auto-SCT for treatment of relapsed multiple myeloma. Bone Marrow Transplantation. 
2013;48(4):568 -73. 
24. Durie BGM, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. 
International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-73.  
25. Jakubowiak A. Management Strategies for Relapsed/Refractory Multiple Mye loma: 
Current Clinical Perspectives. Seminars in Hematology. 2012;49(SUPPL. 1):S16-S32.  
26. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of 
progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 
2012;26(1):149 -57. 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
94 27. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, et al. 
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as 
later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology. 2009;82(6):426-32.  
28. Bensinger WI. The current status of reduced -intensity allogeneic hematopoietic stem cell 
transplantation for multiple myeloma. [Review] [48 refs]. Leukemia. 2006;20(10):1683 -9. 
29. Zeiser R, Finke J. Allogeneic haematopoietic cell transplantation for multiple myeloma: 
reducing transplant -related mortality while harnessing the graft-versus -myeloma effect. [Review] 
[70 refs]. European Journal of Cancer. 2006;42(11):1601 -11. 
30. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale -Schianca F, et al. A 
comparison of allografting with autografting for newly diagnosed myeloma. New England 
Journal of Medicine. 2007;356(11):1110 -20. 
31. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Current Opinion in 
Immunology. 2010;22(2):251 -7. 
32. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T 
cells. Trends in biotechnology. 2011;29(11 ):550 -7. 
33. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. 
Cancer regression in patients after transfer of genetically engineered lymphocytes.[see 
comment]. Science. 2006;314(5796):126-9.  
34. Rosenberg SA. Cell transfer immunot herapy for metastatic solid cancer -what clinicians 
need to know. Nature Reviews Clinical Oncology. 2011;8(10):577-85.  
35. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: 
Harnessing the T cell response. Nature Reviews Immunology. 201 2;12(4):269 -81. 
36. Kershaw MH, Teng MWL, Smyth MJ, Darcy PK. Supernatural T cells: Genetic 
modification of T cells for cancer therapy. Nature Reviews Immunology. 2005;5(12):928-40.  
37. Hoyos V, Savoldo B, Dotti G. Genetic modification of human T lymphocyt es for the 
treatment of hematologic malignancies. Haematologica. 2012;97(11):1622 -31. 
38. Turtle CJ, Hudecek M, Jensen MC, Riddell SR. Engineered T cells for anti -cancer 
therapy. Current Opinion in Immunology. 2012;24(5):633-9.  
39. Brentjens RJ, Rivière I,  Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and 
persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B -cell leukemias. Blood. 2011;118(18):4817-28.  
40. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor 
regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY -ESO -1. Journal of Clinical Oncology. 
2011;29(7):917 -24. 
41. Kochen derfer JN, Wilson WH, Janik JE, Dudley ME, Stetler -Stevenson M, Feldman SA, 
et al. Eradication of B -lineage cells and regression of lymphoma in a patient treated with 
autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-102. 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
95 42. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 
costimulation improves expansion and persistence of chimeric antigen receptor -modified T cells 
in lymphoma patients. Journal of Clinical Investigation. 2011;121(5):1822 -6. 
43. Scholler J, Brady TL, Binder -Scholl G, Hwang WT, Plesa G, Hege KM, et al. Decade-
long safety and function of retroviral -modified chimeric antigen receptor T cells. Science 
Translational Medicine. 2012;4(132).  
44. Recchia A, Bonini C, Magnani Z, Urbinati F, Sartori D, Muraro S, et al. Retroviral vector 
integration deregulates gene expression but has no consequence on the biology and function of 
transplanted T cells. Proceedings of the National Academy of Sciences of the United States of 
America. 2006;103(5):1457-62.  
45. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long -term 
outcome of EBV -specific T-cell infusions to prevent or treat EBV -related lymphoproliferative 
disease in transplant recipients. Blood. 2010;115(5):925 -35. 
46. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, et al. A herceptin-
based chimeric antigen receptor with modified signaling domains leads to enhanced survival of 
transduced T lymphocytes and antitumor activity. Journal of Immunology. 2009;183(9):5563 -74. 
47. Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is 
sufficient to couple to receptor -associated signal transduction pathways. Cell. 1991;64(5):891-
901. 
48. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic 
lymphocytes through chimeric single chains consisting of antibody -binding domains and the 
gamma or zeta subunits of the immunoglobulin and T -cell receptors. Proceedings of the National 
Academy of Sciences of the United  States of America. 1993;90(2):720-4.  
49. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, et al. Antitumor activity and 
long-term fate of chimeric antigen receptor -positive T cells in patients with neuroblastoma. 
Blood. 2011;118(23):6050-6.  
50. Curran KJ, Pegram HJ, Brentjens RJ. Chimeric antigen receptors for T cell 
immunotherapy: Current understanding and future directions. Journal of Gene Medicine. 2012;14(6):405 -15. 
51. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-sp ecific T 
cells engineered to coexpress tumor -specific receptors: persistence and antitumor activity in 
individuals with neuroblastoma.[see comment]. Nature Medicine. 2008;14(11):1264 -70. 
52. Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, e t al. Lysis of 
ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178(1):361-6.  
53. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, et al. In vivo antitumor 
activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55(15):3369 -73. 
54. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A 
phase I study on adoptive immunotherapy using gene -modified T cells for ovarian cancer. 
Clinical Cancer Research. 2006;12(20 Pt 1):6106-15.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
96 55. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. 
Construction and preclinical evaluation of an anti -CD19 chimeric antigen recept or. Journal of 
Immunotherapy. 2009;32(7):689-702.  
56. Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE. Killing of non -
Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol. 
2005;129(3):322-32.  
57. Brentjens RJ, Latouc he JB, Santos E, Marti F, Gong MC, Lyddane C, et al. Eradication 
of systemic B -cell tumors by genetically targeted human T lymphocytes co -stimulated by CD80 
and interleukin-15.[see comment]. Nature Medicine. 2003;9(3):279-86.  
58. Imai C, Mihara K, Andreans ky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric 
receptors with 4 -1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic 
leukemia. Leukemia. 2004;18(4):676 -84. 
59. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teache y D, et al. Chimeric 
receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy: the Journal of the American Society of Gene Therapy. 2009;17(8):1453-64.  
60. Porter DL, BL; Kalos, M et al. Chimeric Antigen Receptor -Modified T Cells in Chronic 
Lymphoid Leukemia. The New England Journal of Medicine. 2011;365(8):725-33.  
61. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, et al. Phenotypic 
and functional attributes of lentivirus -modified CD19 -specific Human CD8 + central memory T 
cells manufactured at clinical scale. Journal of Immunotherapy. 2012;35(9):689 -701.  
62. Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, et al. T -cell 
clones can be rendered specific for CD19: toward the selective augmentation of the graft -versus -
B-lineage leukemia effect. Blood. 2003;101(4):1637-44.  
63. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, et al. Infusing CD19 -
directed T cells to augment diseas e control in patients undergoing autologous hematopoietic 
stem -cell transplantation for advanced B -lymphoid malignancies. Human Gene Therapy. 
2012;23(5):444 -50. 
64. Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez -Ojeda O, Taylor C, et al. 
Manuf acturing validation of biologically functional T cells targeted to CD19 antigen for 
autologous adoptive cell therapy. Journal of Immunotherapy. 2009;32(2):169-80.  
65. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, et al. In vivo persistence, 
tumor l ocalization, and antitumor activity of CAR -engineered T cells is enhanced by 
costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011;71(13):4617 -27. 
66. Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T -lymphocyte 
cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nature Biotechnology. 2002;20(1):70-5.  
67. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, et al. The role of 
extracellular spacer regions in the optimal design of chimeric im mune receptors: Evaluation of 
four different scFvs and antigens. Journal of Immunotherapy. 2005;28(3):203-11.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
97 68. Rossig C, Bar A, Pscherer S, Altvater B, Pule M, Rooney CM, et al. Target antigen 
expression on a professional antigen-presenting cell induces  superior proliferative antitumor T-
cell responses via chimeric T -cell receptors. Journal of Immunotherapy. 2006;29(1):21 -31. 
69. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural 
expression of the CD19 antigen impacts the long -term engraftment but not antitumor activity of 
CD19-specific engineered T cells. Journal of Immunology. 2010;184(4):1885 -96. 
70. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, et al. Genetically 
targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 
2007;13(18 Pt 1):5426-35.  
71. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, et al. CD28 
costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo 
persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 
2006;66(22):10995-1004.  
72. Porter CD, Collins MK, Tailor CS, Parkar MH, Cosset FL, Weiss RA, et al. Comparison 
of efficiency of infection of human gene therapy target cells via four different retroviral 
receptors. Human Gene Therapy. 1996;7(8):913 -9. 
73. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. 
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred 
CD20 /CD19 -specific chimeric antigen receptor redirected T cells in humans. Biology of Blood 
and Marrow Transplantation. 2010;16(9):1245-56.  
74. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, et al. Lymphoma 
Remissions Caused by Anti -CD19 Chimeri c Antigen Receptor T Cells Are Associated With 
High Serum Interleukin-15 Levels. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017;35(16):1803 -13. 
75. Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. 
Immunotherapy of non -Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-
specific chimeric antigen receptor -modified T cells. Science translational medicine. 2016;8(355).  
76. Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, et al. Long -
Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric 
Antigen Receptor T Cell Therapy. Molecular therapy : the journal of the American Society of 
Gene Therapy. 2017;25(10):2245 -53. 
77. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti -
CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-76.  
78. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the 
front seat for hematologic malignancies. Blood. 2014;123(17):2625-35.  
79. Rotolo A, Caputo V, Karadimitris A. The prospects and promise of chimeric antigen 
receptor immunotherapy in multiple myeloma. Br J Haematol. 2016;173(3):350 -64. 
80. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor 
design. Cancer discovery. 2013;3(4):388-98.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
98 81. Davies FE, Rawstron AC, Owen RG, Morgan GJ. Controversies surrounding the 
clonogenic origin of multiple myeloma. Br J Haematol. 2000;110(1):240 -1. 
82. Ghosh N, Mat sui W. Cancer stem cells in multiple myeloma. Cancer Letters. 
2009;277(1):1-7.  
83. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, et al. Single -cell 
genetic analysis reveals the composition of initiating clones and phylogenetic patterns of 
branching and parallel evolution in myeloma. Leukemia. 2014;28(8):1705 -15. 
84. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, et al. 
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nature Com munications. 2014;5.  
85. Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, et al. Phenotypic 
identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential. Leukemia. 2015;29(5):1186-94.  
86. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and 
plasticity of multiple myeloma. Br J Haematol. 2013;163(5):551 -64. 
87. Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. 
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and 
multiple myeloma. Blood. 2013;122(20):3461 -72. 
88. Liebisch P, Eppinger S, Schöpflin C, Stehle G, Munzert G, Döhner H, et al. CD44v6, a 
target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica. 2005;90(4):489 -93. 
89. McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris -Tilden 
CA, et al. Preclinical characterization of SGN -70, a humanized antibody directed against CD70. 
Clin Cancer Res. 2008;14(23):7763 -72. 
90. Benjamin R, Condomines M, Gunset G, Sadelain M. Abstract 3499: CD56 targeted 
chimeric antigen receptors for immunotherapy of multiple myeloma. Cancer Research. 2012;72(8 Supplement):3499 -. 
91. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. 
Characterization of clonogenic multiple myeloma cells. Blood. 2004;103(6):2332 -6. 
92. Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, et al. Clonogenic 
Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Res. 
2008;68(1):190 -7. 
93. Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, et al. CD20 -Directed 
Serotherapy in Patients With Multiple Myeloma: Biolo gic Considerations and Therapeutic 
Applications. Journal of Immunotherapy. 2002;25(1):72 -81. 
94. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem -cell biology to 
cancer. Nat Rev Cancer. 2003;3(12):895 -902.  
95. Garfall AL, Maus MV, Hwang WT , Lacey SF, Mahnke YD, Melenhorst JJ, et al. 
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 
2015;373(11):1040-7.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
99 96. Garfall AL, Stadtmauer EA, Maus MV, Hwang W -T, Vogl DT, Cohen AD, et al. Pilot 
Study of Anti -CD19 Chime ric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage 
Autologous Stem Cell Transplantation for Advanced Multiple Myeloma ABSTRACT. Blood. 
2016;128(22):974 -. 
97. Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, et al. Clinical 
responses with T lymphocytes targeting malignancy -associated kappa light chains. J Clin Invest. 
2016;126(7):2588 -96. 
98. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B -cell 
maturation antigen is a promising target for adoptive T -cell therapy of multiple myeloma. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 2013;19(8):2048-60.  
99. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, et al. 
Expression of BCMA, TACI, a nd BAFF -R in multiple myeloma: A mechanism for growth and 
survival. Blood. 2004;103(2):689-94.  
100. Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, et al. In vivo inhibition 
of human CD19-targeted effector T cells by natural T regulatory cells  in a xenotransplant murine 
model of B cell malignancy. Cancer Res. 2011;71(8):2871 -81. 
101. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. 
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy 
of adoptively transferred CD8+ T cells. The Journal of Clinical Investigation. 2005;115(6):1616 -
26. 
102. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts 
in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188 -95. 
103. Dianzani U, Funaro A, DiFranco D, Garbarino G, Bragardo M, Redoglia V, et al. 
Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 
molecule. The Journal of Immunology. 1994;153(3):952-9.  
104. Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, et al. CD38 and 
CD157: A long journey from activation markers to multifunctional molecules. Cytometry Part B: Clinical Cytometry. 2013;84B(4):207 -17. 
105. Deaglio  S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and 
receptors. Leukemia research. 2001;25(1):1 -12. 
106. Terstappen L, Huang S, Safford M, Lansdorp P, Loken M. Sequential generations of 
hematopoietic colonies derived from single nonl ineage -committed CD34+CD38- progenitor 
cells. Blood. 1991;77(6):1218-27.  
107. Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. 
Leukemia. 2017.  
108. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. Ta rgeting 
CD38 with Daratumumab Monotherapy in Multiple Myeloma. New England Journal of Medicine. 2015;373(13):1207-19.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
100 109. Boles KS, Mathew PA. Molecular cloning of CS1, a novel human natural killer cell 
receptor belonging to the CD2 subset of the immunoglobulin superfamily. Immunogenetics. 
2001;52(3-4):302 -7. 
110. Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a 
therapeutic target in multiple myeloma. Critical Reviews in Oncology/Hematology. 2013;88(1):168 -77. 
111. Boudre ault JS, Touzeau C, Moreau P. The role of SLAMF7 in multiple myeloma: impact 
on therapy. Expert Rev Clin Immunol. 2017;13(1):67-75.  
112. Calpe S, Wang N, Romero X, Berger SB, Lanyi A, Engel P, et al. The SLAM and SAP 
Gene Families Control Innate and Adaptive Immune Responses. Advances in Immunology2008. p. 177-250.  
113. Wu N, Veillette A. SLAM family receptors in normal immunity and immune pathologies. 
Current Opinion in Immunology. 2016;38:45 -51. 
114. Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in 
immunity. Annual review of immunology. 2011;29:665-705.  
115. Malaer JD, Mathew PA. CS1 (SLAMF7, CD319) is an effective immunotherapeutic 
target for multiple myeloma. American journal of cancer research. 2017;7(8):1637 -41. 
116. Ch u J, He S, Deng Y, Zhang J, Peng Y, Hughes T, et al. Genetic modification of T cells 
redirected toward CS1 enhances eradication of myeloma cells. Clinical Cancer Research. 
2014;20(15):3989 -4000.  
117. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab 
Therapy for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 
2015;373(7):621-31.  
118. Lonial S, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P. Update on 
elotuzumab, a novel anti -SLAMF7 monoclona l antibody for the treatment of multiple myeloma. 
Expert Opinion on Biological Therapy. 2016;16(10):1291 -301.  
119. Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D. Novel anti -myeloma 
immunotherapies targeting the SLAM family of receptors. OncoImmunology. 2017;6(5):e1308618.  
120. Cruz-Munoz M -E, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM 
family receptor coupled to the adaptor EAT -2, on natural killer cell function. Nature 
Immunology. 2009;10:297.  
121. Di Stasi A, Tey SK, Dotti G,  Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible 
apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine. 2011;365(18):1673-83.  
122. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, et al. Intravenous s afety 
and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. Journal of clinical pharmacology. 2001;41(8):870-9.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
101 123. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” 
to limit on -target, off -tumor toxicities of chimeric antigen receptor T cells. Frontiers in 
Pharmacology. 2014;5(235).  
124. Straathof KC, Pulè MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible 
caspase 9 safety switch for T -cell therapy. Blood. 2005;105(11):4247-54.  
125. Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. 
Engineering CD19-specific T lymphocytes with interleukin -15 and a suicide gene to enhance 
their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160-70.  
126. Hughe s MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, et al. Transfer of a TCR 
gene derived from a patient with a marked antitumor response conveys highly active T -cell 
effector functions. Human Gene Therapy. 2005;16(4):457-72.  
127. Carpenter RO, Evbuomwan MO , Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B -cell 
maturation antigen is a promising target for adoptive T -cell therapy of multiple myeloma. 
Clinical Cancer Research. 2013;19(8):2048 -60. 
128. Jakubowiak A, Offidani M, Pégourie B, De La Rubia J, Garde ret L, Laribi K, et al. 
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs 
bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016;127(23):2833.  
129. Collins SM, Bakan CE, Alghothani Y, Kwon H, Balasa B, Starling G, et al. The e ffect of 
elotuzumab on natural killer (NK) cell function against multiple myeloma (MM). Journal of Clinical Oncology. 2011;29(15_suppl):2572 -. 
130. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, et al. 
Elotuzumab directly enhances NK  cell cytotoxicity against myeloma via CS1 ligation: evidence 
for augmented NK cell function complementing ADCC. Cancer immunology, immunotherapy : 
CII. 2013;62(12):1841-9.  
131. Benson DM, Jr., Byrd JC. CS1 -directed monoclonal antibody therapy for multiple 
myeloma. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2012;30(16):2013-5.  
132. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, et al. A 
phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552.  
133. Hofmeister CC, Lonial S. How to Integrate Elotuzumab and Daratumumab Into Therapy 
for Multiple Myeloma. Journal of Clinical Oncology. 2016;34(36):4421 -30. 
134. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19 -targeted T 
cells rapidly induce molecular remissions in adults with chemotherapy -refractory acute 
lymphoblastic leukemia. Science translational medicine. 2013;5(177).  
135. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. 
Donor -derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic 
hematopoietic stem cell transplantation. Blood. 2013;122(25):4129-39.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
102 136. Kochen derfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B -
cell depletion and remissions of malignancy along with cytokine -associated toxicity in a clinical 
trial of anti-CD19 chimeric -antigen -receptor –transduced T cells. Blood. 2012;119(12) :2709 -20. 
137. Orange JS. Human natural killer cell deficiencies and susceptibility to infection. 
Microbes and Infection. 2002;4(15):1545 -58. 
138. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene 
therapy with human and mouse T -cell receptors mediates cancer regression and targets normal 
tissues expressing cognate antigen. Blood. 2009;114(3):535-46.  
139. Lee DW, Kochenderfer JN, Stetler -Stevenson M, Cui YK, Delbrook C, Feldman SA, et 
al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in 
children and young adults: A phase 1 dose -escalation trial. The Lancet. 2015;385(9967):517 -28. 
140. Orange JS. Natural killer cell deficiency. Journal of Allergy and Clinical Immunology. 
2013;132(3):515-25.  
141. Hagberg N, Theorell J, Schlums H, Eloranta M -L, Bryceson YT, Rönnblom L. Systemic 
Lupus Erythematosus Immune Complexes Increase the Expression of SLAM Family Members 
CD319 (CRACC) and CD229 (LY -9) on Plasmacytoid Dendritic Cells and CD319 on 
CD56&lt;sup&g t;dim&lt;/sup&gt; NK Cells. The Journal of Immunology. 2013.  
142. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56(bright) natural 
killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458-65.  
143. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 
2008;27:5932.  
144. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased 
intensity lymphodepletion and adoptive immunotherapy - How far can we go? Nature Clinical 
Practice Oncology. 2006;3(12):668 -81. 
145. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and 
antigen presenters: How lymphodepletion enhances T cell -mediated tumor immunotherapy. 
Trends in Immunology. 2005;26(2):111 -7. 
146. Dumitru CA , Moses K, Trellakis S, Lang S, Brandau S. Neutrophils and granulocytic 
myeloid -derived suppressor cells: Immunophenotyping, cell biology and clinical relevance in 
human oncology. Cancer Immunology, Immunotherapy. 2012;61(8):1155 -67. 
147. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell 
therapy for patients with metastatic melanoma: evaluation of intensive myeloablative 
chemoradiation preparative regimens. Journal of Clinical Oncology. 2008;26(32):5233 -9. 
148. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. 
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-4.  
149. O'Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of the 
fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology. 2001;19(5):1414-20.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
103 150. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. 
Determinants of successful CD8 + T -cell adoptive immunotherapy for large established tumors 
in mice. Clinical Cancer Research. 2011;17(16):5343 -52. 
151. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, De Jong LA, Vyth-Dreese FA, 
et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self -
reactive CD8+ T cells. J Exp Med. 2003;198(4):569-80.  
152. Li S, Yang J, Urban FA, MacGregor JN, Hughes DPM, Chang AE, et al. Genetically 
engineered T cells expressing a HER2 -specific  chimeric receptor mediate antigen -specific tumor 
regression. Cancer Gene Therapy. 2008;15(6):382-92.  
153. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological 
malignancies after stem cell transplantation revisited. Cancer Treatment  Reviews. 
2010;36(7):528 -38. 
154. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and winding road: how 
should it be traveled? Bone Marrow Transplantation. 2008;42(9):569-79.  
155. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et  al. International 
Myeloma Working Group consensus criteria for response and minimal residual disease 
assessment in multiple myeloma. The Lancet Oncology. 2016;17(8):e328 -e46.  
156. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic  
Health Evaluation (APACHE) IV: Hospital mortality assessment for today's critically ill patients. Critical Care Medicine. 2006;34(5):1297-310.  
157. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti -BCMA CAR T -
cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine. 2019;380(18):1726-37.  
 
    
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
104 15 APPENDICES  
15.1 APPENDIX A: PERFORMANCE STATUS CRITERIA  
ECOG Performance Status Scale* 
 
Grade Descriptions  
0 Normal activity.  Fully active, able to carry on all pre -disease 
performance without restriction.  
1 Symptoms, but ambulatory.  Restricted in physically strenuous activity, 
but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work).  
2 In bed <50% of the time.  Ambulatory and capable of all self -care, but 
unable to carry out any work activities.  Up and about more than 50% of 
waking hours.  
3 In bed >50% of the time.  Capable of only limited self -care, confined to 
bed or chair more than 50% of waking hours.  
4 100% bedridden.  Completely disabled.  Cannot carry on any self -care.  
Totally confined to bed or chair.  
5 Dead.  
* As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, 
T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.  
 
  
 
 
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
105  
15.2 APPENDIX B: DATA COLLECTION ELEMENTS REQUIRED BY PROTOCOL  
All of the following elements will be recorded in the C3D database:  
 
A. Patient Enrollment  
 
• Date of birth, age, gender, race, ethnicity  
• Height  
• Weight  
• ECOG  
• Date of original diagnosis  
• Plasmacytoma present: Yes or No  
• Tum or Histology and date of confirmation  
• SLAMF7  expression by tumor type of tissue studied and date of confirmation  
• Date of Informed Consent signature, consent version and date of registration 
• Baseline History/Physical 
• Baseline Symptoms  
• Prior therapy  
• Prior radiation  
• Prior Bone Marrow Biopsy that includes the percent of plasma cells and SLAMF7  
results  
• Findings of consultations done at screening  
 B. Study Drug administration and response for each course of therapy given 
• Dates anti -SLAMF7 -CAR-transduced T cells given  
• Dose level, actual dose in CAR+ T cells/kg, schedule and route given  
• Height, weight, and body surface area at start of each course  
• Response assessment for each restaging performed  
• Concomitant medications will not be collected in C3D  
 
         
C. Laboratory and Diagnostic Test Data 
 
1.  All Clinical laboratory and diagnostic test results done at screening and until day 
30 post infusion with the following exceptions:  
Diagnostic tests which are not specified in the protocol, and if the results are not 
needed to document the start or end of  an adverse event that requires reporting.  
Serologies such as CMV, HSV, EBV, toxoplasmosis, adenovirus, TTV data that were not need for eligibility will not be collected.  
2. All staging studies including serum protein electrophoresis, urine protein electropho resis, serum free light chains, bone marrow biopsy reports, flow 
cytometry reports, serum immunoglobulin reports including beta -2 microglobulin, 
complete blood count and differential reports, serum creatinine reports, TBNK 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
106 results, serum protein, urine albumin, serum calcium (including ionized), ESR and 
CRP results. MRI, X -ray, and CT scan results will only be reported if they were 
used for staging.  
D. Adverse Events  
Please see section 6.1.1  Adverse Event Recording  
E. Tumor  response and measurements  
• Restaging studies performed at protocol specified time points and as clinically indic ated . 
• Any physical exam findings will be collected as Adverse Events and labs results.  
 
F. Off study  
• Date and reason for off study  
• Date and cause of death  
• Autopsy findings if available  
 
   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
107 15.3 APPENDIX C:  GUIDELINES FOR MANAGEMENT OF COMMON  TOXICITIES THAT OCCUR 
AFTER CAR  T-CELL INFUSIONS  
 
Infusions of CAR T cells are often complicated by significant acute toxicities in the first 2 to 3 weeks after the infusion.  In many cases the toxicities correlate with serum inflammatory cytokine levels.  
The toxicities most often experienced by patients receiving infusions of CAR T cells include, but are not limited to, tumor lysis syndrome, fever, fatigue, hypotension, tachycardia, acute renal 
failure, and neurological toxicities suc h as aphasia, ataxia, headache, somnolence, and coma.  
Fever is usually the first toxicity to occur.   
Note these are guidelines that might require modification based on clinical circumstances of each 
patient, and failure to exactly follow these guidelines  is not a protocol deviation or violation.  
Administration of corticosteroids should be avoided if possible , to avoid killing or impairing the 
function of the CAR T cells.  
 
General supportive care guidelines 
1. All patients with significant malignancy burdens and without a contradiction such as allerg y should be started on allopurinol at the time of the start of the chemotherapy conditioning 
regimen or 1 day before the CAR T cell infusion.  The suggested allopurinol dose is 200 to 
300 mg/day with a possible loading dose of 300 to 400 mg.  
2. Vital signs should be checked a minimum of every 4 hours during hospitalization.  Increasing the time interval between vital sign checks for patient convenience or other reasons should be avoided.  
3. Strict ins and outs should be recorded on all patients.  
4. As a minimum, keep hemoglobin greater than 8.0 g/dL and platelets greater than 20K/microliter.  
5. Administer fresh frozen plasma (FFP) for a PTT 1.5-fold or more above the upper limit of normal.  
6. For patients with an increased PTT, ch eck the fibrinogen level and keep the fibrinogen level 
above 100 mg/dL with cryoprecipitate.  
7. Fevers should be treated with acetaminophen and comfort measures. NSAIDs and corticosteroids should be avoided.  
8. Patients with a heart rate persistently higher than  115/minute and fever should have vital signs 
checked every 2 hours.  
9. Patients who are neutropenic and febrile should be receiving broad -spectrum antibiotics.  
10.  Avoid meperidine due to seizure risk.  
11. Minimize benzodiazepine use to avoid aggravating delirium.   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
108 12. Patients on this protocol will be placed on strict fall precautions including instructions to get 
out of bed only with assistance under the following conditions:  
 
1.  Any history of syncope or near -syncope within 1 month before CAR T -cell infusion or 
any time after CAR T-cell infusion.  
2. Any blood pressure reading of less than 100 mm Hg systolic blood pressure after anti -
CD19 CAR T -cell infusion if 100 mm Hg is lower than the patients baseline systolic blood 
pressure. 
3. Heart rate greater than 100 beats per mi nute.  
 
13.  Any patient with syncope, near -syncope, or light -headedness will have orthostatic blood 
pressure and heart rate checked and receive intravenous fluids as appropriate.   These patients 
will also receive an ECG.  
 
14. A CBC will be obtained twice daily while the patient is inpatient.  If the absolute neutrophil count becomes less than 500/microliter, Filgrastim will be initiated at a dose of 300 micrograms daily for patients under 70 kg in weight and a dose of 480 micrograms daily for 
patients over 70 kg in weight only in patients with absolute neutrophil counts less than 
500/microliter.  Filgrastim will be discontinued as soon as the absolute neutrophil count 
recovers to 2000/microliter.  
15. Hypotension is a common toxicity requiring intensive care unit (ICU) admission.  In general patients should be kept well -hydrated.  Maintenance I.V. fluids (normal saline (NS) should 
be started on most patients with high fevers especially if oral intake is poor or the patient has 
tachycardia.  I.V. fluids are not necessary f or patients with good oral intake and mild fevers.  
For patients who are not having hypotension or tumor lysis syndrome, a generally even fluid 
balance should be strived for after allowing for insensible fluid losses in patients with high fevers.  The baseline systolic blood pressure is defined for this protocol as the average of all 
systolic blood pressure readings obtained during the 24 hours prior to the CAR T -cell infusion.  
The first treatment for hypotension is administration of IV NS boluses.   
• Patie nts with a systolic blood pressure that is less than 80% of their baseline blood 
pressure and less than 100 mm Hg should receive a 1 L NS bolus.  
•  Patients with a systolic blood pressure less than 90 mm Hg should receive a 1 L 
NS bolus regardless of baseline blood pressure.  
     
These I.V. fluid management suggestions may need to be modified based on the clinical 
characteristics of individual patients such as pulmonary status, cardiac function, edema and other factors.  
 
16. Patients receiving more than 1 fluid  bolus for hypotension should have a stat EKG and 
troponin, and a cardiac echocardiogram as soon as possible.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
109  
ICU transfer  
Patients should be transferred to the ICU after consultation with the ICU physicians under 
these circumstances.  Patients not meeting these criteria could also require ICU admission at the discretion of the clinical team caring for the patient.  
• Systolic b lood pressure less than 75% the patient’s baseline blood pressure and less 
than 100 mm Hg after administration of a 1L NS bolus.  
• Anytime the systolic blood pressure is less than 90 mm Hg after a 1L NS bolus.  
• Continuous tachycardia with a heart rate higher than 125 beats per minute on at least 2 occasions separated by 2 hours.  
• Oxygen requirement of more than a 4L standard nasal cannula  
 
1.  All patients transferred to the ICU for hypotension or tachycardia should have a stat EKG 
and a cardiac echocardiogram wit hin 6 hours of the time of transfer.  
2. Patients with hypotension not responding to IV fluid resuscitation should be started on norepinephrine at doses called for by standard ICU guidelines.  
3. Patients should have a cardiac echocardiogram and an EKG within 6 hours of starting norepinephrine.  
4. Patients in the ICU should get twice -daily labs (CBC with differential, acute care panel, 
mineral panel, hepatic panel, uric acid, LDH.  Patients in the ICU should also get a daily troponin level).  
5. Patients receiving vasopressors should have a cardiac echocardiogram at least every other day. 
 
Immunosuppressive drug administration  
In general, immunosuppressive drugs are administered in a stepwise escalation based on toxicity severity.  The first immunosuppressive drug adminis tered is usually tocilizumab.  If 
toxicity does not improve after tocilizumab, treatment progresses to intermediate -dose or 
high-dose methylprednisolone.  For certain severe toxicities listed below, high-dose 
methylprednisolone must be given immediately.  
Tocilizumab administration 
Tocilizumab should be administered under the following circumstances if the listed disorders are thought to be due to cytokine release from CAR T cells.  Tocilizumab is administered at a dose of 8 mg/kg in patients weighing 30 kg  or more,  infused IV over 1 hour (dose should 
not exceed 800 mg) ; it may be infused up to three additional times if there is no clinical 
improvement in signs and symptoms after the first dose . The interval between consecutive 
doses should be at least 8 hours.  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
110 • Left ventricular ejection fraction less than 45% by echocardiogram  
• Creatinine greater than 2 -fold higher than the most recent level prior to CAR T -cell 
infusion 
• Norepinephrine requirement at a dose greater than 3 µg/minute for 36 hours since 
the first administration of norepinephrine.  
• Requirement of 5 mcg/minute or more of norepinephrine to maintain systolic blood 
pressure greater than 90 mm Hg.  
• Oxygen requirement  of 40% or greater fraction of inspired oxygen (FIO 2) to 
maintain oxygen saturation of >92%.  
• Subjective significant dyspnea and respiratory rate greater than 25 for 2 hours or more. 
• PTT or INR>2x upper limit of normal  
• Bleeding possibly related to cytokine -release syndrome 
• Creatine kinase greater than 5x upper limit of normal  
 
Intermediate-dose methylprednisolone for toxicities not responsive to 
tocilizumab 
1.  Give methylprednisolone 50 mg every 6 hours for any of the toxicities under “Tocilizumab 
administration”  above that don’t improve after tocilizumab administration.  
 
High-dose methylprednisolone should be given immediately under these 
circumstances:  
1.  Give methylprednisolone 200 mg every 6 hours for systolic blood pressure that is less than 
90 mm Hg while the patient is on 15 mcg/minute or higher doses of norepinephrine. If the 
patient has not had tocilizumab, give 8 mg/kg of tocilizumab along with the  
methylprednisolone.   
2. Give methylprednisolone 200 mg every 6 hours for hypotension requiring 15 mcg/minute or 
more of norepinephrine continuously for 8 hours or more.  If the patient has not already had tocilizumab, administer 8 mg/kg tocilizumab in addition to methylprednisolone.  
3. Give methylprednisolone 200 mg every 6 hours for any left ventricular ejection fraction 30% or less.  If the patient has not already had tocilizumab, administer 8 mg/kg tocilizumab in addition to methylprednisolone.  
4.  Give methylp rednisolone 200 mg every 6 hours for any situation in which pulmonary toxicity   
makes mechanical ventilation likely to be required within 4 hours.  If the patient has not had 
tocilizumab, administer 8 mg/kg tocilizumab in addition to methylprednisolone.  
5. In life -threating toxicity not improving after 200 mg of methylprednisolone  Rimiducid should 
be administered , 1000 mg of methylprednisolone can be considered . 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
111 In general, stop corticosteroid use when toxicity improves to a tolerable level.  For example, 
in patients with hypotension, stop methylprednisolone 6 to 12 hours after vasopressors are no longer needed.  
Neurological toxicity 
1. All patients with neurological toxicities other than somnolence and delirium should get a neurology consult.  
2. All patients with significant neurological toxicity should get an MRI of the brain.  
3. All patients with significant neurological toxicity should get a lumbar puncture after MRI if it is safe to perform a lumbar puncture.  
4. CARTOX-10 scale ( Appendix E) will be administered daily in patients  and used to monitor 
for aphasia/dysphasia in patients.  
5. The following patients should receive dexamethasone 10 mg intravenously every 6 hours until  
the toxicities improve.  Note:  for seizures administer standard seizure therapies in addition to 
dexamethasone.  For patients already getting higher doses of corticosteroids for CAR -related 
toxicity, it is not necessary to add dexamethasone 10 mg every 6 hours. Stop dexamethasone 
as soon as toxicity improves to a tolerable level; the duration of dexamethasone use will need 
to be determined on a patient to patient basis. Tocilizumab is possibly not effective for 
neurological toxicity, so it should not be g iven when patients have isolated neurological 
toxicity.  Tocilizumab may be concurrently given with steroids if the patient has evidence of 
CRS in addition to neurological toxicity  
1. Inability of patient to follow simple commands such as “squeeze my fingers”.  
2.  Any generalized seizure 
3. Somnolence severe enough to potentially limit airway protection 
4. Obtundation and stupor  
5. Ataxia severe enough to preclude ambulation  
6. Disorientation to person or place that persists longer than 48 hours  
7. Neurologic toxicity lasting m ore than 2 hours that is severe enough to interfere with 
activities of daily living (ADLs)  
8. Cerebral edema 
 
 
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
112 15.4 APPENDIX D:   INFUSION INSTRUCTIONS    
Equipment:   
Primary IV tubing (2)  
Secondary IV tubing (1)  
NS (sodium chloride 0.9%) 250cc bags (2)  
IV infusion pump 
Gloves  
  
Steps:  Key Points:  
1.     The RN will be informed of the 
approximate time of cell arrival at 
the bedside.   
2.  Verify the physician orders:  
- to administer the cells  
- for the date of administration  
- for premedication orders  
- protocol number  
 • Premeds are acetaminophen 650 mg PO and 
diphenhydramine 12.5 mg IV.  
3.  Verify that the protocol consent  has been 
signed    
4.  Ensure that emergency and monitoring  
equipment are available in the patient’s 
room:  
-  oxygen 
-  suction  
-  vital sign monitor with pulse oximeter  
   and thermometer     
5.  Provide patient education covering 
infusion procedure, potential complications 
and associated symptoms to report.   
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
113 7.  Measure and record baseline vital signs, 
respiratory and circulatory assessments.   
8.  Verify the patency of the patient’s IV access.  A central venous access device such as a non -valved 
PICC line should be used.  
9.  Hang a primary line of 250cc NS at a kvo rate - NEW bag and NEW tubing.  
This MUST  be ready and infusing prior  to 
the cells being delivered to the unit.  
The patient’s pr imary IV hydration can 
infuse via a separate lumen while the cells are infusing, but NO MEDs  should be  
administered during this time.   
Have a second bag of 250cc NS and tubing 
ready as an emergency line.  This will be the dedicated NS line for infusing the 
cells.  Under no circumstances are any other 
substances to be infused into the line.   
Cell death occurs quickly – the infusion must be 
initiated immediately.  
Do not infuse medication during the cell infusion.  If 
emergency meds must be administered, use the 
hydration or emergency NS IV line.  
 This will be the emergency IV solution and can be 
used for medication administration.  
 
Do not use an inline filter for cells.   
10.  The primary RN will be notified 
approximately 10 minutes before the cells 
arrive on the unit.  The cells will be hand 
delivered to the bedside.  
It is critical to be at the bedside awaiting the arrival of the cells for infusion.   
 
 It is critical to be at the bedside awaiting the arrival 
of the cells for infusion; have baseline VS, 
assessment, and IV lines hooked up when the cells 
arrive.  Cell death occurs as soon as the cells are 
removed from the laboratory .  Initiate the infusion 
as quickly as possible . 
 
12.  Prior to spiking the cell bag, two RNs 
will perform the identification procedure.  
Both  RNs must have their names charted in 
the CRIS cellular therapy flow sheet   
13.   Infuse the cells by INFUSION PUMP  
or syringe over 20-30 minutes.  
a. Piggyback the cells into the dedicated 
NS line; use the backflush technique 
to prime the line.  
b.   While the cells are infusing, gently  
agitate the bag of cells every few minutes
. When the cell bag is 
empty, backflush NS to rinse the bag This prevents the cells from clumping in the bag.  
 
   
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
114  
   and infuse this at the same rate as the 
cells; rinse bag until NS runs clear.  
        c.  Note: in some cases cells will arrive 
from DTM in a syringe.  In this case 
infuse the cells via syringe o ver 20- 30 
minutes in the dedicated NS line 
proximal port, see nursing cellular 
infusion SOP for further details.   
14.  Measure and record VS before and after 
the cell infusion, q1h x 4, and then q4h after 
completion of the infusion.   
a. Assess and document the    patient’s 
respiratory and circulatory status 
post cell infusion.    
15.  Documentation:  
a. After the cells have infused, remove 
the adhesive backed “cell therapy 
product” tag from the cell bag and 
place it on a progress note in the patient’s chart.  
b.    Document the cell infusion in     
CRIS using the appropriate screens.    
 
  
 
 
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
115 15.5 APPENDIX E:   CARTOX  (ADAPTED FROM NEELAPU ET AL , 2018):   
- One point is assigned for each task. Normal function defined by overall score 
of 10.  
- TASKS:  
 Orientation to year, month, city, hospital and President of country (maximum 5 poi nts) 
 Name three objects (ex: point to clock, pen, button) (maximum of 3 points)  
 Write a standard sentence (1 point)  
 Count backwards from 100 in tens (1 point)  
  
Abbreviated Title:  Anti-SLAMF7 CAR T cells for MM  
Versio n Date:  April 14, 2020  
 
116 15.6 APPENDIX F:   CYTOKINE RELEASE SYNDROME GRADING ASSESSMENT (ADAPTED FROM 
LEE ET AL , 2019).   
Grade 1 CRS:  
- Fever  and:  
- Constitutional symptoms  
Grade 2 CRS:  
- Fever and:  
- Hypotension; responds to fluids . 
- Hypoxia  requiring low flow nasal cannula or blow -by. 
Grade 3 CRS:  
- Fever and;  
- Hypotension: requires pressor  +/- vasopressin)  
Hypoxia: requiring high-flow nasal cannula, facemask, nonrebreather mask or venturi mask. Grade 
4 CRS:  
- Fever and;  
- Positive pressure  
-  
- Multiple Pressors  
 